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ABSTRACT

Provided are methods for using his-quaternary ammonium
compounds to treat inflammatory pain, neuropathic pain and
nociceptive pain.
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FIGURE 1
Time Course of Effect of ZZ-16-1 C
Rodent Model of Tonic Inflammatory Pain
(Formalin Test)
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FIG. 2
Dose Response Effect of ZZ-16-1 C
Rodent Model of Tonic Inflammatory Pain
(Formalin Test)
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Vincristine*-lnduced Neuropathic Pain in the Rat
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Figure 3
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Effect of Vincristine* on Body Weight in the Rat
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HIS-QUATERNARY AMMONIUM SALTS AS
PAIN MODULATING AGENTS

gastrointestinal toxicity, was thought to be an advance in
NSAID pharmacology. Nonetheless, these agents still have
low efficacy and evidence is now available linking them to
significant cardiovascular events including stroke and myocardial infarction following chronic use. This has resulted in
the removal of both rofecoxib and valdecoxib from the
market. No truly efficacious agent exists for the treatment of
neuropathic pain. GABA-pentin (Neurontin®), an anticonvulsant, has found use for some neuropathic pain syndromes
(e.g., diabetic peripheral neuropathy, postherpetic neuralgia), but it still has limited efficacy. Duloxetine (Cymbalta®), an antidepressant, has recently been approved for
the treatment of diabetic peripheral neuropathy. However, it
has limited efficacy and usefulness for other neuropathic
pain states. The N-methyl-d-aspartate (NMDA) receptor
antagonists (e.g., ketamine) have been proposed for the
treatment of neuropathic pain. Their general use is impractical given the marked side effects including sedation, psychosis and motor impairment. The limitations of the currently available therapies clearly demonstrate the need for a
broad spectrum new class of efficacious and safe analgesic
drugs for the treatment of nociceptive and neuropathic pain.
Given the need for more effective, less toxic, analgesic
drugs, a great deal of emphasis has been placed on identi:tying novel molecular targets that could form the basis for
new analgesics. One of the promising new targets is the
neuronal nicot1mc acetylcholine receptor (nAChR).
nACHR's play an important role in the control of pain and
thus drugs acting at the nicotinic receptor, as agonists, partial
agonists or antagonists may be expected to have analgesic
properties. The his-quaternary ammonia salts of the invention are thought to interact with the nACHR. Nicotinic
receptor drugs have been shown to have a broad spectrum of
analgesic activity in several preclinical models of pain of
nociceptive and neuropathic origin. This includes acute
thermal pain models (tail flick, hot plate), inflammatory pain
models (formalin or carrageenan injection into the paw) and
nerve injury (neuropathic pain) models (spinal or sciatic
nerve ligation). Both anti-hyperalgesic and anti-allodynic
effects were observed in the neuropathic pain models.
Thus, it appears that nicotine drugs have promise as
analgesic agents for the treatment of several types of clinical
pain, specifically nociceptive, neuropathic and inflammatory
pain.

FIELD OF THE INVENTION
The invention relates to his-quaternary ammonium salts
and their use as agents for pain modulation, treatment,
reversal and/or prevention of inflammatory pain, neuropathic pain or nociceptive pain.
10

BACKGROUND OF THE INVENTION
The treatment of pain is a critical health issue. Acute (e.g.,
postoperative pain) and chronic (e.g., arthritis, low back,
cancer) pain affects tens of millions of people annually in the
US. Each year some 30 million people visit a physician with
a complaint of a painful condition. Some 10% of these
patients are seen with chronic pain as their main complaint.
The financial loss due to pain has been estimated to exceed
100 billion dollars a year as a result of medical fees,
decreased productivity, litigation and the cost of drugs. New
therapeutic agents with broader efficacy, for nociceptive,
neuropathic and mixed nociceptive-neuropathic pain syndromes, and with fewer side effects would result in significant societal benefit.
Pain can be broadly divided into two categories: nociceptive and neuropathic pain. Nociceptive pain occurs as a
result of activation of peripheral nociceptors, actually free
nerve endings by noxious stimuli (heat, pressure, inflammatory mediators). Examples of nociceptive pain include postsurgical pain, inflammatory pain (e.g., arthritis) and low
back pain. Such a pain is often described as "a constant, dull,
aching pain". Neuropathic pain occurs as a result of damage
to the peripheral or central nervous system. Examples of
neuropathic pain include radiculopathy (e.g., disc impingement on a nerve), complex regional pain syndrome (CRPS
I, II), diabetic peripheral neuropathy or central pain (stroke,
spinal cord injury, multiple sclerosis). Patients typically
describe neuropathic pain as "burning and tingling" in
nature. It is characterized by hyperalgesia (increased painful
response to a noxious stimulus) and allodynia (pain to a
previously non-noxious stimulus).
In many pain patients, in particular those with chronic
pain conditions of both malignant (cancer-related pain) and
non-malignant origin, pain is inadequately managed with
currently available drugs. Available drugs are simple modifications (e.g., extended release) of drugs from classes which
have been available for decades including the opioids,
nonsteroidal anti-inflammatory agents (NSAID's) or various
adjuvants (antidepressants, anticonvulsants) initially
approved for other uses besides pain. Opioids (e.g., morphine, oxycodone) are often successfully used for the treatment of moderate to severe nociceptive pain. Chronic neuropathic pain is much less responsive to opioids. Use of
opioid analgesics is associated with a broad range of significant side effects including cognitive impairment, respiratory depression and constipation. In addition, long-term
opioid dosing results in the development of tolerance to the
analgesic effect, drug abuse and dependence. The NSAID's
(e.g., ibuprofen) act by inhibition of the cyclo-oxygenase
(Cox-1 ,2) enzyme. They are especially useful in nociceptive
pain of inflammatory origin (e.g., arthritis). However, the
NSAID's have limited efficacy when compared to the opioids. In addition, NSAID's have significant side effects
(renal, gastrointestinal, cardiovascular). The discovery of
the Cox-2 selective agents (e.g., rofecoxib-Vioxx®; celecoxib-Celebrex®; valdecoxib-Bextra®) which have far less
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In one embodiment, compounds corresponding to the
following structure which are useful in treating inflammatory pain, neuropathic pain or nociceptive pain are provided.
X 2 8EBR 1-H2 C-L 1 -Q-L2 -CH2 -R2 EB8X 1
18
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(1)

X
and X
are each independently an organic or
inorganic anion.
Q is
selected from phenylene,
biphenylene,
---CH=CH-, ---CH=CH---CH=CH-, -C C-,
---C C---C C-, -O-(CH 2 ) 2 -0-, and - 0 (CH 2 ) 2 ---0-(CH 2 ) 2 ---0-.
L 1 and L 2 are each independently selected from alkyl,
substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl,
substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, heterocyclic, substituted
heterocyclic; SOY 1 , S0 2 Y 1 , S0 2 0Y 1 or S0 2 NHY\ where
Y 1 is selected from hydrogen, lower alkyl, alkenyl, alkynyl
or aryl, and where Y 1 is not hydrogen in SOY 1 and ifY 1 is

US 9,499,518 B2
3

4

alkenyl or alkynyl, the site ofunsaturation is not conjugated
with a heteroatom; COY2, where Y 2 is selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted
cycloalkyl, alkoxy, alkenyl, substituted alkenyl, alkynyl,
substituted alkynyl, aryl, substituted aryl, aryloxy, alkylaryl,
substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, heterocyclic, or substituted heterocyclic, and
where ifY2 comprises alkenyl or alkynyl, the site ofunsaturation is not conjugated with the carbonyl group; OY3,
where Y 3 is selected from hydrogen, alkyl, substituted alkyl,
cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl,
alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, acyl, alkylsulfonyl, arylsulfonyl, heterocyclic, or substituted heterocyclic, where ifY3 comprises
alkenyl or alkynyl, the site ofunsaturation is not conjugated
with the oxygen; NY4Ys where Y4 and ys are each independently selected from hydrogen, alkyl, substituted alkyl,
cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl,
alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, acyl, alkyisulfonyl, arylsulfonyl, heterocyclic, or substituted heterocyclic, where if Y4 or ys
comprises alkenyl or alkynyl, the site of unsaturation is not
conjugated with the nitrogen; SY6, where Y 6 is selected
from hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, alkylaryl, substituted
alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl,
heterocyclic, or substituted heterocyclic, and where if Y 6
comprises alkenyl or alkynyl, the site of unsaturation is not
conjugated with the sulfur.
R1 and R 2 are each independently five or six membered
nitrogen containing rings as shown in formulas (IIA) and
(liB).

sulfur or oxygen or joins a ring atom with an unsaturated
bond and is a nitrogen, both Rs and R 6 are absent.
A 3 is carbon, nitrogen, sulfur or oxygen, provided that
when A 3 is a carbon and joins a ring atom with an unsaturated bond or is a nitrogen, R7 is absent, and when A 3 is
sulfur or oxygen or joins a ring atom with an unsaturated
bond and is a nitrogen, both R7 and R 8 are absent.
A4 is carbon, nitrogen, sulfur or oxygen, provided that
when A4 is a carbon and joins a ring atom with an unsaturated bond or is a nitrogen, R9 is absent, and when A4 is
sulfur or oxygen or joins a ring atom with an unsaturated
bond and is a nitrogen, both R9 and RIO are absent.
As is carbon, nitrogen, sulfur or oxygen, provided that
when As is a carbon and joins a ring atom with an unsaturated bond or is a nitrogen, R 11 is absent, and when As is
sulfur or oxygen or joins a ring atom with an unsaturated
bond and is a nitrogen, both R 11 and R 12 are absent.
A 6 is carbon, nitrogen, sulfur or oxygen, provided that
when A 6 is a carbon and joins a ring atom with an unsaturated bond or is a nitrogen, R 14 is absent, and when A 6 is
sulfur or oxygen or joins a ring atom with an unsaturated
bond and is a nitrogen, both R 14 and R 1s are absent.
A 7 is carbon, nitrogen, sulfur or oxygen, provided that
when A 7 is a carbon and joins a ring atom with an unsaturated bond or is a nitrogen, R 16 is absent, and when A 7 is
sulfur or oxygen or joins a ring atom with an unsaturated
bond and is a nitrogen, both R 16 and R 17 are absent.
A 8 is carbon, nitrogen, sulfur or oxygen, provided that
when A 8 is a carbon and joins a ring atom with an unsaturated bond or is a nitrogen, R 18 is absent, and when A 8 is
sulfur or oxygen or joins a ring atom with an unsaturated
bond and is a nitrogen, both R 18 and R 19 are absent.
A 9 is carbon, nitrogen, sulfur or oxygen, provided that
when A 9 is a carbon and joins a ring atom with an unsaturated bond or is a nitrogen, R 20 is absent, and when A 9 is
sulfur or oxygen or joins a ring atom with an unsaturated
bond and is a nitrogen, both R 20 and R 21 are absent.
R 13 or R 22 is absent when any of the bonds to the
ammonium nitrogen is unsaturated, and R 13 or R 22 is a
straight chain or branched alkyl group of four carbons or
fewer when all of the bonds to the ammonium nitrogen are
saturated.
R3, R4, Rs, R6, R7, R8, R9, RIO, Ru, andR12, orR14' R1s,
R 16 , R 17 , R 18 , R 19 , R 20 , and R21 , when present, are each
independently selected from hydrogen, alkyl, substituted
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl,
alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, heterocyclic, substituted heterocyclic,
halo, cyano, nitro, orR4 andRs togetherwithA 1 andA2, or
Rs and R7 together withA2 andA3, or R 1s and R 16 together
with A 6 and A 7, or R 16 and R 18 together with A 7 and A 8
independently form a three to eight member cyclolkane,
substituted cycloalkane, cycloalkene, substituted cycloalkene, aryl, substituted aryl, heterocycle with one to three
hetero atoms of nitrogen, oxygen or sulfur in the ring, or
substituted heterocycle with one to three hetero atoms of
nitrogen, oxygen or sulfur in the ring; and when all of the
bonds to the ring ammonium nitrogen are saturated, then any
ofR3, R4, Rs, R6, R7, R8, R9, RIO, Ru, Rl2, Rl3, R14, R1s,
R 16 , R 17 , R 18 , R 19 , R 20 , R 21 or R 22 which is attached to the
ammonium nitrogen is a straight or branched alkyl group of
four carbons or fewer.
In another embodiment, a composition is provided comprising a pharmaceutically acceptable carrier and a compound as described above.
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A 1 is carbon, nitrogen, sulfur or oxygen, provided that
when A 1 is a carbon and joins a ring atom with an unsaturated bond or is a nitrogen, R3 is absent, and when A 1 is
sulfur or oxygen or joins a ring atom with an unsaturated
bond and is a nitrogen, both R3 and R4 are absent.
A 2 is carbon, nitrogen, sulfur or oxygen, provided that
when A 2 is a carbon and joins a ring atom with an unsaturated bond or is a nitrogen, Rs is absent, and when A 2 is

60

65
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In another embodiment, a method is provided for selectively modulating the function of a nicotinic acetylcholine
receptor comprising administering a therapeutically effective amount of a compound as described above to a mammalian subject in need thereof.
In another embodiment, a method is provided for modulating, preventing, treating and/or reversing acute, chronic or
cancer pain of central and/or peripheral origin that is
referred to as nociceptive, neuropathic, visceral, inflammatory or somatic in nature comprising administering a therapeutically effective amount of a compound as described
above to a mmalian subject in need thereof.

The term "lower alkyl" refers to straight or branched
chain alkyl radicals having in the range of 1 to 4 carbon
atoms.
The term "alkyl" refers to straight or branched chain alkyl
radicals having 1 to 19 carbon atoms, and "substituted alkyl"
refers to alkyl radicals further bearing one or more substituents including, but not limited to, hydroxy, alkoxy (of a
lower alkyl group), mercapto (of a lower alkyl group), aryl,
heterocyclic, halogen, trifluoromethyl, cyano, nitro, amino,
carboxyl, carbamate, sulfonyl, and sulfonamide.
The term "cycloalkyl" refers to cyclic ring-containing
moieties containing 3 to 8 carbon atoms, and "substituted
cycloalkyl" refers to cycloalkyl moieties further bearing one
or more substituents as set forth above.
The term "alkenyl" refers to straight or branched chain
hydrocarbyl groups having at least one carbon-carbon
double bond and having 2 to 19 carbon atoms, and "substituted alkenyl" refers to alkenyl groups further bearing one or
more substituents as set forth above.
The term "alkynyl" refers to straight or branched chain
hydrocarbyl moieties having at least one carbon-carbon
triple bond and having 2 to 19 carbon atoms, and "substituted alkynyl" refers to alkynyl moieties further bearing one
or more substituents as set forth above.
The term "aryl" refers to aromatic groups having 6 to 24
carbon atoms, and "substituted aryl" refers to aryl groups
further bearing one or more substituents as set forth above.
The term "alkylaryl" refers to alkyl-substituted aryl
groups, and "substituted alkylaryl" refers to alkylaryl groups
further bearing one or more substituents as set forth above.
The term "arylalkyl" refers to aryl-substituted alkyl
groups, and "substituted arylalkyl" refers to arylalkyl groups
further bearing one or more substituents as set forth above.
The term "arylalkenyl" refers to aryl-substituted alkenyl
groups, and "substituted arylalkenyl" refers to arylalkenyl
groups further bearing one or more substituents as set forth
above.
The term "arylalkynyl" refers to aryl-substituted alkynyl
groups, and "substituted arylalkynyl" refers to arylalkynyl
groups further bearing one or more substituents as set forth
above.
The term "heterocyclic" refers to cyclic moieties containing one or more heteroatoms as part of the ring structure and
having 3 to 24 carbon atoms, and "substituted heterocyclic"
refers to heterocyclic moieties further bearing one or more
substituents as set forth above.
The term "acyl" refers to alkyl-carbonyl groups, and
"substituted acyl" refers to acyl groups further bearing one
or more substituents as set forth above.
The term "halogen" refers to fluoride, chloride, bromide
or iodide groups.
It is understood that in all substituted groups defined
above, polymers arrived at by defining substituents with
further substituents to themselves (e.g. substituted aryl having a substituted aryl group as a substituent which is itself
substituted with a substituted aryl group, etc.) are not
intended for inclusion herein. In such cases, the maximum
number of such substituents is three. That is to say that each
of the above definitions is constrained by a limitation that,
for example, substituted aryl groups are limited to -substituted aryl-(substituted aryl)-substituted aryl.
Compounds of the present invention are his-quaternary
ammonium salts disclosed in PCT/US2007/011635, filed
May 14, 2007 corresponding to Formula (1):

BRIEF DESCRIPTION OF DRAWINGS
FIG. 1 shows the time course of the analgesic effects of
ZZ-1-61 C in the rodent formalin persistent inflmatory
pain model following intraperitoneal administration. Data
are mean±SEM (n=6 rats/dose).
FIG. 2 shows the dose response of the analgesic effects of
ZZ-1-61C in the rodent persistent inflmatory pain model
following intraperitoneal administration. Data are mean
S.E.M. (n=6 rats/dose).
FIG. 3 provides a graph showing the anti-hyperalgesic
effects of ZZ-1-61C in the paw pressure test.
FIG. 4 provides a graph showing the anti-allodynic effect
of ZZ-1-61C in a rodent model of chemotherapy-induced
pain by determining paw withdrawal frequency.
FIG. 5 provides a graph showing the effect of ZZ-1-61C
on the toxicity (body weight loss) of vineristine in a rodent
model of chemotheraopy-induced pain.
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Before the present compositions and methods are
described, it is to be understood that the invention is not
limited to the particular methodologies, protocols, assays,
and reagents described, as these may vary. It is also to be
understood that the terminology used herein is intended to
describe particular embodiments of the present invention,
and is in no way intended to limit the scope of the present
invention as set forth in the appended claims.
It must be noted that as used herein and in the appended
claims, the singular forms "a," "an," and "the" include plural
references unless the context clearly dictates otherwise.
Unless defined otherwise, all technical and scientific
terms used herein have the same meanings as commonly
understood by one of ordinary skill in the art to which this
invention belongs. All publications cited herein are incorporated herein by reference in their entirety for the purpose
of describing and disclosing the methodologies, reagents,
and tools reported in the publications that might be used in
connection with the invention. Nothing herein is to be
construed as an admission that the invention is not entitled
to antedate such disclosure by virtue of prior invention.
The term "agonist" refers to a substance which interacts
with a receptor and increases or prolongs a physiological
response (i.e. activates the receptor).
The term "partial agonist" refers to a substance which
interacts with and activates a receptor to a lesser degree than
an agonist.
The term "antagonist" refers to a substance which interacts with and decreases the extent or duration of a physiological response of that receptor.
The terms "disorder," "disease," and "condition" are used
inclusively and refer to any status deviating from normal.
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X 18 and X 28 are each independently an organic or
inorganic anion.
Q 1s selected from phenylene, biphenylene,
-CH=CH-, ---CH=CH---CH=CH-, ---C C-,
-C==C---C C-, ---O-(CH 2 ) 2 -0-, and - 0 (CH 2 ) 2 -0-(CH 2 ) 2 ---0-.
L 1 and L 2 are each independently selected from alkyl,
substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl,
substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, heterocyclic, substituted
heterocyclic; SOY\ S0 2 Y\ S0 2 0Y 1 or S0 2 NHY 1 where
Y 1 is selected from hydrogen, lower alkyl, alkenyl, alkynyl
or aryl, and where Y 1 is not hydrogen in SOY 1 and ifY 1 is
alkenyl or alkynyl, the site ofunsaturation is not conjugated
with a heteroatom; COY2 , where Y 2 is selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted
cycloalkyl, alkoxy, alkenyl, substituted alkenyl, alkynyl,
substituted alkynyl, aryl, substituted aryl, aryloxy, alkylaryl,
substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, heterocyclic, or substituted heterocyclic, and
where ifY2 comprises alkenyl or alkynyl, the site ofunsaturation is not conjugated with the carbonyl group; OY3 ,
where Y 3 is selected from hydrogen, alkyl, substituted alkyl,
cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl,
alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, acyl, alkylsulfonyl, arylsulfonyl, heterocyclic, or substituted heterocyclic, where ifY3 comprises
alkenyl or alkynyl, the site ofunsaturation is not conjugated
with the oxygen; NY4 Ys, where Y 4 and ys are each independently selected from hydrogen, alkyl, substituted alkyl,
cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl,
alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, acyl, alkylsulfonyl, arylsulfonyl, heterocyclic, or substituted heterocyclic, where if Y 4 or ys
comprises alkenyl or alkynyl, the site of unsaturation is not
conjugated with the nitrogen; SY 6 , where Y 6 is selected
from hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, alkylaryl, substituted
alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl,
heterocyclic, or substituted heterocyclic, and where if Y 6
comprises alkenyl or alkynyl, the site of unsaturation is not
conjugated with the sulfur.
R 1 and R 2 are each independently five or six membered
nitrogen containing rings as shown in formulas (IIA) and
(liB).

-continued
(liB)
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A 1 is carbon, nitrogen, sulfur or oxygen, provided that
when A 1 is a carbon and joins a ring atom with an unsaturated bond or is a nitrogen, R3 is absent, and when A 1 is
sulfur or oxygen or joins a ring atom with an unsaturated
bond and is a nitrogen, both R3 and R4 are absent.
A 2 is carbon, nitrogen, sulfur or oxygen, provided that
when A 2 is a carbon and joins a ring atom with an unsaturated bond or is a nitrogen, Rs is absent, and when A 2 is
sulfur or oxygen or joins a ring atom with an unsaturated
bond and is a nitrogen, both Rs and R 6 are absent.
A 3 is carbon, nitrogen, sulfur or oxygen, provided that
when A 3 is a carbon and joins a ring atom with an unsaturated bond or is a nitrogen, R7 is absent, and when A 3 is
sulfur or oxygen or joins a ring atom with an unsaturated
bond and is a nitrogen, both R7 and R 8 are absent.
A 4 is carbon, nitrogen, sulfur or oxygen, provided that
when A 4 is a carbon and joins a ring atom with an unsaturated bond or is a nitrogen, R9 is absent, and when A 4 is
sulfur or oxygen or joins a ring atom with an unsaturated
bond and is a nitrogen, both R9 and R 10 are absent.
As is carbon, nitrogen, sulfur or oxygen, provided that
when As is a carbon and joins a ring atom with an unsaturated bond or is a nitrogen, R 11 is absent, and when As is
sulfur or oxygen or joins a ring atom with an unsaturated
bond and is a nitrogen, both R 11 and R 12 are absent.
A 6 is carbon, nitrogen, sulfur or oxygen, provided that
when A 6 is a carbon and joins a ring atom with an unsaturated bond or is a nitrogen, R 14 is absent, and when A 6 is
sulfur or oxygen or joins a ring atom with an unsaturated
bond and is a nitrogen, both R 14 and R 1 s are absent.
A 7 is carbon, nitrogen, sulfur or oxygen, provided that
when A 7 is a carbon and joins a ring atom with an unsaturated bond or is a nitrogen, R 16 is absent, and when A 7 is
sulfur or oxygen or joins a ring atom with an unsaturated
bond and is a nitrogen, both R 16 and R 17 are absent.
A 8 is carbon, nitrogen, sulfur or oxygen, provided that
when A 8 is a carbon and joins a ring atom with an unsaturated bond or is a nitrogen, R 18 is absent, and when A 8 is
sulfur or oxygen or joins a ring atom with an unsaturated
bond and is a nitrogen, both R 18 and R 19 are absent.
A 9 is carbon, nitrogen, sulfur or oxygen, provided that
when A 9 is a carbon and joins a ring atom with an unsaturated bond or is a nitrogen, R 20 is absent, and when A 9 is
sulfur or oxygen or joins a ring atom with an unsaturated
bond and is a nitrogen, both R 20 and R 21 are absent.
R 13 or R 22 is absent when any of the bonds to the
ammonium nitrogen is unsaturated, and R 13 or R 22 is a
straight chain or branched alkyl group of four carbons or
fewer when all of the bonds to the monium nitrogen are
saturated.
R3 , R4 , Rs, R 6 , R7 , R 8 , R9 , R 10 , R 11 , andR 12 , orR 14, R 1 s,
R 16 , R 17 , R 18 , R 19 , R 20 , and R21 , when present, are each
independently selected from hydrogen, alkyl, substituted
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl,
alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, sub-
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stituted arylalkynyl, heterocyclic, substituted heterocyclic,
halo, cyano, nitro, or R4 and R5 together withA 1 andA2, or
R5 and R 7 together withA2 andA3, or R 15 and R 16 together
with A 6 and A 7 , or R 16 and R 18 together with A 7 and A 8
independently form a three to eight member cyclolkane,
substituted cycloalkane, cycloalkene, substituted cycloalkene, aryl, substituted aryl, heterocycle with one to three
hetero atoms of nitrogen, oxygen or sulfur in the ring, or
substituted heterocycle with one to three hetero atoms of
nitrogen, oxygen or sulfur in the ring; and when all of the
bonds to the ring ammonium nitrogen are saturated, then any
ofR3, R4, R5, R 6, R 7 , R 8, R9, R 10 , R 11 , R 12 , R 13 , R 14, R 15 ,
R 16 , R 17 , R 18 , R 19 , R 20 , R 21 or R 22 which is attached to the
ammonium nitrogen is a straight or branched alkyl group of
four carbons or fewer.
For example, R 1 and R 2 include pyrrole, pyrrolidine,
pyrazole, imidazole, oxazole, isoxazole, thiazole, isothiazole, oxadiazole, oxatriazole, dioxazole, 1,2,3-triazole, 1,2,
4-triazole, pyridine, pyrimidine, piperidine, quinoline, tetrahydroquinoline, isoquinoline, tetrahydroisoquinoline,
pyrazine, piperazine, pyridazine, tnazme, oxazine,
phenazine, pteridine, benzoxazine, phthalazine, naphthridine, quinoxaline, quinazoline, ciunoline, quinuclidine, benzothiazole, benzisoxazole, benzoxazole, indazole, pyranopyrrole, cyclopentapyridine, benzimidazole, isoindole,
3H-indole, indolene and triazine.
As another example, R3, R4, R5, R 6, R 7 , R 8, R9, RIO, R 11 ,
12
R , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , and R 21 , include
hydrogen, methyl, ethyl, propyl, butyl, hydroxymethyl,
hydroxyethyl, hydroxypropyl, trifluoromethyl, chloro,
bromo, phenyl, pyrrolidine, N-alkyl pyrrolidine (for
example where the alkyl chain is methyl, ethyl or propyl),
unsaturated pyrrolidine, unsaturated N-alkyl pyrrolidine (for
example where the alkyl chain is methyl, ethyl or propyl),
aziridine, N-methyl aziridine, azetidine, N-methyl azetidine,
unsaturated azetidine, unsaturated N-methyl azetidine, piperidine, N-methyl piperidine, unsaturated piperidine,
unsaturated N-methyl piperidine, azepane, N-methyl
azepane, unsaturated azepane, unsaturated N-methyl
azepane, azocane, N-methyl azocane, unsaturated azocane,
unsaturated N-methyl azocane, 1-aza-bicyclo [3.2.1] octane,
1-aza-bicyclo [2.2.1] heptane, 8-methyl-8-aza-bicyclo
[3.2.1] octane, 1-aza-tricyclo [3.3.1.13,7] decane, methyl
cycloalkyl, methyl substituted cycloalkyl, methyl pyrrolidine, methyl N-alkyl pyrrolidine (for example where the
alkyl chain is methyl, ethyl or propyl), methyl unsaturated
pyrrolidine, methyl unsaturated N-alkyl pyrrolidine (for
example where the alkyl chain is methyl, ethyl or propyl),
methyl aziridine, methyl N-methyl aziridine, methyl azetidine, methyl N-methyl azetidine, methyl unsaturated azetidine, methyl unsaturated N-methyl azetidine, methyl piperidine, methyl N-methyl piperidine, methyl unsaturated
piperidine, methyl unsaturated N-methyl piperidine, methyl
azepane, methyl N-methyl azepane, methyl unsaturated
azepane, methyl unsaturated N-methyl azepane, methyl azocane, methyl N-methyl azocane, methyl unsaturated azocane, methyl unsaturated N-methyl azocane, methyl-1-azabicyclo [3.2.1] octane, methyl-1-aza-bicyclo [2.2.1]
heptane, 8-methyl-8-aza-bicyclo [3 .2.1] octane, and methyl1-aza-tricyclo [3.3.1.13'7] decane.
As a further example, when R4 and R5 together with A 1
andA2, or R5 and R 7 togetherwithA2 andA3, or R 15 andR 16
togetherwithA 6 andA7 , or R 16 andR 18 togetherwithA7 and
A 8 independently form a three to eight-membered ring, that
ring may be a heterocycle containing up to three hetero
atoms (for example nitrogen, oxygen or sulfur) in the ring,
and further may be substituted with one or more substitu-

ents. For example, possible rings include benzene, pyridine,
pyran, indene, isoindene, benzofuran, isobenzofuran, benzo
[b ]thiophene, benzo[ c]thiophene, indole, indolenine, isoindole, cyclopental[b ]pyridine, pyrano[3,4-b ]pynrole, indazole, indoxazine, benzoxazole, anthranil, naphthalene,
tetralin, decalin, chromene, coumarin, chroman-4-one, isocoumarin, isochromen-3-one, quinoline, isoquinoline, cinnoline, quinazoline, naphthyrdine, pyrido[3,4-b ]-pyridine,
pyridol[3,2-b ]pyridine, pyrido[ 4,3,-b ]-pyridine, benzoxazine, anthracene, phenanthrene, phenalene, fluorene, carazole, xanthene, acnidine, octahydro-[1]pyridine, 1-methyloctahydro-[1]pyridine,
octahydroindole,
1-methyloctahydro-indole, octahydro-cyclopenta[b]pyrrole,
1-methyloctahydro-cyclopenta[b]pyrrole, decahydroquinoline, and 1-methyldecahydroquinoline.
X 18 and X 28 , for example F-, Cl-, Br-, I-, N0 2-, HS04-,
S04-, HP04-, P042-, methanesulfonate, trifluromethane
sulfate, p-toluenesulfonate, benzenesulfonate, salicylate,
proprionate, ascorbate, aspartate, fumarate, galactarate,
maleate, citrate, glutamate, glycolate, lactate, malate,
maleate, tartrate, oxalate, succinate, or similar pharmaceutically acceptable organic acid addition salts, including the
pharmaceutically acceptable salts listed in the Journal of
Pharmaceutical Sciences volume 66, page 2, 1977, which
are hereby incorporated by reference. The above salt forms
may be in some cases hydrates or solvates with alcohols and
other solvents.
In a compound of Formula (I), preferably R 1 and R2 are
substituted, six-membered, aromatic rings. More preferably,
R 1 and R2 are substituted pyridinium rings. In other preferred embodiments, R 1 and R2 are quinoline, isoquinoline,
tetrahydroquinoline or tetrahydroisoquinoline.
In a compound of Formula (I), preferably R 13 is absent.
In a compound of Formula (I), preferably R3, R4, R5, R 6,
R7 , R 8, R9, RIO, R 11 or R 12 is absent or is hydrogen, alkyl,
hydroxyalkyl, halo, phenyl or 1-alkyl-2-pyrrolidinyi. More
preferably, R3, R4, R5, R 6, R7 , R 8, R9, RIO, R 11 or R 12 is
absent or is hydrogen, methyl, ethyl, propyl, butyl,
hydroxymethyl, hydroxyethyl, hydroxypropyl, bromo, phenyl or 1-methyl-2-pyrrolidinyl.
In a compound of Formula (I), preferably Q is phenylene,
---CH=CH---CH=CH-,
---C Cbiphenylene,
C C- and ---O-(CH 2)2-0-(CH 2)2-0-.
In a compound of Formula (I), preferably L 1 and L 2 are
the same and are ---CH 2- , -(CH 2)2- , -(CH 2)3- ,
-(CH 2)4- , ---C C-, ---CH 2---C C- or -(CH 2)2C C-.
In a compound of Formula (I), preferably X 1 SYMBOL
and X 2 SYMBOL are halogens. More preferably, X 1 SYMBOL and X 2 SYMBOL are chloride or bromide.
In another embodiment, the compound of Formula (I) is
defined wherein -L 1-Q-L 2- is -(CH 2)4-1,2-phenylene(CH2)4-, -(CH 2)4-1,3-phenylene-(CH 2)4- , -(CH 2k1,
4-phenylene-(CH 2)3- ,
-(CH 2)2-4,4'-biphenylene(CH2)2-,
-(CH 2)2---C C-1,2-phenylene-C C(CH2)2-,
-(CH 2)2---C C-1,3-phenylene-C C(CH2)2-, -CH 2-C C-1,4-phenylene-C C-CH 2- ,
---C C-4,4'-biphenylene-C C-,
-(CH 2)3CH=CH-CH=CH-(CH2)3-,
-(CH 2)3---C CC C-(CH 2)3- or ---CH 2---0-(CH 2)2---0-(CH 2)2O---CH 2- , R 1 and R 2 are pyridinium rings, R3 is hydrogen
or methyl, R5 is hydrogen, methyl, ethyl, butyl, phenyl,
1-methyl-2-pyrrolidinyl,
bromo,
hydroxymethyl
or
hydroxypropyl, R7 is hydrogen or methyl, R9 is hydrogen or
methyl, R 11 is hydrogen, and X 1 and X 2 are chloride or
bromide.
In another embodiment, the compound of Formula (I) is
defined wherein -L 1-Q-L 2- is -(CH 2)4-1,2-phenylene-
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dibro(CH 2)4 - , -(CH 2)4 -1,3-phenylene-(CH 2)4 - , -(CH 2k1,
1,2-bis-[ 5-(2-methy1-pyridinium)-pentyl]-benzene
4-phenylene-(CH 2)3- ,
-(CH 2)2-4,4'-biphenylenemide;
(CH2)2-,
-(CH 2)2---C C-1,2-phenylene-C Cdibro1,2-bis-[5-(3-methyl-pyridinium)-pentyl]-benzene
(CH2)2-,
-(CH 2)2---C C-1,3-phenylene-C Cmide;
(CH2)2-, ---CH 2-C C-1,4-phenylene-C C-CH 2- , 5 1,2-bis-[ 5-(4-methyl-pyridinium)-pentyl]-benzene
dibro-C==C-4,4'-biphenylene-C C-,
-(CH 2)3mide;
CH=CH-CH=CH-(CH2)3-,
-(CH 2)3---C C1,2-bis-[ 5-(2,4-dimethyl-pyridinium)-penty1]-benzene
C C-(CH 2)3- or -CH 2-0-(CH 2)2---0-(CH 2)2dibromide;
2
1
0-CH2-, R and R are quinoline, isoquinoline,
1
,2-bis-[
5-(3 ,4-dimethyl-pyridinium)-penty1]-benzene
tetrahydroquinoline or tetrahydroisoquinoline, and X 1 and 10
dibromide;
2
X are chloride or bromide.
1,2-bis-[ 5-(3,5-methyl-pyridinium)-pentyl]-benzene dibroExemplary compounds of the present invention include:
mide;
cis-cis-N,N'-(dodeca-5, 7-diene-1, 12-diyl)-bis-[3-(2'-5-11
,2-bis-(
5-quinolinium-pentyl)-benzene dibromide;
methyl-pyrrolidin-2-yl)-pyridinium] dibromide;
cis-cis-N,N'-(dodeca-5, 7-diene-1, 12-diyl)-bis-{ 2-methyl-1- 15 1,2-bis-( 5-isoquinolinium -pentyl)-benzene dibromide;
1,2-bis-( 5-S-nicotinium-pentyl)-benzene dibromide;
pyridinium) dibromide;
1,2-bis-[ 5-(3-n-butyl-pyridinium)-pentyl]-benzene
dibrocis-cis-N,N'-(dodeca-5, 7-diene-1, 12-diyl)-bis-(3-methylmide;
pyridinium) dibromide;
dibro1,2-bis-[ 5-(3-bromo-pyridinium)-penty!]-benzene
cis-cis-N,N'-(dodeca-5, 7-diene-1 s 12-diyl)-bis-(4-methylmide;
pyridinium) dibromide;
20
1,2-bis-( 5-pyridinium-pentyl)-benzene dibromide;
cis-cis-N,N'-(dodeca-5, 7-diene-1, 12-diyl)-bis-(5,6, 7 ,8-tetra1,3-bis-[ 5-(2-methyl-pyridinium)-pent-1-ynyl]-benzene
hydro-quinolinium) dibromide;
cis-cis-N,N'-(dodeca-5, 7-diene-1, 12-diyl)-bis-(5,6, 7 ,8-tetradibromide;
1,3-bis-[ 5-(3-methyl-pyridinium)-pent-1-ynyl]-benzene
hydro-isoquinolinium) dibromide;
cis-cis-N,N'-(dodeca-5, 7-diene-1, 12-diyl)-bis-(2,4-dim25
dibromide;
1,3-bis-[ 5-(4-methyl-pyridinium)-pent-1-ynyl]-benzene
ethyl-pyridinium) dibromide;
cis-cis-N,N'-(dodeca-5, 7-diene-1, 12-diyl)-bis-(3,4-dimdibromide;
1,3-bis-[ 5-(2,4-dimethyl-pyridinium)-pent-1-ynyl]-benzene
ethyl-pyridinium) dibromide;
cis-cis-N,N'-(dodeca-5, 7-diene-1, 12-diyl)-bis-(3,5-dimdibromide;
30 1,3-bis-[ 5-(3,4-dimethyl-pyridinium)-pent-1-ynyl]-benzene
ethyl-pyridinium) dibromide;
N,N'-[1 ,4-phenylenedi-(4-butanyl)]-bis-[3-(2'-S-1-methyldibromide;
1,3-bis-[ 5-(3,5-dimethyl-pyridinium)-pent-1-ynyl]-benzene
pyrrolidin-2-y 1)- pyridinium] dibromide;
N,N'-[1 ,4-phenylenedi-(4-butanyl)]-bis-(2-methylpyridibromide;
1,3-bis-( 5-quinolinium-pent-1-ynyl)-benzene dibromide;
dinium) dibromide;
35 1,3-bis-(5-isoquinolinium-pent-1-ynyl)-benzene dibromide;
N,N'-[1 ,4-phenylenedi-(4-butanyl)]-bis-(3-methylpyri1,3-bis-( 5-S-nicotinium-pent-1-ynyl)-benzene dibromide;
dinium) dibromide;
1,3-bis-[ 5-(3-n-butyl-pyridinium)-pent-1-ynyl]-benzene
N,N'-[1 ,4-phenylenedi-(4-butanyl)]-bis-( 4-methylpyridinium) dibromide;
dibromide;
N,N'- [ 1,4-pheny lenedi -(4-butany I) ]-bis-(3-ethylpyridinium)
1,3-bis-[ 5-(3-phenyl-pyridinium)-pent-1-ynyl]-benzene
dibromide;
dibromide;
40
N,N'-[1 ,4-phenylenedi-(4-butanyl)]-bis-( 5,6, 7,8-tetrahydro1,3-bis-[ 5-pyridinium-pent-1-ynyl)-benzene dibromide;
1,3-bis-[ 5-(2-methyl-pyridinium)-pentyl]-benzene
dibroquinolinium) dibromide;
N,N'-[1 ,4-phenylenedi-(4-butanyl)]-bis-( 5,6, 7,8-tetrahymide;
1,3-bis-[5-(3-methyl-pyridinium)-pentyl]-benzene
dibrodroisoquinolinium) dibromide;
N,N'-[1 ,4-phenylenedi-(4-butanyl)]-bis-[3-(3-hydroxy-pro- 45
mide;
1,3-bis-[5-(4-methyl-pyridinium)-pentyl]-benzene
dibropyl)-pyridinium] dibromide;
mide;
N,N'- [ 1,4-pheny lenedi -(4-butany I) ]-bis-(2,4-dimethylpyri1,3 -bis-[ 5-(2,4-dimethyl-pyridinium)-penty1]-benzene
dinium) dibromide;
dibromide;
N,N'-[1 ,4-phenylenedi-{ 4-butanyl) ]-bis-(3,4-dimethylpyridinium) dibromide;
50 1,3-bis-[ 5-(3,4-dimethyl-pyridinium)-pentyl]-benzene
N,N'-[1 ,4-phenylenedi-{ 4-butanyl) ]-bis-(3,5-dimethylpyridibromide;
dinium) dibromide;
1,3 -bis-[ 5-(3 ,5 -dimethyl-pyridinium)-penty1]-benzene
1,2-bis-[ 5-(2-methyl-pyridinium)-pent-1-ynyl]-benzene
dibromide;
dibromide;
1,3-bis-( 5-quinolinium-pentyl)-benzene dibromide;
1,2-bis-[ 5-(3-methyl-pyridinium)-pent-1-ynyl]-benzene
55 1,3-bis-(5-isoquinolinium-pentyl)-benzene dibromide;
N,N'-[ (1, 1'-biphenyl)-4,4'-di-(3-propanyl) ]-bis-[3-(2'-S-1dibromide;
1,2-bis-[ 5-( 4-methyl-pyridinium)-pent-1-ynyl]-benzene
methyl-pyrrolidin-2-yl)-pyridinium] dibromide;
N,N'-[ (1, 1'-biphenyl)-4,4'-di-(3-propanyl) ]-bis-(3,5-dimethdibromide;
1,2-bis-[ 5-(2,4-dimethyl-pyridinium)-pent-1-ynyl]-benzene
ylpyridinium) dibromide;
dibromide;
60 N,N'-[ (1, 1'-biphenyl)-4,4'-di-(3-propanyl) ]-bis-(3,4-dimeth1,2-bis-[ 5-(3,4-dimethyl-pyridinium)-pent-1-ynyl]-benzene
ylpyridinium) dibromide;
dibromide;
N,N'-[ (1, 1'-biphenyl)-4,4'-di-(3-propanyl) ]-bis-(2,4-dimeth1,2-bis-[ 5-(3,5-dimethyl-pyridinium)-pent-1-ynyl]-benzene
ylpyridinium) dibromide;
N,N'-[ (1, 1'-biphenyl)-4,4'-di-(3-propanyl) ]-bis-[3-(3-hydibromide;
1,2-bis-( 5-quinolinium-pent-1-ynyl)-benzene dibromide;
65
droxy -propyl)-pyridinium] dibromide;
1,2-bis-( 5-isoquinolinium-pent-1-ynyl)-benzene dibromide;
N,N'-[ (1, 1'-biphenyl)-4,4'-di-(3-propanyl) ]-bis-[ 5,6, 7,8-tet1,2-bis-( 5-S-nicotinium -pent-1-ynyl)-benzene dibromide;
rahydroquinolinium]dibromide;
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N,N'-[ (1, 1'-biphenyl)-4,4'-di -(3-propanyl)]-bis-[ 5,6, 7,8-tetrahydroisoquinolinium ]dibromide;
N,N'-[ (1, 1'-biphenyl)-4,4'-di -(3-propanyl)]-bis-( 4-methylpyridinium) dibromide;
N,N'-[ (1, 1'-biphenyl)-4,4'-di -(3-propanyl)]-bis-(3-methyipyridinium) dibromide;
N,N'-[ (1, 1'-biphenyl)-4,4'-di -(3-propanyl)]-bis-(2-methylpyridinium) dibromide;
N,N'-{ 2,2'-[ oxybis(2, 1-ethandiyloxy)]bis-ethyl }-bis-[3-(2'S-1-methyl-pyrrolidin-2-yl)-pyridinium]dichloride;
N,N'-{ 2,2'-[ oxybis(2, 1-ethandiyloxy)]bis-ethyl }-bis(2methylpyridinium) dichloride;
N,N'-{ 2,2'-[ oxybis(2, 1-ethandiyloxy)]bis-ethyl }-bis(3methylpyridinium) dichloride;
N,N'-{ 2,2'-[ oxybis(2, 1-ethandiyloxy)]bis-ethyl }-bis(4methylpyridinium) dichloride;
N,N'-{ 2,2'-[ oxybis(2, 1-ethandiyloxy)]bis-ethyl }-bis(5,6, 7,
8-tetrahydroquinolinium) dichloride;
N,N'-{ 2,2'-[ oxybis(2, 1-ethandiyloxy)]bis-ethyl }-bis(5,6, 7,
8-tetrahydroisoquinolinium) dichloride;
N,N'-{ 2,2'-[ oxybis(2, 1-ethandiyloxy)]bis-ethyl }-bis-[3-(3hydroxypropy1)-pyridinium] dichloride;
N,N'-{ 2,2'-[ oxybis(2, 1-ethandiyloxy)]bis-ethyl }-bis(3-hydroxymethylpyridinium) dichloride;
N,N'-{ 2,2'-[ oxybis(2, 1-ethandiyloxy)]bis-ethyl }-bis(2,4-dimethylpyridinium) dichloride;
N,N'-{ 2,2'-[ oxybis(2, 1-ethandiyloxy)]bis-ethyl }-bis(3,4-dimethylpyridinium) dichloride;
N,N'-{ 2,2'-[ oxybis(2, 1-ethandiyloxy)]bis-ethyl }-bis(3,5-dimethylpyridinium) dichloride;
N,N'-(5, 7 -dodecadiyn-1, 12-diyl)-bis-(2-methylpyridinium)
dichloride;
N,N'-(5, 7 -dodecadiyn-1, 12-diyl)-bis-(3-methylpyridinium)
dichloride;
N,N'-(5, 7 -dodecadiyn-1, 12-diyl)-bis-(4-methylpyridinium)
dichloride;
N,N'-(5, 7 -dodecadiyn-1, 12-diyl)-bis-(3,4-dimethylpyridinium) dichloride;
N,N'-(5, 7 -dodecadiyn-1, 12-diyl)-bis-(3,5-dimethylpyridinium) dichloride;
N,N'-(5, 7 -dodecadiyn-1, 12-diyl)-bis-(5,6, 7 ,8-tetrahydroisoquinolinium) dichloride;
N,N'-[ (1 ,4-phenylene)-bis-(4-butynyl)]-bis-(3-methyl-pyridinium) dibromide;
N,N'-[ (1 ,4-phenylene)-bis-(4-butynyl)]-bis-( 4-methyl-pyridinium) dibromide;
N,N'-[ (1 ,4-phenylene)-bis-(4-butynyl)]-bis-( 5,6, 7,8-tetrahydroisoquiolinium) dibromide;
N,N'-[ (1 ,4-phenylene)-bis-(4-butynyl)]-bis-(3,4-dimethylpyridinium) dibromide;
N,N'-[ (1 ,4-phenylene)-bis-(4-butynyl)]-bis-(3,5-dimethylpyridiniuim) dibromide;
N,N'-[ (1, 1'-biphenyl)-4,4'-di -(1-propyn-3-yl) ]-bis-(3-methylpyridinium) dibromide;
N,N'-[ (1, 1'-biphenyl)-4,4'-di -(1-propyn-3-yl) ]-bis-(4-methylpyridinium) dibromide;
N,N'-[ (1, 1'-biphenyl)-4,4'-di -(1-propyn-3-yl) ]-bis-(3,4-dimethylpyridinium) dibromide.
The compounds of the present invention may contain one
or more stereocenters. The invention includes all possible
diastereomers and all enantiomeric forms as well as all
combinations of diastereomers and enantiomers, including
racemic mixtures. The compounds can be separated into
substantially optically pure compounds.
Pain from nervous system disorders of central and/or
peripheral origin, which may be treated according to the
method of the present invention and includes any disorders

involving pain including those types of pain referred to as
nociceptive, neuropathic (chemical, viral or disease-induced), inflammatory (arthritis, irritable bowel disease,
Crohn's) as well as acute, chronic, cancer-related, and
surgical, as well as pain resulting from any and all injuries,
diseases or toxin induced injuries of the central or peripheral
nervous systems including pain accompanying stroke, multiple sclerosis, parkinson's disease and pain from peripheral
neuropathy as a result of diabetes, AIDs, chemotherapeutic
drugs, and/or alcohol.
Pain from cancer which may have its origin at any
peripheral or central site and be caused by tumor invasion of
bone, tissue or nerve. In another embodiment, the present
invention is directed to a method for treating and/or preventing neuropathy resulting from a medication which
causes neuropathic pain as a side effect. For example, the
compounds of the present invention may be used to treat
and/or prevent pain associated with chemotherapy drugs
such as vincristine. This is a very serious clinical condition
associated with anticancer drugs.
In yet another embodiment, the present invention is
directed to a method for preventing and/or treating inflammatory pain disorders comprising administering to a mammalian subject in need thereof a therapeutically effective
amount of a compound of Formula (I).
Inflammatory pain disorders which may be treated
according to the method of the present invention include
ankylosing spondylitis, benign prostatic hyperplasia, cholecystitis, ulcerative colitis, Crohn's disease, diabetes mellitus, gastritis, glomerulonephritis, irritable bowel syndrome,
multiple sclerosis, osteoarthritis, pancreatitis, polymyositis,
psoriasis and rheumatoid arthritis.
The compounds of the present invention can be delivered
to a mammalian organism, including a human, directly or in
pharmaceutical compositions along with suitable carriers or
excipients, as is well known in the art. For example, a
pharmaceutical composition of the invention may include a
conventional additive, such as a stabilizer, buffer, salt,
preservative, filler, flavor enancer and the like, as known to
those skilled in the art. Exemplary buffers include phosphates, carbonates, citrates and the like. Exemplary preservatives include EDTA, EGTA, BHA, BHT and the like.
An effective amount of such agents can readily be determined by routine experimentation, as can the most effective
and convenient route of administration and the most appropriate formulation. Various formulations and drug delivery
systems are available in the art. See, e.g., Gennaro, A. R., ed.
(1995) Remington's Pharmaceutical Sciences.
Suitable routes of administration may, for example,
include oral, rectal, transmucosal, nasal, or intestinal administration and parenteral delivery, including intramuscular,
subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal,
intranasal, or intraocular injections. In addition, the agent or
composition thereof may be administered sublingually or via
a spray, including a sublingual tablet or a sublingual spray.
The agent or composition thereof may be administered in a
local rather than a systemic manner. For example, a suitable
agent can be delivered via injection or in a targeted drug
delivery system, such as a depot or sustained release formulation.
The pharmaceutical compositions of the present invention
may be manufactured by any of the methods well-known in
the art, such as by conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes. As noted above,
the compositions of the present invention can include one or
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more physiologically acceptable carriers such as excipients
and auxiliaries that facilitate processing of active molecules
into preparations for pharmaceutical use.
Proper formulation is dependent upon the route of administration chosen. For injection, for example, the composition
may be formulated in aqueous solutions, preferably in
physiologically compatible buffers such as Hanks' solution,
Ringer's solution, or physiological saline buffer. For transmucosal or nasal administration, penetrants appropriate to
the barrier to be permeated are used in the formulation. Such
penetrants are generally known in the art. In a preferred
embodiment of the present invention, the present compounds are prepared in a formulation intended for oral
administration. For oral administration, the compounds can
be formulated readily by combining the active compounds
with pharmaceutically acceptable carriers well known in the
art. Such carriers enable the compounds of the invention to
be formulated as tablets, pills, dragees, capsules, liquids,
gels, syrups, slurries, suspensions and the like, for oral
ingestion by a subject. The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases
such as cocoa butter or other glycerides.
Pharmaceutical preparations for oral use can be obtained
as solid excipients, optionally grinding a resulting mixture,
and processing the mixture of granules, after adding suitable
auxiliaries, if desired, to obtain tablets or dragee cores.
Suitable excipients are, in particular, fillers such as sugars,
including lactose, sucrose, marmitol, or sorbitol; cellulose
preparations such as, for example, maize starch, wheat
starch, rice starch, potato starch, gelatin, gum tragacanth,
methyl cellulose, hydroxypropylmethyl-cellulose, sodium
carboxymethylcellulose,
and/or
polyvinylpyrrolidone
(PVP). If desired, disintegrating agents may be added, such
as the cross-linked polyvinyl pyrrolidone, agar, or alginic
acid or a salt thereof such as sodium alginate. Also, wetting
agents such as sodium dodecyl sulfate may be included.
Dragee cores are provided with suitable coatings. For this
purpose, concentrated sugar solutions may be used, which
may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium
dioxide, lacquer solutions, and suitable organic solvents or
solvent mixtures. Dyestuffs or pigments may be added to the
tablets or dragee coatings for identification or to characterize
different combinations of active compound doses.
Pharmaceutical preparations for oral administration
include push-fit capsules made of gelatin, as well as soft,
sealed capsules made of gelatin and a plasticizer, such as
glycerol or sorbitol. The push-fit capsules can contain the
active ingredients in admixture with filler such as lactose,
binders such as starches, and/or lubricants such as talc or
magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended
in suitable liquids, such as fatty oils, liquid paraffin, or liquid
polyethylene glycols. In addition, stabilizers may be added.
All formulations for oral administration should be in dosages suitable for such administration.
In one embodiment, the compounds of the present invention can be administered transdermally, such as through a
skin patch, or topically. In one aspect, the transdermal or
topical formulations of the present invention can additionally comprise one or multiple penetration enhancers or other
effectors, including agents that enhance migration of the
delivered compound. Transdermal or topical administration
could be preferred, for example, in situations in which
location specific delivery is desired.

For administration by inhalation, the compounds for use
according to the present invention are conveniently delivered in the form of an aerosol spray presentation from
pressurized packs or a nebulizer, with the use of a suitable
propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, or
any other suitable gas. In the case of a pressurized aerosol,
the appropriate dosage unit may be determined by providing
a valve to deliver a metered amount. Capsules and cartridges
of, for example, gelatin, for use in an inhaler or insuf!Iator
may be formulated. These typically contain a powder mix of
the compound and a suitable powder base such as lactose or
starch.
Compositions formulated for parenteral administration by
injection, e.g., by bolus injection or continuous infusion can
be presented in unit dosage form, e.g., in ampoules or in
multi-dose containers, with an added preservative. The
compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may
contain formulatory agents such as suspending, stabilizing
and/or dispersing agents. Formulations for parenteral administration include aqueous solutions or other compositions in
water-soluble form.
Suspensions of the active compounds may also be prepared as appropriate oily injection suspensions. Suitable
lipophilic solvents or vehicles include fatty oils such as
sesame oil and synthetic fatty acid esters, such as ethyl
oleate or triglycerides, or liposomes. Aqueous injection
suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl
cellulose, sorbitol, or dextran. Optionally, the suspension
may also contain suitable stabilizers or agents that increase
the solubility of the compounds to allow for the preparation
of highly concentrated solutions. Alternatively, the active
ingredient may be in powder form for constitution with a
suitable vehicle, e.g., sterile pyrogen-free water, before use.
As mentioned above, the compositions of the present
invention may also be formulated as a depot preparation.
Such long acting formulations may be administered by
implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the
present compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion
in an acceptable oil) or ion exchange resins, or as sparingly
soluble derivatives, for example, as a sparingly soluble salt.
Suitable carriers for the hydrophobic molecules of the
invention are well known in the art and include co-solvent
systems comprising, for example, benzyl alcohol, a nonpolar
surfactant, a water-miscible organic polymer, and an aqueous phase. The co-solvent system may be the VPD cosolvent system. VPD is a solution of3% w/v benzyl alcohol,
8% w/v of the nonpolar surfactant polysorbate 80, and 65%
w/v polyethylene glycol 300, made up to volume in absolute
ethanol. The VPD co-solvent system (VPD:5W) consists of
VPD diluted 1: 1 with a 5% dextrose in water solution. This
co-solvent system is effective in dissolving hydrophobic
compounds and produces low toxicity upon systemic administration. Naturally, the proportions of a co-solvent system
may be varied considerably without destroying its solubility
and toxicity characteristics. Furthermore, the identity of the
co-solvent components may be varied. For example, other
low-toxicity nonpolar surfactants may be used instead of
polysorbate 80, the fraction size of polyethylene glycol may
be varied, other biocompatible polymers may replace polyethylene glycol, e.g., polyvinyl pyrrolidone, and other sugars or polysaccharides may substitute for dextrose.
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Alternatively, other delivery systems for hydrophobic
molecules may be employed. Liposomes and emulsions are
well known examples of delivery vehicles or carriers for
hydrophobic drugs. Liposomal delivery systems are discussed above in the context of gene-delivery systems. Certain organic solvents such as dimethylsulfoxide also may be
employed, although usually at the cost of greater toxicity.
Additionally, the compounds may be delivered using sustained-release systems, such as semi-permeable matrices of
solid hydrophobic polymers containing the effective amount
of the composition to be administered. Various sustainedrelease materials are established and available to those of
skill in the art. Sustained-release capsules may, depending
on their chemical nature, release the compounds for a few
weeks up to over 100 days. Depending on the chemical
nature and the biological stability of the therapeutic reagent,
additional strategies for stabilization may be employed.
For any composition used in the present methods of
treatment, a therapeutically effective dose can be estimated
initially using a variety of techniques well known in the art.
For example, in a cell culture assay, a dose can be formulated in animal models to achieve a circulating concentration
range that includes the IC 50 as determined in cell culture.
Dosage ranges appropriate for human subjects can be determined, for example, using data obtained from cell culture
assays and other animal studies. A therapeutically effective
dose of an agent refers to that amount of the agent that
results in amelioration of symptoms or a prolongation of
survival in a subject. Toxicity and therapeutic efficacy of
such molecules can be determined by standard pharmaceutical procedures in cell cultures or experimental animals,
e.g., by determining the LD 50 (the dose lethal to 50% of the
population) and the ED 5 0 (the dose therapeutically effective
in 50% of the population). The dose ratio of toxic to
therapeutic effects is the therapeutic index, which can be
expressed as the ratio LD 50 /ED 50 . Agents that exhibit high
therapeutic indices are preferred.
Dosages preferably fall within a range of circulating
concentrations that includes the ED 50 with little or no
toxicity. Dosages may vary within this range depending
upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration, and dosage should be chosen, according to methods
known in the art, in view of the specifics of a subject's
condition.
The amount of agent or composition administered will, of
course, be dependent on a variety of factors, including the
sex, age, and weight of the subject being treated, the severity
of the affliction, the manner of administration, and the
judgment of the prescribing physician.
The present compositions may, if desired, be presented in
a pack or dispenser device containing one or more unit
dosage forms containing the active ingredient. Such a pack
or device may, for example, comprise metal or plastic foil,
such as a blister pack. The pack or dispenser device may be
accompanied by instructions for administration. Compositions comprising a compound of the invention formulated in
a compatible pharmaceutical carrier may also be prepared,
placed in an appropriate container, and labeled for treatment
of an indicated condition.
These and other embodiments of the present invention
will readily occur to those of ordinary skill in the art in view
of the disclosure herein, and are specifically contemplated.

plary of the invention. The present invention is not limited
in scope by the exemplified embodiments, which are
intended as illustrations of single aspects of the invention
only. Any methods that are functionally equivalent are
within the scope of the invention. Various modifications of
the invention in addition to those described herein will
become apparent to those skilled in the art from the foregoing description. Such modifications fall within the scope
of the appended claims.
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The invention is further understood by reference to the
following examples, which are intended to be purely exem-

Synthesis of Compound cis-cis-N,N'-(dodeca-5,7diene-1, 12-diyl)-bis-[3-(2'-S-1-methyl-pyrrolidin-2yl)-pyridinium] dibromide

cis-cis-1,12-Dibromo-dodeca-5,7-diene (1 mmol) was
added to a solution ofS-nicotine (3 mmol) in acetonitrile and
the solution refluxed for 24 hours. The acetonitrile was
removed in vacuum and the resulting residue was partitioned
between ether and water. The aqueous layer was washed
extensively with ether until no S-nicotine left in the aqueous
layer. The resulting aqueous solution of the product was
lyophilized to yield the pure product. (70% ). 1 HNMR (300
MHZ, D 2 0, ppm) 8.60 (s, 2H), 8.59 (d, 2H), 8.32 (d, 1=8.4,
2H), 7.88 (t, 1=5.7, 2H), 6.12-6.20 (m, 2H), 5.30-5.40 (m,
2H), 4.43 (t, 1=7.2, 4H), 3.39 (t, 1=8.4, 2H), 3.01-3.06 (m,
2H), 2.16-2.34 (m, 4H), 2.01-2.09 (m, 10H), 1.64-1.88 (m,
10H), 1.25 (p, 1=7.5, 4H). 13 CNMR, 144.67, 143.35, 132.20,
128.45, 124.12, 67.65, 62.05, 56.65, 39.41, 33.76, 30.32,
26.34, 25.47, 22.36.
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Example 2

ether and water. The aqueous layer was washed extensively
with ether until no picoline left in the aqueous layer. The
resulting aqueous solution of the product was lyophilized to
yield the pure product. (76%). 1 HNMR (300 MHZ, D 2 0,
ppm) 8.50 (s, 2H), 8.44 (d, 1=6.3, 2H), 8.16 (d, 1=7.8, 2H),
7.74 (dd, 1=7.8, 1=6.3, 2H), 6.15-6.18 (m, 2H), 5.38-5.38
(m, 2H), 4.38 (t, 1=5.7, 4H), 2.35 (s, 6H), 2.06 (q, 1=7.5,
4H), 1.83 (p, 1=7.5, 4H), 1.25 (p, 1=7.5, 4H). 13 CNMR,
145.99, 143.71, 141.30, 139.95, 132.19, 127.46, 124.06,
61.69, 30.27, 26.35, 25.44, 17.93.

Synthesis of Compound cis-cis-N,N'-(dodeca-5,7diene-1, 12-diyl)-bis-(2-methyl-pyridinium) dibromide

Br
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Synthesis of Compound cis-cis-N,N'-(dodeca-5,7diene-1 ,12-diyl)-bis-( 4-methyl-pyridinium) dibromide
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cis-cis-1,12-Dibromo-dodeca-5,7-diene was added to a
solution of 2-picoline (3 mmol) in acetonitrile and the
solution refluxed for 24 hours. The acetonitrile was removed
in vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no picoline left in the aqueous layer. The
resulting aqueous solution of the product was lyophilized to
yield the pure product. (76%). 1 HNMR (300 MHz, D 2 0,
ppm) 8.52 (dd, 1=6.3, 2H), 8.17 (dt, 1=7.8, 1=1.5, 2H), 7.72
(d, 1=7.8, 2H), 7.64 (t, 1=6.3, 2H), 6.18-6.23 (m, 2H),
5.33-5.41 (m, 2H), 4.37 (t, 1=7.1, 4H), 2.66 (s, 6H), 2.09 (q,
1=7.5, 4H), 1.72-1.82 (m, 4H), 1.36 (p, 1=7.5, 4H).
13
CNMR, 155.26, 145.01, 144.73, 132.25, 130.23, 125.64,
124.15, 58.06, 29.10, 26.38, 25.61, 19.73.

#

25

0

--

N

30

-eN

2Br

35

Example 3
40

Synthesis of Compound cis-cis-N,N'-(dodeca-5,7diene-1, 12-diyl)-bis-(3-methyl-pyridinium) dibromide
45
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cis-cis-1,12-Dibromo-dodeca-5,7-diene was added to a
solution of 4-picoline (3 mmol) in acetonitrile and the
solution refluxed for 24 hours. The acetonitrile was removed
in vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no picoline left in the aqueous layer. The
resulting aqueous solution of the product was lyophilized to
yield the pure product. (75%). 1 HNMR (300 MHZ, D 2 0,
ppm), 8.45 (d, 1=6.9, 4H), 7.68 (d, 1=6.9, 4H), 6.14-6.19 (m,
2H), 5.31-5.39 (m, 2H), 4.35 (t, 1=7.2, 4H), 2.47 (s, 6H),
2.07 (q, 1=7.2, 4H), 1.83 (p, 1=7.5, 4H), 1.25 (p, 1=7.5, 4H).
Example 5
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Synthesis of Compound cis-cis-N,N'-(dodeca-5,7diene-1, 12-diyl)-bis-(5,6, 7 ,8-tetrahydro-quinolinium) dibromide
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cis-cis-1,12-Dibromo-dodeca-5,7-diene was added to a
solution of 3-picoline (3 mmol) in acetonitrile and the
solution refluxed for 24 hours. The acetonitrile was removed
in vacuum and the resulting residue was partitioned between
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-continued

(m, 8H), 1.22 (p, 1=7.2, 4H). CNMR158.82, 143.10, 139.60,
138.96, 132.28, 127.92, 124.09, 60.82, 49.13, 30.07, 29.35,
26.32, 26.20, 25.43, 21.01.
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Synthesis of Compound cis-cis-N,N'-(dodeca-5,7diene-1, 12-diyl)-bis-(2,4-dimethyl-pyridinium)
dibromide

10

cis-cis-1,12-Dibromo-dodeca-5,7-diene was added to a
solution of 5,6,7,8-tetrahydro-quinoline (3 mmol) in
acetonitrile and the solution refluxed for 24 hours. The
acetonitrile was removed in vacuum and the resulting residue was partitioned between ether and water. The aqueous
layer was washed extensively with ether until no quinoline
left in the aqueous layer. The resulting aqueous solution of
the product was lyophilized to yield the pure product. (75%).
1
HNMR (300 MHz, D 2 0, ppm) 8.35 (d, 1=6.3, 2H), 7.97 (d,
1-8.1, 2H), 7.52 (dd, 1=8.1, 1=6.3, 2H), 6.16-6.22 (m, 2H),
5.32-5.42 (m, 2H), 4.30 (t, 1=7.8, 4H), 2.92 (t, 1=6.2, 4H),
2.79 (t, 1=6.2, 4H), 2.09 (q, 1-7.2, 4H), 1.60-1.83 (m, 12H),
1.36 (p, 1=7.5S 4H).
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Example 6
Synthesis of Compound cis-cis-N,N'-(dodeca-5,7diene-1, 12-diyl)-bis-(5,6, 7 ,8-tetrahydro-isoquinolinium) dibromide
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cis-cis-1,12-Dibromo-dodeca-5,7-diene was added to a
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acetonitrile and the solution refluxed for 24 hours. The
acetonitrile was removed in vacuum and the resulting residue was partitioned between ether and water. The aqueous
layer was washed extensively with ether until no isoquinoline left in the aqueous layer. The resulting aqueous solution
of the product was lyophilized to yield the pure product.
(75%). 1 HNMR (300 MHz, D 2 0, ppm) 8.30 (s, 2H), 8.19 (d,
1=6.6, 2H), 7.50 (d, 1=6.3, 2H), 6.09-6.16 (m, 2H), 5.28-5.36
(m, 2H), 4.27 (t, 1=7.2, 4H), 2.29-2.82 (br, 4H), 2.67-2.74
(br, 4H), 2.02 (q, 1=7.2, 4H), 1.81 (p, 1=7.2, 4H), 1.62-1.69
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cis-cis-1,12-Dibromo-dodeca-5,7-diene was added to a
solution of 2, 4-lutidine {3 mmol) in acetonitrile and the
solution refluxed for 24 hours. The acetonitrile was removed
in vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no 2, 4-lutidine left in the aqueous layer. The
resulting aqueous solution of the product was lyophilized to
yield the pure product. (75%). 1 HNMR (300 MHZ, D 2 0,
ppm) 8.31 (d, 1=6.3, 2H), 7.53 (s, 2H), 7.46 (d, 1=6.9, 2H),
6.16-6.22 (m, 2H), 5.32-5.40 (m, 2H), 4.28 (t, 1=8.1, 4H),
2.58 (s, 3H), 2.38 (s, 3H), 2.07 (q, 1=7.2, 4H), 1.74 (p, 1=7.5,
4H), 1.33 (p, 1=7.5, 4H). CNMR, 159.20, 153.87, 143.69,
132.32, 130.44, 126.34, 124.18, 57.19, 29.10, 26.41, 25.63,
21.19, 19.46.

US 9,499,518 B2
23

24

u

Example 8
Synthesis of Compound cis-cis-N,N'-(dodeca-5,7diene-1, 12-diyl)-bis-(3,4-dimethyl-pyridinium)
dibromide
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cis-cis-1,12-Dibromo-dodeca-5,7-diene was added to a
solution of 3, 4-lutidine (3 mmol) in acetonitrile and the
solution refluxed for 24 hours. The acetonitrile was removed
in vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no 3, 4-lutidine left in the aqueous layer. The
resulting aqueous solution of the product was lyophilized to
yield the pure product. (75%). 1 HNMR (300 MHZ, D 2 0,
ppm) 8.34 (s, lH), 8.29 (d, 1=6.3, lH), 7.60 (d, 1=6.3, lH),

Br

Br

cis-cis-1,12-Dibromo-dodeca-5,7-diene was added to a
solution of 3, 5-lutidine (3 mmol) in acetonitrile and the
solution refluxed for 24 hours. The acetonitrile was removed
in vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no 3, 5-lutidine left in the aqueous layer. The
resulting aqueous solution of the product was lyophilized to
yield the pure product. (75%). 1 HNMR (300 MHZ, D 2 0,
ppm) 8.29 (s, 4H), 7.99 (s, 2H), 6.12-6.18 (m, 2H), 5.30-5.38
(m, 2H), 4.31 (t, 1=7.5, 4H), 2.30 (s, 6H), 2.05 (q, 1=7.2,
4H), 1.81 (p, 1=7.5, 4H), 1.24 (p, 1-7.5, 4H). CNMR, 146.56,
140.96, 139.11, 132.28, 124.09, 61.49, 30.21, 26.34, 25.43,
17.73.
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Example 10
Synthesis of Compound N,N'[1,4-phenylenedi-(4butanyl) ]-bis-[3-(2'-S-1-methyl-pyrrolidin-2-yl)pyridinium] dibromide

2Br0

6.13-6.18 (m, 2H), 5.30-5.38 (m, 2H), 4.31 (t, 1=7.2, 4H),
2.37 (s, 3H), 2.25 (s, 3H), 2.05 (q, 1=7.2, 4H), 1.81 (p, 1=7.5,
4H), 1.24 (p, 1=7.5, 4H). CNMR, 158.66, 142.37, 140.71,
138.65, 132.25, 128.23, 124.07, 60.80, 30.11, 26.31, 25.42,
19.69, 16.34.

50

Example 9

55

Synthesis of Compound cis-cis-N,N'-(dodeca-5,7diene-1, 12-diyl)-bis-(3,5-dimethyl-pyridinium)
dibromide

60

Br
65
Br

1,4-Bis-(4-bromo-butyl)-benzene was added to a solution
of S-nicotine (3 mmol) in acetonitrile and the solution
refluxed for 24 hours. The acetonitrile was removed in
vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no S-nicotine left in the aqueous layer. The
resulting aqueous solution of the product was lyophilized to
yield the pure product. (75%). 1 HNMR (300 MHZ, D 2 0,
ppm) 8.57-8.59 (m, 4H), 8.35 (d, 1=8.1, 2H), 7.88 (dd, 1=7.8,
1=6.6, 2H), 7.01 (s, 4H), 4.45 (t, 1=7.5, 4H), 3.40 (t, 2H),
3.04-3.10 (m, 2H), 2.49 (t, 1=7.5, 4H), 2.30-2.40 (m, 2H),
2.18-2.29 (m, 2H), 2.03 (s, 6H), 1.80-1.90 (m, 8H), 1.401.55 (m, 4H). CNMR, 144.65, 143.48, 143.30, 139.76,
128.74, 128.42, 67.61, 61.99, 56.62, 39.37, 33.96, 33.73,
30.17, 27.28, 22.33.

US 9,499,518 B2
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Example 11

1,4-Bis-(4-bromo-butyl)-benzene was added to a solution
of 3-picoline (3 mmol) in acetonitrile and the solution
refluxed for 24 hours. The acetonitrile was removed in
vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no 3-picoline left in the aqueous layer. The
resulting aqueous solution of the product was lyophilized to
yield the pure product. (75%). 1 HNMR (300 MHZ, D 2 0,
ppm) 8.45 (s, 2H), 8.40 (d, 1=6.6, 2H), 8.16 (d, 1=8.1, 2H),
7.72 (dd, 1=8.1, 1=6.0, 2H), 7.00 (s, 4H), 4.37 (t, 1=7.5, 4H),
2.47 (t, 1=7.5, 4H), 2.34 (s, 6H), 1.82 (p, 1=7.5, 4H), 1.46 (p,
1=7.5, 4H). CNMR. 146.02, 143.68, 141.68, 139.96, 139.79,
128.75, 127.46, 61.69, 34.04, 30.14, 27.28, 17.90.

Synthesis of Compound N,N'[1,4-phenylenedi-( 4butanyl)]-bis-(2-methylpyridinium) dibromide
5

Br

Br

--

10

Example 13
Synthesis of Compound N,N'[1,4-phenylenedi-(4butanyl)]-bis-(4-methylpyridinium) dibromide
2Br0

1,4-Bis-(4-bromo-butyl)-benzene was added to a solution
of 2-picoline (3 mmol) in acetonitrile and the solution
refluxed for 24 hours. The acetonitrile was removed in
vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no 2-picoline left in the aqueous layer. The
resulting aqueous solution of the product was lyophilized to
yield the pure product. (75%). 1 HNMR (300 MHZ, D 2 0,
ppm) 8.49 (dd, 1=6.0, 1.2, 2H), 8.17 (dt, 1=8.1, 1=1.5, 2H),
7.70 (d, 1=8.1, 2H), 7.65 (dt, 1=8.1, 1=1.2, 2H), 7.04 (s, 4H),
4.37 (t, 1=7.2, 4H), 2.62 (s, 6H), 2.51 (t, 1=7.2, 4H), 1.77 (p,
1=7.8, 4H), 1.57 (p, 1=7.8, 4H). CNMR. 145.05, 144.73,
139.79, 130.24, 128.78, 125.64, 58.02, 34.11, 29.01, 27.49,
19.70.

20
Br

25

Br

»

--

I#
~
2Br0

30

35

Example 12
Synthesis of Compound N,N'[1,4-phenylenedi-( 4butanyl)]-bis-(3-methylpyridinium) dibromide
40

1,4-Bis-(4-bromo-butyl)-benzene was added to a solution
of 4-picoline (3 mmol) in acetonitrile and the solution
refluxed for 24 hours. The acetonitrile was removed in
vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no 4-picoline left in the aqueous layer. The
resulting aqueous solution of the product was lyophilized to
yield the pure product. (75%). 1 HNMR (300 MHZ, D 2 0,
ppm) 8.38 (d, 1-6.9, 4H), 7.64 (d, 1=6.9, 4H), 6.98 (s, 4H),
4.33 (t, 1=7.2, 4H), 2.46 (t, 1=7.2, 4H), 2.44 (s, 6H), 1.81 (p,
1=7.5, 4H), 1.45 (p, 1=7.5, 4H). CNMR. 159.99, 143.04,
139.79, 128.74, 128.65, 60.99, 34.02, 30.03, 27.26, 21.50.

45

Example 14
50

2Br0

Br

Br

Synthesis of Compound N,N'[1,4-phenylenedi-(4butanyl)]-bis-(3-ethylpyridinium) dibromide

-~~

v

2Br0

US 9,499,518 B2
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1,4-Bis-(4-bromo-butyl)-benzene was added to a solution
of 3-ethylpyridine (3 mmol) in acetonitrile and the solution
refluxed for 24 hours. The acetonitrile was removed in
vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no 3-ethylpyridine left in the aqueous layer.
The resulting aqueous solution of the groduct was
lyophilized to yield the pure product. (75%). HNMR (300
MHZ, D 2 0, ppm) 8.45 (s, 2H), 8.41 (d, 1-6.0, 2H), 8.19 (d,
1=8.4, 2H), 7.73 (dd, 1=8.1, 1=6.0, 2H), 6.97 (s, 4H), 4.37 (t,
1=7.2, 4H), 2.66 (q, 7.8, 2H), 2.49 (t, 1-7.2, 1.83 (p, 1=7.5,
4H), 1.45 (p, 1-1.5, 4H), 1.09 (t, 1=7.8, 6H). CNMR. 145.61,
145.08, 143.09, 141.51, 139.78, 128.75, 127.68, 61.70,
34.01, 30.13, 27.24, 25.70, 13.92.

-continued

10
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Example 15
Synthesis of Compound N,N'[1,4-phenylenedi-( 4butanyl)]-bis-(5,6,7,8-tetrahydroquinolinium) dibromide

N~

v

5

20

1,4-Bis-(4-bromo-butyl)-benzene was added to a solution
of tetrahydroquinoline (3 mmol) in acetonitrile and the
solution refluxed for 24 hours. The acetonitrile was removed
in vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no tetrahydroquinoline left in the aqueous
layer. The resulting aqueous solution of the product was
lyophilized to yield the pure product. (75%). 1 HNMR (300
MHZ, D 2 0, ppm) 8.30 (d, 1=6.3, 2H), 7.95 (d, 1=7.8, 2H),
7.49 (dd, 1=8.1, 1=6.3, 2H), 7.02 (s, 4H), 4.28 (t, 7.5, 4H),
2.83 (t, 1=7.5, 4H), 2.77 (t, 1=7.5, 4H), 2.49 (t, 1=7.5, 4H),
1.66-1.80 (m, 8H), 1.35-1.63 (m, 8H).
Example 16

Br

Br-
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Synthesis of Compound N,N'[1,4-phenylenedi-(4butanyl)]-bis-(5,6,7,8-tetrahydroisoquinolinium)
dibromide

Br

Br-

~~
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1,4-Bis-(4-bromo-butyl)-benzene was added to a solution
of tetrahydroisoquinoline (3 mmol) in acetonitrile and the
solution refluxed for 24 hours. The acetonitrile was removed
in vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no tetrahydroisoquinoline left in the aqueous
layer. The resulting aqueous solution of the product was
lyophilized to yield the pure product. (75%). 1 HNMR (300
MHZ, D 2 0, ppm) 8.21 (s, 2H), 8.13 (d, 1=6.3, 2H), 7.46 (d,
1=6.3, 2H), 6.96 (s, 4H), 4.25 (t, 1=7.2, 4H), 2.2.78-2.84 (br,
4H), 2.63-2.70 (br, 4H), 2.44 (t, 1=7.2, 4H), 1.78 (p, 1=7.5,
4H), 1.64-1.70 (m, 8H), 1.42 (p, 1=7.5, 4H). CNMR, 158.77,
143.03, 139.78, 139.56, 138.88, 128.72, 127.84, 60.79,
49.11, 34.01, 29.91, 29.31, 27.16, 26.16, 20.99.
Example 17
Synthesis of Compound N,N'[1,4-phenylenedi-(4butanyl)]-bis-[3-(3-hydroxy-propyl)-pyridinium]
dibromide

Br

Br-

US 9,499,518 B2
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-continued
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1,4-Bis-(4-bromo-butyl)-benzene was added to a solution
of {3-hydroxy-propyl)-pyridine (3 mmol) in acetonitrile and
the solution refluxed for 24 hours. The acetonitrile was
removed in vacuum and the resulting residue was partitioned
between ether and water. The aqueous layer was washed
extensively with ether until no (3-hydroxy-propyl)-pyridine
left in the aqueous layer. The resulting aqueous solution of
the product was lyophilized to yield the pure product. (75%).
1
HNMR (300 MHZ, D 2 0, ppm) 8.49 (s, 2H), 8.43 (d, 1=6.0,
2H), 8.22 (d, 1=8.1, 2H), 7.75 (dd, 1=7.8, 1=6.0, 2H), 6.98
(s, 4H), 4.38 (t, 1=7.2, 4H), 3.45 (t, 1=6.6, 4H), 2.72 (t, 1=7.8,
4H), 2.46 (t, 1=7.5, 4H), 1.83 (p, 1-7.5, 4H), 1.70-1.75)m,
4H), 1.44 (p, 1-7.5, 4H). CNMR, 145.53, 143.51, 141.78,
139.78, 128.75, 127.78, 61.75, 60.67, 34.01, 32.17, 30.13,
28.81, 27.24.
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Example 18
Synthesis of Compound N,N'[1,4-phenylenedi-( 4butanyl)]-bis-(2,4-dimethylpyridinium) dibromide
30

Br

-continued

Br--

1,4-Bis-(4-bromo-butyl)-benzene was added to a solution
of 3,4-lutidine (3 mmol) in acetonitrile and the solution
refluxed for 24 hours. The acetonitrile was removed in
vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no 3,4-lutidine left in the aqueous layer. The
resulting aqueous solution of the product was lyophilized to
yield the pure product. (75%). 1 HNMR (300 MHZ, D 2 0,
ppm) 8.25 (s, 2H), 8.22 (d, 1-6.0, 2H), 7.55 (d, 1=6.0, 2H),
6.96 (s, 4H), 4.27 (t, 1=7.2, 4H), 2.45 (t, 1=7.2, 4H), 2.34 (s,
6H), 2.21 (s, 6H), 1.79 (p, 1=7.5, 4H), 1.42 (p, 1=7.5, 4H).
CNMR, 158.64, 142.28, 140.66, 139.78, 138.61, 128.72,
128.18, 34.02, 29.94, 27.20, 19.67, 16.29.
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Example 20

I#

2Br

6

1,4-Bis-(4-bromo-butyl)-benzene was added to a solution
of 2,4-lutidine (3 mmol) in acetonitrile and the solution
refluxed for 24 hours. The acetonitrile was removed in
vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no 2,4-lutidine left in the aqueous layer. The
resulting aqueous solution of the product was lyophilized to
yield the pure product. (75%). 1 HNMR (300 MHZ, D 2 0,
ppm) 8.27 (d, 1=6.6, 2H), 7.50 (s, 2H), 7.45 (d, 1=6.6, 2H),
7.02 (s, 4H), 4.28 (t, 1=7.2, 4H), 2.52 (s, 6H), 2.48 (t, 1=7.2,
4H), 2.38 (s, 6H), 2.20 (s, 3H), 1.79 (p, 1=7.5, 4H), 1.42 (p,
1=7.5, 4H).
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Example 19
Synthesis of Compound N,N'[1,4-phenylenedi-( 4butanyl)]-bis-(3,4-dimethylpyridinium) dibromide
[ZZ 1 81]

Br

Br

--

Synthesis of Compound N,N'[1,4-phenylenedi-(4butanyl)]-bis-(3,5-dimethylpyridinium) dibromide
[ZZ 1 82]

60

65

1,4-Bis-(4-bromo-butyl)-benzene was added to a solution
of 3,5-lutidine (3 mmol) in acetonitrile and the solution
refluxed for 24 hours. The acetonitrile was removed in
vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no 3,5-lutidine left in the aqueous layer. The
resulting aqueous solution of the product was lyophilized to
yield the pure product. (75%). 1 HNMR (300 MHZ, D 2 0,
ppm) 8.23 (s, 4H), 7.97 (s, 2H), 6.97 (s, 4H), 4.29 (t, 1=7.2,
4H), 2.45 (t, 1=7.2, 4H), 2.27 (s, 12H), 1.81 (p, 1=7.5, 4H),
1.45 (p, 1=7.5, CNMR, 146.50, 140.89, 139.79, 139.04,
128.74, 63.46, 34.04, 30.03, 27.22, 17.70.

US 9,499,518 B2
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Example 21

ppm; 13 C NMR (75 MHz, CDC1 3 ) o 18.6, 31.8, 32.7, 80.7,
91.8, 125.9, 127.6, 131.9 ppm.

Synthesis of Compound 5-[2-(5-hydroxy-pent-1ynyl)-phenyl]-pent-4-yn-1-ol

Example 23
Synthesis of Compound 1,2-bis-[5-(2-methyl-pyridinium)-pent-1-ynyl]-benzene dibromide

CC

Br

OH

--

~

10

Br

#
15

1,2-Dibromobenzene (10.94 g, 46.37 mmol), 4-pentyn-1ol (9.36 g, 111.30 mmol), and bis(triphenylphosphine)palladium(II) dichloride (650 mg, 0.93 mmol) was stirred in
triethylamine (150 mL) under nitrogen for 5 min. Copper(!)
iodide (88 mg, 0.46 mmol) was added and the mixture was
stirred for 4 hrs at 85° C. for 6 days. The mixture was cooled
to room temperature and filtered through a celite pad, rinsed
with ethylacetate. The combined filtrate was evaporated to
dryness under reduced pressure. The resulting residue was
purified by colunm chromatography (chloroform:methanol
30:1) to afford 5.33 g of the title compound. Yield: 47%. 1 H
NMR (300 MHZ, D 2 0, ppm) o 1.85 (m, 4H), 2.58 (t, 1=6.6
Hz, 4H), 3.82 (t, 1=6.0 Hz, 4H), 7.18 (m, 2H), 7.36 (m, 2H)
ppm; 13 C NMR (75 MHz, CDC1 3 ) o 16.3, 31.4, 62.4, 80.2,
93.3, 126.0, 127.4, 131.8 ppm.
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Example 22
Synthesis of Compound
1,2-bis-(5-bromo-pent-1-ynyl)-benzene

--

~

OH

40

--

A mixture of 1,2-bis-(5-bromo-pent-1-ynyl)-benzene
(264 mg, 0.72 mmol) and 2-picoline (1 mL) was heated at
60-70° C. for 12 hrs. The resulted mixture was washed with
diethyl ether and then dissolved in water (15 mL), the
aqueous solution was extracted with diethyl ether (30
mLx3). Water was removed by lyophilization to afford 327
mg of the title compound. Yield: 82%. 1 H NMR (300 MHz,
CD 3 0D) o2.35 (m, 4H), 2.81 (t, 1=6.6 Hz, 4H), 3.02 (s, 6H),
4.91 (t, 1=7.5 Hz, 4H)," 7.27-7.50 (m, 4H), 7.92-8.15 (m,
4H), 8.45 (t, 1=7.8 Hz, 2H), 9.11 (d, 1=6.3 Hz, 2H) ppm; 13 C
NMR (75 MHz, CD 3 0D) o17.6, 21.1, 30.1, 58.2, 81.9, 92.9,
126.4, 127.0, 129.2, 129.3, 131.5, 133.1, 146.4, 156.7 ppm.
Example 24

OH
45

Synthesis of Compound 1,2-bis-[5-(3-methyl-pyridinium)-pent-1-ynyl]-benzene dibromide

Br

Br
50

--

Br

5-[2-( 5-Hydroxy-pent-1-yny I)-phenyl]-pent-4-yn-1-ol
(2.40 g, 9.90 mmol) and carbon tetrabromide (8.21 g, 24.75
mmol) were dissolved in dry methylene chloride (30 mL)
and cooled to oo C. Triphenyl phosphine (6.82 g, 25.99
mmol) in methylene chloride (15 mL) was added dropwise
and the mixture was stirred for 1 h at oo C. The mixture was
poured into hexanes (200 mL) and then filtered through a
short silica gel column, washed with ethylacetate/hexanes
(1/4). The combined organic solvents were evaporated to
dryness under reduced pressure. The resulting residue was
purified by colunm chromatography (hexanes:ethylacetate
30:1) to afford 2.48 g of the title compound. Yield: 68%. 1 H
NMR (300 MHz, CDC1 3 ) o2.16 (m, 4H), 2.68 (t, 1=6.6 Hz,
4H), 3.65 (dt, 1=6.6, 0.6 Hz, 4H), 7.20 (m, 2H), 7.38 (m, 2H)

Br
55

60

65

US 9,499,518 B2
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A mixture of 1,2-bis-(5-bromo-pent-1-ynyl)-benzene
(270 mg, 0.73 mmol) and 3-picoline (1 mL) was heated at
60-70° C. for 12 hrs. The resulted mixture was washed with
diethyl ether and then dissolved in water (15 mL), the
aqueous solution was extracted with diethyl ether (30
mLx3). Water was removed by lyophilization to afford 350
mg of the title compound. Yield: 86%. 1 H NMR (300 MHz,
CD 3 0D) o2.45 (m, 4H), 2.56 (s, 6H) 2.78 (t, 1=6.6 Hz, 4H),
4.95 (t, 1=7.2 Hz, 4H), 7.22-7.42 (m, 4H), 8.05 (dd, 1=8.1,
6.0 Hz, 2H), 8.39 (d, 1=7.8 Hz, 2H), 9.10 (d, 1=6.0 Hz, 2H),
9.19 (s, 2H) ppm; 13 C NMR (75 MHz, CD 3 0D) o17.6, 18.9,
31.2, 61.9, 81.6, 92.8, 126.4, 128.7, 129.0, 132.9, 140.9,
143.1, 145.6, 147.3 ppm.

-continued
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Synthesis of Compound 1,2-bis-[5-(4-methyl-pyridinium)-pent-1-ynyl]-benzene dibromide
20
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2Br8
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Example 25

by-
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A mixture of 1,2-bis-(5-bromo-pent-1-ynyl)-benzene
(268 mg, 0.73 mmol) and 2,4-lutidine (1 mL) was heated at
60-70° C. for 12 hrs. The resulted mixture was washed with
diethyl ether and then dissolved in water (15 mL), the
aqueous solution was extracted with diethyl ether (30
mLx3). Water was removed by lyophilization to afford 343
mg of the title compound. Yield: 81%. 1 H NMR (300 MHz,
CD 3 0D) o 2.34 (m, 4H), 2.52 (s, 3H), 2.84 (t, 1-6.6 Hz, 4H),
2.97 (s, 3H), 4.87 (t, 1=7.5 Hz, 4H), 7.27-7.45 (m, 4H), 7.80
(d, 1=6.3 Hz, 2H), 7.87 (s, 2H), 8.99 (d, 1=6.3 Hz, 2H) ppm;
13
C NMR (75 MHz, CD 3 0D) o17.6, 20.9, 22.0, 30.1, 57.5,
81.6, 93.0, 126.4, 127.6, 129.1, 131.7, 133.0, 145.5, 155.5,
160.3 ppm.
Example 27
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Synthesis of Compound 1,2-bis-[5-(3,4-dimethylpyridinium)-pent-1-ynyl]-benzene dibromide [GZ
581 B]

2Br8

A mixture of 1,2-bis-(5-bromo-pent-1-ynyl)-benzene
(268 mg, 0.73 mmol) and 4-picoline (1 mL) was heated at
60-70° C. for 12 hrs. The resulted mixture was washed with
diethyl ether and then dissolved in water (15 mL), the
aqueous solution was extracted with diethyl ether (30
mLx3). Water was removed by lyophilization to afford 435
mg of the title compound. Yield: 86%. 1 H NMR (300 MHz,
CD 3 0D) o2.41 (m, 4H), 2.51 (s, 6H), 2.78 (t, 1=6.6 Hz, 4H),
4.91 (t, 1=6.6 Hz, 4H), 7.30 (s, 4H), 7.92 (d, 1=6.3 Hz, 4H),
9.05 (d, 1=6.3 Hz, 4H) ppm; 13 C NMR (75 MHz, CD 3 0D)
0 17.5, 22.3, 31.0, 61.4, 81.5, 92.8, 126.4, 129.0, 129.8,
132.9, 144.9, 161.1 ppm.
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Example 26
Synthesis of Compound 1,2-bis-[5-(2,4-dimethylpyridinium)-pent-1-yny!]-benzene dibromide

55

60

Br

-Br

65

A mixture of 1,2-bis-(5-bromo-pent-1-ynyl)-benzene
(276 mg, 0.75 mmol) and 3,4-lutidine (1 mL) was heated at
60-70° C. for 12 hrs. The resulted mixture was washed with
diethyl ether and then dissolved in water (15 mL), the
aqueous solution was extracted with diethyl ether (30
mLx3). Water was removed by lyophilization to afford 355
mg of the title compound. Yield: 81%. 1 H NMR (300 MHz,
CD 3 0D) o 2.37 (s, 3H), 2.40 (s, 3H), 2.44 (m, 4H), 2.79 (t,
1=6.6 Hz, 4H), 4.88 (t, 1=6.6 Hz, 4H), 7.29 (s, 4H), 7.86 (d,
1=6.3 Hz, 2H), 8.95 (d, 1=6.3 Hz, 2H), 9.06 (s, 2H), ppm;
13
C NMR (75 MHz, CD 3 0D) o17.3, 17.7, 20.4, 31.1, 61.2,
81.3, 93.0, 126.5, 129.0, 129.4, 132.8, 139.5, 142.7, 144.3,
159.8 ppm.
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Synthesis of Compound 1,2-bis-[5-(3,5-dimethylpyridinium)-pent-1-ynyl]-benzene dibromide [GZ
581 A]
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A mixture of 1,2-bis-(5-bromo-pent-1-ynyl)-benzene
(249 mg, 0.68 mmol) and quinoline (1 mL) was heated at
60-70° C. for 12 hrs. The resulted mixture was washed with
diethyl ether and then dissolved in water (30 mL), the
aqueous solution was extracted with chloroform (20 mLx3).
Water was removed by lyophilization to afford 317 mg of the
title compound. Yield: 75%. 1 H NMR (300 MHz, CD 3 0D)
o 2.42 (m, 4H), 2.78 (t, 1=6.6 Hz, 4H), 5.36 (t, 1=6.9 Hz,
4H), 7.02-7.28 (m, 4H), 7.97 (t, 1=7.5 Hz, 2H), 8.07-8.40
(m, 4H), 8.67 (d, 1=9.0 Hz, 2H), 9.15 (d, 1=8.4 Hz, 2H), 9.15
(d, 1=8.4 Hz, 2H), 9.70 (d, 1=5.7 Hz, 2H) ppm; 13 C NMR
(75 MHz, CD 3 0D) o 17.8, 29.8, 58.5, 81.6, 92.9, 119.7,
123.2, 126.2, 129.0, 130.5, 131.3, 132.0, 132.7, 137.2,
139.0, 149.0, 150.6 ppm.
Example 30

35

A mixture of 1,2-bis-(5-bromo-pent-1-ynyl)-benzene
(280 mg, 0.76 mmol) and 3,5-lutidine (1 mL) was heated at
60-70° C. for 12 hrs. The resulted mixture was washed with
diethyl ether and then dissolved in water (15 mL), the
aqueous solution was extracted with diethyl ether (30
mLx3). Water was removed by lyophilization to afford 363
mg of the title compound. Yield: 82%. 1 H NMR (300 MHz,
CD 3 0D) o2.42 (m, 4H), 2.51 (s, 6H), 2.76 (t, 1-6.9 Hz, 4H),
4.86 (t, 1=6.9 Hz, 4H), 7.30 (m, 4H), 8.13 (s, 2H), 8.95 (s,
4H) ppm; 13 C NMR (75 MHz, CD 3 0D) o17.7, 18.7, 31.2,
61.9, 81.6, 92.9, 126.6, 129.0, 132.8, 140.2, 142.9, 147.9
ppm.
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Example 29
Synthesis of Compound
1,2-bis-[ 5-quinolinium-pent-1-ynyl)-benzene
dibromide

Br
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Br

Synthesis of Compound
1,2-bis-[ 5-isoquinolinium -pent-1-ynyl)-benzene
dibromide [GZ 582 B]

65

A mixture of 1,2-bis-(5-bromo-pent-1-ynyl)-benzene
(252 mg, 0.68 mmol) and isoquinoline (1 mL) was heated at
60-70° C. for 12 hrs. The resulted mixture was washed with
diethy!ether and then dissolved in water (30 mL), the
aqueous solution was extracted with chloroform (20 mLx3).
Water was removed by lyophilization to afford 319 mg of the
title compound. Yield: 74%. 1 H NMR (300 MHz, CD 3 0D)
o 2.46 (m, 4H), 2.77 (t, 1=6.3 Hz, 4H), 5.01 (t, 1=6.6 Hz,
4H), 6.91 (m, 2H), 7.04 (m, 2H), 7.90-8.50 (m, 10H), 8.78

US 9,499,518 B2
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(d, 1=6.9 Hz, 2H), 10.10 (s, 2H) ppm; 13 C NMR (75 MHz,
CD 3 0D) o17.8, 30.8, 62.1, 81.3, 92.7, 125.7, 127.3, 128.1,
128.5, 131.2, 131.4, 132.1, 132.2, 135.6, 137.9, 138.4, 150.8
ppm.

-continued
OH

Example 31
Synthesis of Compound 1,2-bis-[5-(2'-S-nicotiniumpent-1-ynyl)]benzene dibromide

OH
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Br
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5-[2-( 5-Hydroxy-pent-1-ynyl)-phenyl]-pent-4-yn-1-ol
(2.70 g, 11.14 mmol) was dissolved in ethanol (30 mL) and
10% Pd!C (2.5% w/w) was added. The resulting mixture was
hydrogenated on a Parr hydrogenation apparatus (45 psi) for
4 hrs. The catalyst was removed by filtration through a Celite
pad. The filter cake was rinsed with methanol, and the
combined organic liquors were concentrated under reduced
pressure. The crude product was purified by colunm chromatography (chloroform:methanol 20:1) to afford 2.55 g of
the title compound. Yield: 91%. 1 H NMR (300 MHz,
CDC1 3 ) o 1.38-1.67 (m, 12H), 2.60 (t, 1=7.8 Hz, 4H), 3.59
(t, 1=6.6 Hz, 4H), 7.11 (m, 4H) ppm; 13 C NMR (75 MHz,
CDC1 3 ) o 26.0, 31.3, 32.6, 32.8, 62.6, 125.8, 129.1, 140.2
ppm.
Example 33

30

Synthesis of Compound
1,2-bis-[ 5-bromo-pentyl)-benzene

OH
35

A mixture of 1,2-bis-(5-bromo-pent-1-ynyl)-benzene
(330 mg, 0.90 mmol) and S-nicotine (1 mL) was heated at
60-70° C. for 12 hrs. The resulted mixture was washed with
diethyl ether and then dissolved in water (20 mL), the
aqueous solution was extracted with chloroform (20 mLx3).
Water was removed by lyophilization to afford 340 mg of the
title compound. Yield: 55%. 1 H NMR (300 MHz, CD 3 0D)
o 2.00-2.82 (m, 16H), 2.55 (s, 6H), 2.90 (m, 2H), 3.55 (m,
2H), 4.17 (m, 2H), 4.95 (t, 1=6.9 Hz, 4H), 7.27 (m, 2H), 7.37
(m, 2H), 8.17 (dd, 1=7.8, 6.3 Hz, 2H), 8.69 (d, 1=8.4 Hz,
2H), 9.15 (d, 1=6.0 Hz, 2H), 9.40 (s, 2H) ppm; 13 C NMR (75
MHz, CD 3 0D) o 17.5, 23.5, 30.9, 34.1, 40.3, 57.6, 62.4,
68.7, 81.9, 92.7, 126.4, 129.1, 129.6, 133.0, 141.1, 145.8,
146.0, 146.5 ppm.
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Example 32
Synthesis of Compound
5-[2-( 5-hydroxy-pentyl)-phenyl]-pentan-1-ol

60

OH

OH

55

65

Br

5-[2-(5-Hydroxy-penty])-phenyl]-pentan-1-ol (2.50 g,
10.00 mmol) and carbon tetrabromide (8.29 g, 25.00 mmol)
were dissolved in dry methylene chloride (30 mL) and
cooled to oo C. Triphenylphosphine (6.88 g, 26.25 mmol)
in methylene chloride (15 mL) was added dropwise and the
mixture was stirred for 1 h at oo C. The mixture was poured
into hexanes (200 mL) and then filtered through a short silica
gel column, washed with ethylacetate/hexanes (3/4). The
combined organic solvents were evaporated to dryness
under reduced pressure. The resulting residue was purified
by colunm chromatography (hexanes:ethylacetate30: 1) to
afford 3.76 g of the title compound. Yield: 99%. 1 H NMR
(300 MHz, CDC1 3 ) 61.47-1.73 (m, 8H), 1.91 (m, 4H), 2.63
(t, 1=7.8 Hz, 4H), 3.42 (t, 1=6.9 Hz, 4H), 7.15 (s, 4H) ppm;
13
C NMR (75 MHz, CDC1 3 ) o 28.5, 30.6, 32.7, 32.9, 34.0,
126.0, 129.2, 139.9 ppm.
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Example 34

-continued

u

Synthesis of Compound
1,2-bis-[5-(2-methyl-pyridinium)-pentyl]-benzene
dibromide

2Bfl
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A mixture of 1,2-bis-(5-bromo-pentyl)-benzene (280 mg,
0.74 mmol) and 2-picoline (1 mL) was heated at 60-70° C.
for 12 hrs. The resulted mixture was washed with diethyl
ether and then dissolved in water (15 mL), the aqueous
solution was extracted with diethyl ether (30 mLx3). Water
was removed by lyophilization to afford 400 mg of the title
compound. Yield: 95%. 1 H NMR (300 MHz, CD 3 0D) o
1.54 (m, 4H), 1.68 (m, 4H), 2.01 (m, 4H), 2.69 (t, 1=7.5 Hz,
4H), 2.90 (s, 6H), 4.61 (t, 1=7.8 Hz, 4H), 7.02-7.19 (m, 4H),
7.92 (t, 1=6.6 Hz, 2H), 8.00 (d, 1=7.8 Hz, 2H), 8.44 (dt,
1=7.8, 1.2 Hz, 2H), 8.93 (dd, 1=6.3, 1.2 Hz, 2H) ppm; 13 C
NMR (75 MHz, CD 3 0D) o20.8, 27.4, 31.2, 32.0, 33.4, 59.3,
126.9, 127.0, 130.3, 131.5, 141.0, 146.3, 146.4, 156.6 ppm.
Example 35

A mixture of 1,2-bis-(5-bromo-pentyl)-benzene (296 mg,
0.79 mmol) and 3-picoline (1 mL) was heated at 60-70° C.
for 12 hrs. The resulted mixture was washed with diethyl
ether and then dissolved in water (15 mL), the aqueous
solution was extracted with diethyl ether (30 mLx3). Water
was removed by lyophilization to afford 382 mg of the title
compound. Yield: 86%. 1 H NMR (300 MHz, CD 3 0D) o
1.47 (m, 4H), 1.66 (m, 4H), 2.08 (m, 4H), 2.59 (s, 6H), 2.65
(t, 1=7.5 Hz, 4H), 4.64 (t, 1=7.5 Hz, 4H), 7.01-7.19 (m, 4H),
7.99 (d, 1=7.5, 6.0 Hz, 2H), 8.43 (dd, 1=8.1, 0.6 Hz, 2H),
8.86 (d, 1=6.0 Hz, 2H), 8.96 (s, 2H) ppm; 13 C NMR (75
MHz, CD 3 0D) o 18.7, 27.2, 32.0, 32.6, 33.5, 62.9, 127.1,
128.7, 130.3, 141.0, 141.2, 143.1, 145.5, 147.2 ppm.
Example 36
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Synthesis of Compound
1,2-bis-[ 5-( 4-methyl-pyridinium)-pentyl]-benzene
dibromide
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Synthesis of Compound
1,2-bis-[5-(3-methyl-pyridinium)-pentyl]-benzene
dibromide

Q
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A mixture of 1,2-bis-(5-bromo-pentyl)-benzene (290 mg,
0.77 mmol) and 4-picoline (1 mL) was heated at 60-70° C.
for 12 hrs. The resulted mixture was washed with diethyl
ether and then dissolved in water (15 mL), the aqueous
solution was extracted with diethyl ether (30 mLx3). Water
was removed by lyophilization to afford 387 mg of the title
compound. Yield: 89%. 1 H NMR (300 MHz, CD 3 0D) o
1.44 (m, 4H), 1.65 (m, 4H), 2.04 (m, 4H), 2.64 (t, 1=7 .5 Hz,
4H), 2.68 (s, 6H), 4.58 (t, 1=7.5 Hz, 4H), 7.02-7.15 (m, 4H),
7.92 (d, 1=6.3 Hz, 4H), 8.83 (dd, 1=5.1, 1.8 Hz, 4H) ppm;
13
C NMR (75 MHz, CD 3 0D) o22.3, 27.0, 31.9, 32.3, 33.3,
62.0, 127.0, 129.8, 130.2, 140.9, 144.7, 160.8 ppm.
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Example 37

A mixture of 1,2-bis-(5-bromo-pentyl)-benzene (270 mg,
0.72 mmol) and 3,4-lutidine (1 mL) was heated at 60-70° C.
for 12 hrs. The resulted mixture was washed with diethyl
ether and then dissolved in water (15 mL), the aqueous
solution was extracted with diethyl ether (30 mLx3). Water
was removed by lyophilization to afford 329 mg of the title
compound. Yield: 78 1 H NMR (300 MHz, CD 3 0D) o 1.43
(m, 4H), 1.65 (m, 4H), 2.03 (m, 4H), 2.48 (s, 6H), 2.59 (s,
6H), 2.64 (t, 1=7.5 Hz, 4H), 4.54 (t, 1=7.5 Hz, 4H), 7.02-7.17
(m, 4H), 7.85 (d, 1=6.3 Hz, 2H), 8.67 (d, 1=4.8 Hz, 2H), 8.77
(s, 2H) ppm; 13 C NMR (75 MHz, CD 3 0D) o 17.3, 20.6,
27.1, 31.9, 32.4, 33.3, 61.8, 126.9, 129.4, 130.2, 139.7,
140.9, 142.4, 144.0, 159.5 ppm.

Synthesis of Compound 1,2-bis-[5-(2,4-dimethylpyridinium)-pentyl]-benzene dibromide
5
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Br
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Example 39
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Synthesis of Compound 1,2-bis-[5-(3,5-dimethylpyridinium)-pentyl]-benzene dibromide [GZ 584 A]

NY

Br
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A mixture of 1,2-bis-(5-bromo-pentyl)-benzene (270 mg,
0.72 mmol) and 2,4-lutidine (1 mL) was heated at 60-70° C.
for 12 hrs. The resulted mixture was washed with diethyl
ether and then dissolved in water (15 mL), the aqueous
solution was extracted with diethyl ether (30 mLx3). Water 30
was removed by lyophilization to afford 355 mg of the title
compound. Yield: 84%. 1 H NMR (300 MHz, CD 3 0D) o
1.52 (m, 4H), 1.68 (m, 4H), 2.01 (m, 4H), 2.61 (s, 6H), 2.68
(t, 1=7.5 Hz, 4H), 2.82 (s, 6H), 4.53 (t, 1=7.8 Hz, 4H),
35
7.02-7.19 (m, 4H), 7.73 (dd, 1=6.3, 1.2 Hz, 2H), 7.82 (d,
13
1-1.5 Hz, 2H), 8.72 (d, 1=6.3 Hz, 2H) ppm; C NMR (75
MHz, CD 3 0D) o 20.5, 22.0, 27.4, 31.2, 32.0, 33.4, 58.4,
127.0, 127.6, 130.3, 131.6, 141.0, 145.4, 155.2, 160.2 ppm.
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Example 38
Synthesis of Compound 1,2-bis-[5-(3,4-dimethylpyridinium)-pentyl]-benzene dibromide [GZ 584 B]
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A mixture of 1,2-bis-(5-bromo-pentyl)-benzene (290 mg,
0.77 mmol) and 3,5-lutidine (1 mL) was heated at 60-70° C.
for 12 hrs. The resulted mixture was washed with diethyl
ether and then dissolved in water (15 mL), the aqueous
solution was extracted with diethyl ether (30 mLx3). Water
was removed by lyophilization to afford 321 mg of the title
compound. Yield: 71%. 1 H NMR (300 MHz, CD 3 0D) o
1.50 (m, 4H), 1.65 (m, 4H), 2.12 (m, 4H), 2.58 (s, 12H), 2.64
(t, 1=6.3 Hz, 4H), 4.68 (t, 1=7.5 Hz, 4H), 7.02-7.19 (m, 4H),
8.33 (s, 2H), 8.91 (s, 4H) ppm; 13 C NMR (75 MHz, CD 3 0D)
0 18.7, 27.2, 31.9, 32.5, 33.4, 62.5, 126.9, 130.2, 140.0,
140.9, 142.6, 147.7 ppm.
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Example 40

-continued
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Synthesis of Compound
1,2-bis-[5-quinolinium-pentyl)-benzene dibromide

2Bf3
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A mixture of 1,2-bis-(5-bromo-pentyl)-benzene (271 mg,
0.72 mmol) and isoquinoline (1 mL) was heated at 60-70° C.
for 12 hrs. The resulted mixture was washed with diethyl
ether and then dissolved in water (20 mL), the aqueous
solution was extracted with chloroform (20 mLx3). Water
was removed by lyophilization to afford 392 mg of the title
compound. Yield: 86%. 1 H NMR (300 MHz, CD 3 0D) o
1.38-1.70 (m, 8H), 2.20 (m, 4H), 2.52 (t, 1=7.2 Hz, 4H), 4.92
(t, 1=7.5 Hz, 4H), 6.83-7.05 (m, 4H), 7.99 (dd, 1=6.9, 1.2 Hz,
2H), 8.18 (dt, 1=8.1, 0.9, 2H), 8.28 (d, 1-8.4 Hz, 2H),
8.45-8.60 (m, 4H), 8.84 (dd, 1=6.9, 1.2 Hz, 2H), 10.21 (s,
2H) ppm; 13 C NMR (75 MHz, CD 3 0D) o 27.0, 31.6, 32.2,
33.1, 62.5, 126.7, 127.2, 128.2, 128.5, 129.9, 131.2, 132.2,
135.6, 137.9, 138.3, 140.6, 150.3 ppm.
Example 42
Synthesis of Compound
1,2-bis-[ 5-(2' -S-nicotinium -pentyl)]benzene
dibromide

30

A mixture of 1,2-bis-(5-bromo-pentyl)-benzene (282 mg,
0.75 mmol) and quinoline (1 mL) was heated at 60-70° C.
for 12 hrs. The resulted mixture was washed with diethyl
ether and then dissolved in water (20 mL), the aqueous
solution was extracted with chloroform (20 mL *3 ). Water
was removed by lyophilization to afford 411 mg of the title
compound. Yield: 86%. 1 H NMR (300 MHz, CD 3 0D) o
1.41-1.73 (m, 8H), 2.13 (m, 4H), 2.47 (t, 1=6.6 Hz, 4H), 5.22
(t, 1=7.5 Hz, 4H), 6.91 (m, 4H), 8.00 (t, 1=7.8 Hz, 2H), 8.16
(m, 2H), 8.31 (t, 1-7.2 Hz, 2H), 8.44 (d, 1-7.8 Hz, 2H), 8.65
(d, 1=8.7 Hz, 2H), 9.30 (d, 1=8.1 Hz, 2H), 9.70 (d, 1=5.4 Hz,
2H) ppm; 13 C NMR (75 MHz, CD 3 0D) o27.3, 30.9, 31.6,
33.1, 59.2, 119.8, 123.0, 126.7, 129.8, 131.0, 131.1, 131.8,
137.1, 138.6, 140.6, 148.6, 150.2 ppm.
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Example 41
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Synthesis of Compound
1,2-bis-[5-isoquinolinium-pentyl)-benzene
dibromide [GZ 585 B]
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A mixture of 1,2-bis-(5-bromo-pentyl)-benzene (278 mg,
0.74 mmol) and S-nicotine (1 mL) was heated at 60-70° C.
for 12 hrs. The resulted mixture was washed with diethyl
ether and then dissolved in water (20 mL), the aqueous
solution was extracted with chloroform (20 mLx3), Water
was removed by lyophilization to afford 390 mg of the title
compound. Yield: 75%. 1 H NMR (300 MHz, CD 3 0D) o
1.40-1.75 (m, 8H), 2.08-2.45 (m, 10H), 2.67 (s, 6H), 2.552.75 (m, 8H), 3.07 (m, 2H), 3.67 (m, 2H), 4.43 (t, 1=6.9 Hz,
4H), 7.02-7.22 (m, 4H), 8.24 (dd, 1=7.8, 6.3 Hz, 2H), 8.85
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(d, 1=8.1 Hz, 2H), 9.17 (d, 1=6.0 Hz, 2H), 9.39 (s, 2H) ppm;
13
C NMR (75 MHz, CD 3 0D) o23.4, 27.1, 31.8, 32.2, 33.2,
33.7, 40.2, 57.6, 63.2, 68.9, 126.9, 129.6, 130.2, 139.8,
140.9, 145.8, 146.4 ppm.

-continued

Example 43

~

Synthesis of Compound
1,2-bis-[5-(3-n-butyl-pyridinium)-pentyl]-benzene
dibromide

-

h~ Br
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A mixture of 1,2-bis-(5-bromo-pentyl)-benzene (235 mg,
0.72 mmol) and 3-bromopyridine (1 mL) was heated at
15 60-70° C. for 12 hrs. The resulted mixture was washed with
diethyl ether and then dissolved in water (15 mL), the
aqueous solution was extracted with diethyl ether (30
mLx3). Water was removed by lyophilization to afford 410
mg of the title compound. Yield: 95%. 1 H NMR (300 MHz,
20
CD 3 0D) o 1.30-1.75 (m, 8H), 2.13 (m, 4H), 2.63 (t, 1=7.5
Hz, 4H), 4.79 (t, 1=7.5 Hz, 4H), 7.00-7.21 (m, 4H), 8.12 (dd,
1-8.1, 6.0 Hz, 2H), 8.84 (d, 1=7.8 Hz, 2H), 9.24 (d, 1=5.7 Hz,
2H), 9.58 (s, 2H) ppm; 13 C NMR (75 MHz, CD 3 0D) o27.2,
31.9, 32.5, 33.4, 63.2, 124.0, 127.0, 130.2, 140.9, 144.9,
147.1, 149.4 ppm.
Example 45
Synthesis of Compound
1,2-bis-[5-pyridinium-pentyl)-benzene dibromide

A mixture of 1,2-bis-(5-bromo-pentyl)-benzene (232 mg,
0.62 mmol) and 4-n-butylpyridine (0.5 mL) was heated at
60-70° C. for 12 hrs. The resulted mixture was washed with
diethyl ether and then dissolved in water (20 mL), the
aqueous solution was extracted with chloroform (20 mLx3).
Water was removed by lyophilization to afford 154 mg of the
title compound. Yield: 39%. 1 H NMR (300 MHz, CD 3 0D)
o 0.98 (t, 1=7.2 Hz, 6H), 1.30-1.87 (m, 16H), 2.09 (m, 4H),
2.64 (t, 1=7.5 Hz, 4H), 2.92 (t, 1-7.2 Hz, 4H), 4.70 (t, 1=6.6
Hz, 4H), 6.98-7.18 (m, 4H), 8.05 (dd, 1=8.1, 5.4 Hz, 2H),
8.49 (d, 1=8.1 Hz, 2H), 9.95 (d, 1=5.7 Hz, 2H), 10.08 (s, 2H)
ppm; 13 C NMR (75 MHz, CD 3 0D) o14.4, 23.3, 27.2, 31.9,
32.6, 33.3, 33.4, 33.8, 62.8, 127.0, 128.9, 130.3, 140.9,
143.3, 145.2, 145.5, 146.5 ppm.
Example 44
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Synthesis of Compound
1,2-bis-[5-(3-bromo-pyridinium)-pentyl]-benzene
dibromide

I

65

A mixture of 1,2-bis-(5-bromo-pentyl)-benzene (244 mg,
0.65 mmol) and pyridine (1 mL) was heated at 60-70° C. for
12 hrs. The resulted mixture was washed with diethyl ether
and then dissolved in water (15 mL), the aqueous solution
was extracted with diethyl ether (30 mLx3). Water was
removed by lyophilization to afford 317 mg of the title
compound. Yield: 92%. 1 H NMR (300 MHz, CD 3 0D) o
1.48 (m, 4H), 1.65 (m, 4H), 2.10 (m, 4H), 2.63 (t, 1-7.5 Hz,
4H), 4.74 (t, 1=7.5 Hz, 4H), 7.02-7.20 (m, 4H), 8.16 (t, 1=6.9
Hz, 4H), 8.64 (t, 1=7.8 Hz, 2H), 9.13 (d, 1=5.4 Hz, 4H) ppm;
13
C NMR (75 MHz, CD 3 0D) o27.1, 31.9, 32.5, 33.3, 62.9,
127.0, 129.4, 130.3, 140.9, 145.8, 146.7 ppm.
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Example 46

-continued

Br

Synthesis of Compound 5-[3-(5-hydroxy-pent-1ynyl)-phenyl]-pent-4-yn-1-ol
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1,3-Dibromobenzene (7.48 g, 31.71 mmol), 4-pentyn-1-ol
(6.40 g, 76.10 mmol), and &M(triphenylphosphine)palladium(II) dichloride (445 mg, 0.63 mmol) was stirred in
triethylamine (150 mL) under nitrogen for 5 min. Copper(!)
iodide (61 mg, 0.32 mmol) was added and the mixture was
stirred for 18 hrs at 75° C. The mixture was cooled to room
temperature and filtered through a celite pad, rinsed with
ethylacetate. The combined filtrate was evaporated to dryness under reduced pressure. The resulting residue was
purified by colunm chromatography (chloroform:methanol
20:1) to afford 7.24 g of the title compound. Yield: 94%. 1 H
NMR (300 MHz, CDC1 3 ) o 1.85 (m, 4H), 2.53 (t, 1=6.9 Hz,
4H), 3.81 (t, 1=6.0 Hz, 4H), 7.16-7.31 (m, 3H), 7.42 (t, 1=1.2
Hz, lH) ppm; 13 C NMR (75 MHz, CDC1 3 ) o 16.2, 31.6,
61.9, 80.6, 90.0, 124.0, 128.3, 130.8, 134.7 ppm.

30

5-[3-( 5-Hydroxy-pent-1-ynyl)-phenyl]-pent-4-yn-1-ol
(2.86 g, 11.80 mmol) and carbon tetrabromide (9.78 g, 29.50
mmol) were dissolved in dry methylene chloride (30 mL)
and cooled to oo C. Triphenyl phosphine (8.13 g, 30.98
mmol) in methylene chloride (20 mL) was added dropwise
and the mixture was stirred for 1 h at oo C. The mixture was
poured into hexanes (200 mL) and then filtered through a
short silica gel column, washed with ethylacetate/hexanes
(1/4). The combined organic solvents were evaporated to
dryness under reduced pressure. The resulting residue was
purified by colunm chromatography (hexanes:ethylacetate
30:1) to afford 3.64 g of the title compound. Yield: 84%. 1 H
NMR (300 MHz, CDC1 3 ) o 2.13 (m, 4H), 2.60 (t, 1=6.6 Hz,
4H), 3.58 (dt, 1=6.6 Hz, 4H), 7.18-7.32 (m, 3H), 7.43 (t,
1=1.5 Hz, lH) ppm; 13 C NMR (75 MHz, CDC1 3 ) o 18.4,
31.7, 32.7, 81.1, 88.7, 123.8, 128.4, 131.0, 134.8 ppm.
Example 48
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Synthesis of Compound 1,3-bis-[5-(2-methyl-pyridinium)-pent-1-ynyl]-benzene dibromide
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Example 47
Synthesis of Compound
1,3-bis-(5-bromo-pent-1-ynyl)-benzene
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A mixture of 1,3-bis-(5-bromo-pent-1-ynyl)-benzene
(368 mg, 1.00 mmol) and 2-picoline (1.5 mL) was heated at
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60-70° C. for 12 hrs. The resulted mixture was washed with
diethyl ether and then dissolved in water (20 mL), the
aqueous solution was extracted with diethyl ether (30
mLx3). Water was removed by lyophilization to afford 472
mg of the title compound. Yield: 84%. 1 H NMR (300 MHz,
CD 3 0D) o2.29 (m, 4H), 2.69 (t, 1=6.6 Hz, 4H), 2.97 (s, 6H),
4.81 (t, 1=7.5 Hz, 4H), 7.23-7.38 (m, 3H), 7.43 (d, 1=1.5 Hz,
IH), 7.95 (t, 1=6.9 Hz, 2H), 8.01 (d, 1=7.8 Hz, 2H), 8.43 (dt,
1=7.8, 1.5 Hz, 2H), 8.99 (dd, 1=6.3, 1.5 Hz, 2H) ppm; 13 C
NMR (75 MHz, CD 3 0D) o17.4, 20.9, 29.9, 58.3, 82.1, 89.6,
124.7, 127.0, 129.8, 131.5, 132.2, 135.2, 146.5, 146.6, 156.8
ppm.

Example 50

Example 49

Synthesis of Compound 1,3-bis-[5-( 4-methyl-pyridinium)-pent-1-ynyl]-benzene dibromide
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Synthesis of Compound 1,3-bis-[5-(3-methyl-pyridinium)-pent-1-ynyl]-benzene dibromide
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A mixture of 1,3-bis-(5-bromo-pent-1-ynyl)-benzene
(350 mg, 0.94 mmol) and 4-picoline (1.5 mL) was heated at
60-70° C. for 12 hrs. The resulted mixture was washed with
diethyl ether and then dissolved in water (20 mL), the
aqueous solution was extracted with diethyl ether (30
mLx3). Water was removed by lyophilization to afford 478
mg of the title compound. Yield: 92%. 1 H NMR (300 MHz,
CD 3 0D) o2.33 (m, 4H), 2.58 (s, 6H), 2.63 (t, 1=6.6 Hz, 4H),
4.77 (t, 1=6.9 Hz, 4H), 7.28 (s, 4H), 7.93 (d, 1=6.3 Hz, 4H),
8.90 (d, 1=6.6 Hz, 4H) ppm; 13 C NMR (75 MHz, CD 3 0D)
0 17.3, 22.3, 30.8, 61.4, 81.9, 89.5, 124.7, 129.9, 132.1,
135.2, 145.0, 161.2 ppm.

I

A mixture of 1,3-bis-(5-bromo-pent-1-ynyl)-benzene
(348 mg, 0.94 mmol) and 3-picoline (1.5 mL) was heated at
60-70° C. for 12 hrs. The resulted mixture was washed with
diethyl ether and then dissolved in water (20 mL), the
aqueous solution was extracted with diethyl ether (30
mLx3). Water was removed by lyophilization to afford 469
mg of the title compound. Yield: 90%. 1 H NMR (300 MHz,
CD 3 0D) o2.35 (m, 4H), 2.56 (s, 6H) 2.63 (t, 1=6.6 Hz, 4H),
4.80 (t, 1=7.2 Hz, 4H), 7.22-7.33 (m, 3H), 7.37 (s, IH), 8.00
(dd, 1=8.1, 6.3 Hz, 2H), 8.39 (d, 1=7.8 Hz, 2H), 8.91 (d, 1-6.3
Hz, 2H), 9.00 (s, 2H) ppm; 13 C NMR (75 MHz, CD 3 0D) o
17.3, 18.8, 31.0, 62.1, 82.1, 89.4, 124.7, 128.7, 129.7, 132.1,
135.4, 141.1, 143.3, 145.7, 147.4 ppm.

Example 51
50

Synthesis of Compound 1,3-bis-[5-(2,4-dimethylpyridinium)-pent-1-ynyl]-benzene dibromide
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diethyl ether and then dissolved in water (15 mL), the
aqueous solution was extracted with diethyl ether (30
mLx3). Water was removed by lyophilization to afford 261
mg of the title compound. Yield: 65%. 1 H NMR (300 MHz,
CD 3 0D) o 2.36 (s, 3H), 2.43 (s, 3H), 2.47 (m, 4H), 2.66 (t,
1=6.6 Hz, 4H), 4.77 (t, 1=6.9 Hz, 4H), 7.18-7.36 (m, 4H),
7.87 (d, 1=6.3 Hz, 2H), 8.82 (d, 1=6.3 Hz, 2H), 8.92 (s, 2H),
ppm; 13 C NMR (75 MHz, CD 3 0D) o17.2, 17.4, 20.4, 30.8,
61.5, 81.9, 89.5, 124.9, 129.5, 129.8, 132.0, 135.3, 139.8,
142.9, 144.5, 160.0 ppm.
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Example 53
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A mixture of 1,3-bis-(5-bromo-pent-1-ynyl)-benzene
(249 mg, 0.68 mmol) and 2,4-lutidine (1 mL) was heated at
60-70° C. for 12 hrs. The resulted mixture was washed with
diethyl ether and then dissolved in water (15 mL), the
aqueous solution was extracted with diethyl ether (30
mLx3). Water was removed by lyophilization to afford 357
mg of the title compound. Yield: 91%. 1 H NMR (300 MHz,
CD 3 0D) o2.29 (m, 4H), 2.51 (s, 3H), 2.73 (t, 1=6.6 Hz, 4H),
2.94 (s, 3H), 4.79 (t, 1=7.5 Hz, 4H), 7.33 (d, 1=0.9 Hz, 4H),
7.78 (dd, 1=6.6, 2.1 Hz, 2H), 7.85 (s, 2H), 8.89 (d, 1=6.6 Hz,
2H) ppm; 13 C NMR (75 MHz, CD 3 0D) o17.4, 20.6, 22.0,
29.9, 57.6, 82.0, 89.7, 124.8, 127.6, 129.9, 131.7, 132.1,
135.1, 145.6, 155.5, 160.5 ppm.

Synthesis of Compound 1,3-bis-[5-(3,5-dimethylpyridinium)-pent-1-ynyl]-benzene dibromide
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Example 52
Synthesis of Compound 1,3-bis-[5-(3,4-dimethylpyridiniiim)-pent-1-ynyl]-benzene dibromide [GZ
570 B]
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A mixture of 1,3-bis-(5-bromo-pent-1-ynyl)-benzene
(253 mg, 0.69 mmol) and 3,4-lutidine (1 mL) was heated at
60-70° C. for 12 hrs. The resulted mixture was washed with

60

65

A mixture of 1,3-bis-(5-bromo-pent-1-ynyl)-benzene
(249 mg, 0.68 mmol) and 3,5-lutidine (1 mL) was heated at
60-70° C. for 12 hrs. The resulted mixture was washed with
diethyl ether and then dissolved in water (15 mL), the
aqueous solution was extracted with diethyl ether (30
mL *3). Water was removed by lyophilization to afford 356
mg of the title compound. Yield: 90%. 1 H NMR (300 MHz,
CD 3 0D) o2.35 (m, 4H), 2.51 (s, 6H), 2.64 (t, 1=6.3 Hz, 4H),
4.75 (t, 1=7.2 Hz, 4H), 7.28 (d, 1=1.2 Hz, 3H), 7.33 (s, lH),
8.19 (s, 2H), 8.82 (s, 4H) ppm; 13 C NMR (75 MHz, CD 3 0D)
0 17.4, 18.7, 31.0, 61.8, 81.9, 89.7, 124.6, 129.7, 132.0,
135.2, 140.1, 142.8, 147.9 ppm.
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Synthesis of Compound
1,3-bis-( 5-quinolinium-pent-1-ynyl)-benzene
dibromide [GZ571A]
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A mixture of 1,3-&fs-(5-bromo-pent-1-ynyl)-benzene
(257 mg, 0.70 mmol) and isoquinoline (1 mL) was heated at
60-70° C. for 12 hrs. The resulted mixture was washed with
20

25

30

~~~~~~s :t~l~ti~~~!~:~t~;~:~lv~fthi~h~~~%~~2~~Lxt~)~
Water was removed by lyophilization to afford 316 mg of the
title compound. Yield: 72%. 1 H NMR (300 MHz, CD 3 0D)
o 2.47 (m, 4H), 2.74 (t, 1=6.3 Hz, 4H), 5.01 (t, 1=6.9 Hz,
4H), 6.54 (s, lH), 6.85-7.03 (m, 3H), 8.01 (dt, 1=6.0, 1.5 Hz,
2H), 8.11-8.22 (m, 4H), 8.40-8.57 (m, 4H), 8.79 (dd, 1=6.9,
1.2 Hz, 2H), 10.15 (s, 2H) ppm; 13 C NMR (75 MHz,
CD 3 0D) o17.6, 30.6, 62.6, 82.0, 89.2, 124.4, 127.5, 128.4,
129.2, 129.3, 131.5, 131.7, 132.5, 134.7, 136.0, 138.4,
139.1, 151.5 ppm.
Example 56

A mixture of 1,3-bis-(5-bromo-pent-1-ynyl)-benzene
(253 mg, 0.69 mmol) and quinoline (1 mL) was heated at
60-70° C. for 12 hrs. The resulted mixture was washed with
diethyl ether and then dissolved in water (30 mL), the
aqueous solution was extracted with chloroform (20 mLx3).
Water was removed by lyophilization to afford 271 mg of the
title compound. Yield: 63%. 1 H NMR (300 MHz, CD 3 0D)
o 2.45 (m, 4H), 2.73 (t, 1=6.6 Hz, 4H), 5.31 (t, 1=7.5 Hz,
4H), 7.14 (d, 1-1.2 Hz, lH), 7.20-7.30 (m, 3H), 8.02-8.17
(m, 4H), 8.31 (dt, 1=7.2, 1.2 Hz, 2H), 8.41 (dd, 1=8.4, 1.5
Hz, 2H), 8.67 (d, 1=9.0 Hz, 2H), 9.17 (d, 1=8.7 Hz, 2H), 9.54
(dd, 1=5.7, 1.5 Hz, 2H) ppm; 13 C NMR (75 MHz, CD 3 0D)
0 17.5, 29.6, 58.7, 81.8, 89.8, 119.7, 123.1, 124.4, 129.6,
131.2, 131.4, 131.9, 132.1, 135.0, 137.3, 139.1, 149.1, 150.6
ppm.

Synthesis of Compound 1,3-bis-[5-(2'-S-nicotiniumpent -1-yny I) ]benzene dibromide
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Example 55
Synthesis of Compound
1,3-bis-( 5-isoquinolinium-pent-1-ynyl)-benzene
dibromide
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A mixture of 1,3-bis-(5-bromo-pent-1-ynyl)-benzene
(244 mg, 0.66 mmol) and S-nicotine (1 mL) was heated at
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60-70° C. for 12 hrs. The resulted mixture was washed with
diethyl ether and then dissolved in water (20 mL), the
aqueous solution was extracted with chloroform (20 mLx3).
Water was removed by lyophilization to afford 388 mg of the
title compound. Yield: 85%. 1 H NMR (300 MHz, CD 3 0D)
o 1.75-2.15 (m, 6H), 2.35 (s, 6H), 2.33-2.50 (m, 6H), 2.63
(t, 1=6.6 Hz, 4H), 3.37 (m, 2H), 3.74 (m, 2H), 4.87 (t, 1=6.9
Hz, 4H), 7.23-7.35 (m, 3H), 7.41 (s, lH), 8.12 (dd, 1-8.1, 6.0
Hz, 2H), 8.61 (dd, 1=7.8, 0.9 Hz, 2H), 9.03 (dd, 1=6.0, 0.9
Hz, 2H), 9.18 (s, 2H) ppm; 13 C NMR (75 MHz, CD 3 0D) o
17.2, 23.9, 30.8, 35.5, 40.7, 57.8, 62.3, 68.5, 82.2, 89.3,
124.7, 129.4, 129.7, 132.2, 135.4, 144.9, 145.1, 145.4, 146.1
ppm.

Example 58
Synthesis of Compound 1,3-bis-[5-(3-phenyl-pyridinium)-pent-1-ynyl]-benzene dibromide
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Example 57
Synthesis of Compound 1,3-bis-[5-(3-n-butyl-pyridinium)-pent-1-ynyl]-benzene dibromide
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A mixture of 1,3-bis-(5-bromo-pent-1-ynyl)-benzene
(242 mg, 0.66 mmol) and 4-n-butylpyridine (0.5 mL) was
heated at 60-70° C. for 12 hrs. The resulted mixture was
washed with diethyl ether and then dissolved in water (30
mL), the aqueous solution was extracted with chloroform
(20 mLx3). Water was removed by lyophilization to afford
347 mg of the title compound. Yield: 83%. 1 H NMR (300
MHz, CD 3 0D) o 0.98 (t, 1=7.2 Hz, 6H), 0.95 (t, 1=7.2 Hz,
6H), 1.40 (m, 4H), 1.67 (m, 4H), 2.39 (m, 4H), 2.67 (t, 1=6.6
Hz, 4H), 2.88 (t, 1=7.8 Hz, 4H), 4.90 (t, 1=6.9 Hz, 4H), 7.29
(d, 1=1.2 Hz, 3H), 7.33 (s, lH), 8.07 (dd, 1=7.8, 6.0 Hz, 2H),
8.45 (d, 1=8.1 Hz, 2H), 9.04 (d, 1-6.3 Hz, 2H), 9.14 (s, 2H)
ppm; 13 C NMR (75 MHz, CD 3 0D) o14.4, 17.3, 23.3, 31.0,
33.3, 33.6, 62.1, 82.1, 89.4, 124.7, 129.0, 129.7, 132.2,
135.4, 143.5, 145.4, 145.5, 146.8 ppm.

A mixture of 1,3-bis-(5-bromo-pent-1-ynyl)-benzene
(243 mg, 0.66 mmol) and 3-bromopyridine (0.5 mL) was
heated at 60-70° C. for 12 hrs. The resulted mixture was
washed with diethyl ether and then dissolved in water (30
mL), the aqueous solution was extracted with chloroform
(20 mLx3). Water was removed by lyophilization to afford
390 mg of the title compound. Yield: 87%. 1 H NMR (300
MHz, CD 3 0D) o 2.41 (m, 4H), 2.70 (t, 1=6.6 Hz, 4H), 5.00
(t, 1=6.9 Hz, 4H), 7.15 (d, "1=1.2 Hz, lH), 7.18 (m, 3H),
7.45-7.58 (m, 6H), 7.77-7.87 (m, 4H), 8.14 (dd, 1-8.1, 6.0
Hz, 2H), 8.74 (ddd, 1=8.1, 1.5, 1.2 Hz, 2H), 9.13 (d, 1=6.0
Hz, 2H), 9.56 (s, 2H) ppm; 13 C NMR (75 MHz, CD 3 0D) o
17.4, 30.9, 62.4, 82.0, 89.5, 124.5, 128.6, 129.5, 129.6,
130.6, 131.4, 132.0, 134.1, 135.3, 142.1, 143.9, 144.0, 144.2
ppm.
Example 59
Synthesis of Compound
1,3-bis-( 5-pyridinium-pent-1-ynyl)-benzene
dibromide
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psi) for 12 hrs. The catalyst was removed by filtration
through a Celite pad. The filter cake was rinsed with
methanol, and the combined organic liquors were concentrated under reduced pressure. The crude product was purified by colunm chromatography (chloroform:methanol 20:1)
to afford 3.12 g of the title compound. Yield: 89%. 1 H NMR
(300 MHz, CDC1 3 ) o 1.30-1.45 (m, 4H), 1.50-1.72 (m, 8H),
2.59 (t, 1=7.8 Hz, 4H), 3.62 (t, 1=6.6 Hz, 4H), 6.99 (m, 3H),
7.18 (m, lH) ppm; 13 C NMR (75 MHz, CDC1 3 ) o25.7, 31.5,
32.8, 36.1, 63.0, 125.8, 128.3, 128.7, 142.5 ppm.
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Example 61

N

A mixture of 1,3-bis-(5-bromo-pent-1-ynyl)-benzene
(240 mg, 0.65 mmol) and pyridine (1 mL) was heated at
60-70° C. for 12 hrs. The resulted mixture was washed with
diethyl ether and then dissolved in water (15 mL), the
aqueous solution was extracted with diethyl ether (30
mLx3). Water was removed by lyophilization to afford 322
mg of the title compound. Yield: 94%. 1 H NMR (300 MHz,
CD 3 0D) o 2.40 (m, 4H), 2.68 (t, 1=6.9 Hz, 4H), 4.94 (t,
1=7.5 Hz, 4H), 7.32 (m, 3H), 7.39 (d, 1=1.2 Hz, lH), 8.19
(dd, 1=7.8, 6.9 Hz, 4H), 8.63 (m, 2H), 9.23 (dd, 1=7.2, 1.2
Hz, 4H) ppm; 13 C NMR (75 MHz, CD 3 0D) o 17.2, 31.0,
62.1, 82.1, 89.4, 124.6, 129.4, 129.7, 132.2, 135.3, 146.0,
146.9 ppm.
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Synthesis of Compound
1,3-bis-( 5-bromo-pentyl)-benzene
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Example 60
Synthesis of Compound
5-[3-( 5-hydroxy-pentyl)-phenyl]-pentan-1-ol
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5-[3-( 5-Hydroxy-pent-1-ynyl)-phenyl]-pent-4-yn-1-ol
(3.40 g, 14.03 mmol) was dissolved in methanol (60 mL)
and 10% Pd!C (2.5% w/w) was added. The resulting mixture
was hydrogenated on a Parr hydrogenation apparatus (45

65

5-[3-(5-Hydroxy-pentyl)-phenyl]-pentan-1-ol (2.26 g,
9.03 mmol) and carbon tetrabromide (7.49 g, 22.58 mmol)
were dissolved in dry methylene chloride (20 mL) and
cooled to oo C. Triphenylphosphine (6.22 g, 23.70 mmol)
in methylene chloride (15 mL) was added dropwise and the
mixture was stirred for 1 h at oo C. The mixture was poured
into hexanes (200 mL) and then filtered through a short silica
gel column, washed with ethylacetate/hexanes (1/4). The
combined organic solvents were evaporated to dryness
under reduced pressure. The resulting residue was purified
by colunm chromatography (hexanes:ethylacetate30: 1) to
afford 2.80 g of the title compound. Yield: 82%. 1 H NMR
(300 MHz, CDC1 3 ) o1.46 (m, 4H), 1.61 (m, 4H), 1.88 (m,
4H), 2.59 (t, 1=7.8 Hz, 4H), 3.40 (t, 1=6.9 Hz, 4H), 7.00 (m,
3H), 7.19 (m, lH) ppm; 13 C NMR (75 MHz, CDC1 3 ) o28.1,
30.9, 32.9, 34.1, 36.0, 125.9, 128.3, 128.6, 142.4 ppm.
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Synthesis of Compound
1,3-bis-[5-(2-methyl-pyridinium)-pentyl]-benzene
dibromide
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A mixture of 1,3-bis-(5-bromo-pentyl)-benzene (265 mg,
0.70 mmol) and 3-picoline (1 ml) was heated at 60-70° C.
for 12 hrs. The resulted mixture was washed with diethyl
20 ether and then dissolved in water (15 mL), the aqueous
solution was extracted with diethyl ether (30 mLx3). Water
was removed by lyophilization to afford 362 mg of the title
compound. Yield: 91%. 1 H NMR (300 MHz, CD 3 0D) o
1.44 (m, 4H), 1.69 (m, 4H), 2.10 (m, 4H), 2.59 (t, 1=7.8 Hz,
25 4H), 2.62 (s, 6H), 4.70 (t, 1=7.5 Hz, 4H), 6.94-7.09 (m, 3H),
7.16 (t, 1=1.5 Hz, lH), 8.03 (dd, 1=8.1, 6.0 Hz, 2H), 8.48 (d,
1=8.1 Hz, 2H), 8.96 (d, 1=6.0 Hz, 2H), 9.08 (s, 2H) ppm; 13 C
NMR (75 MHz, CD 3 0D) o18.9, 26.6, 31.9, 32.3, 36.5, 62.6,
126.9, 128.6, 129.3, 129.6, 140.9, 142.9, 143.3, 145.3, 147.1
30
ppm.
Example 64

A mixture of 1,3-bis-(5-bromo-pentyl)-benzene (240 mg,
0.64 mmol) and 2-picoline (1 mL) was heated at 60-70° C.
for 12 hrs. The resulted mixture was washed with diethyl
ether and then dissolved in water (15 mL), the aqueous
solution was extracted with diethyl ether (30 mLx3). Water
was removed by lyophilization to afford 328 mg of the title
compound. Yield: 91%. 1 H NMR (300 MHz, CD 3 0D) o
1.54 (m, 4H), 1.73 (m, 4H), 2.02 (m, 4H), 2.63 (t, 1=7.5 Hz,
4H), 2.95 (s, 6H), 4.67 (t, 1-7.5 Hz, 4H), 6.98-7.22 (m, 4H),
7.97 (t, 1=6.9 Hz, 2H), 8.07 (d, 1=8.1 Hz, 2H), 8.49 (t, 1=7.8
Hz, 2H), 9.05 (d, 1=6.3 Hz, 2H) ppm; 13 C NMR (75 MHz,
CD 3 0D) o20.9, 26.9, 31:0, 32.0, 36.5, 59.2, 126.85, 126.88,
129.3, 129.6, 131.4, 143.3, 146.2, 146.3, 156.4 ppm.
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Synthesis of Compound
1,3-bis-[ 5-( 4-methyl-pyridinium)-pentyl]-benzene
dibromide
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Example 63
Synthesis of Compound
1,3-bis-[5-(3-methyl-pyridinium)-pentyl]-benzene
dibromide
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A mixture of 1,3-bis-(5-bromo-pentyl)-benzene (240 mg,
0.64 mmol) and 4-picoline (1 mL) was heated at 60-70° C.
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for 12 hrs. The resulted mixture was washed with diethyl
ether and then dissolved in water (15 mL), the aqueous
solution was extracted with diethyl ether (30 mLx3). Water
was removed by lyophilization to afford 332 mg of the title
compound. Yield: 92%. 1 H NMR (300 MHz, CD 3 0D) o
1.42 (m, 4H), 1.67 (m, 4H), 2.06 (m, 4H), 2.59 (t, 1-7.5 Hz,
4H), 2.69 (s, 6H), 4.66 (t, 1=7.5 Hz, 4H), 6.95-7.08 (m, 3H),
7.16 (t, 1=7.5 Hz, lH), 7.97 (d, 1=6.3 Hz, 4H), 8.94 {d, 1=6.3
Hz, 4H) ppm; 13 C NMR (75 MHz, CD 3 0D) o 22.4, 26.6,
31.9, 32.2, 36.5, 61.9, 126.9, 129.3, 129.6, 129.8, 143.3,
144.7, 160.7 ppm.

Example 66
Synthesis of Compound 1,3-bis-[5-(3,4-dimethylpyridinium)-pentyl]-benzene dibromide [GZ 578 B]
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Example 65
15

Synthesis of Compound 1,3-bis-[5-(2,4-dimethylpyridinium)-pentyl]-benzene dibromide

Br

~

20

~~
25

-

e

2Br

~

E0

30
Br

y

N

e

2Br

A mixture of 1,3-bis-(5-bromo-pentyl)-benzene (235 mg,
0.62 mmol) and 3,4-lutidine (1 mL) was heated at 60-70° C.
for 12 hrs. The resulted mixture was washed with diethyl
ether and then dissolved in water (15 mL), the aqueous
solution was extracted with diethyl ether (30 mLx3). Water
was removed by lyophilization to afford 350 mg of the title
40 compound. Yield: 97%. 1 H NMR (300 MHz, CD 0D) o
3
1.44 (m, 4H), 1.68 (m, 4H), 2.09 (m, 4H), 2.51 (s, 6H), 2.59
(t, 1=7.8 Hz, 4H), 2.60 (s, 6H), 4.65 (t, 1-7.5 Hz, 4H),
6.96-7.20 (m, 4H), 7.92 (d, 1=6.3 Hz, 2H), 8.82 (d, 1=6.3 Hz,
2H), 8.96 (s, 2H) ppm; 13 C NMR (75 MHz, CD 3 0D) o17 .3,
~45 20.7, 26.6, 31.9, 32.2, 36.5, 61.7, 126.8, 129.2, 129.3, 129.5,
139.6, 142.3, 143.2, 143.9, 159.4 ppm.
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Example 67
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Synthesis of Compound 1,3-bis-[5-(3,5-dimethylpyridinium)-pentyl]-benzene dibromide
A mixture of 1,3-bis-(5-bromo-pentyl)-benzene (237 mg,
0.63 mmol) and 2,4-lutidine (1 mL) was heated at 60-70° C.
for 12 hrs. The resulted mixture was washed with diethyl
ether and then dissolved in water (15 mL), the aqueous
solution was extracted with diethyl ether (30 mLx3). Water
was removed by lyophilization to afford 323 mg of the title
compound. Yield: 87%. 1 H NMR (300 MHz, CD 3 0D) o
1.51 (m, 4H), 1.71 (m, 4H), 1.99 (m, 4H), 2.62 (t, 1=7.5 Hz,
4H), 2.64 (s, 6H), 2.87 (s, 6H), 4.58 (t, 1=7.5 Hz, 4H),
6.96-7.12 (m, 3H), 7.17 (t, 1-7.5 Hz, lH), 7.78 (dd, 1=6.6,
1.5 Hz, 2H), 7.89 (d, 1=1.5 Hz, 2H), 8.82 (d, 1=6.6 Hz, 2H)
ppm; 13 C NMR (75 MHz, CD 3 0D) o20.5, 22.1, 26.9, 31.1,
32.1, 36.6, 58.4, 126.9, 127.5, 129.3, 129.6, 131.6, 143.3,
145.3, 155.1, 160.1 ppm.
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solution was extracted with chloroform (20 mLx3). Water
was removed by lyophilization to afford 383 mg of the title
compound. Yield: 90%. 1 H NMR (300 MHz, CD 3 0D) o
1.52 (m, 4H), 1.64 (m, 4H), 2.13 (m, 4H), 2.51 (t, 1=7.5 Hz,
4H), 5.17 (t, 1=7.5 Hz, 4H), 6.81-7.06 (m, 4H), 8.03 (t, 1=7.8
Hz, 2H), 8.12 (dd, 1=8.4, 6.0 Hz, 2H), 8.31 (dt, 1-6.0, 1.5 Hz,
2H), 8.45 (dd, 1=8.4, 0.9 Hz, 2H), 8.61 (d, 1=9.0 Hz, 2H),
9.27 (d, 1=8.4 Hz, 2H), 9.59 (d, 1=5.7 Hz, 2H) ppm; 13 C
NMR (75 MHz, CD 3 0D) o 27.0, 30.9, 31.9, 36.4, 59.3,
119.8, 123.0, 126.8, 129.1, 129.4, 131.2, 131.3, 132.0,
137.2, 138.9, 143.1, 148.7, 150.2 ppm.
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Example 69

A mixture of 1,3-bis-(5-bromo-pentyl)-benzene (246 mg,
0.65 mmol) and 3,5-lutidine (1 mL) was heated at 60-70° C.
for 12 hrs. The resulted mixture was washed with diethyl
ether and then dissolved in water (15 mL), the aqueous
solution was extracted with diethyl ether (30 mLx3). Water
was removed by lyophilization to afford 371 mg of the title
compound. Yield: 96%. 1 H NMR (300 MHz, CD 3 0D) o
1.46 (m, 4H), 1.68 (m, 4H), 2.11 (m, 4H), 2.58 (s, 12H), 2.63
(t, 1=6.6 Hz, 4H), 4.66 (t, 1=7.5 Hz, 4H), 6.95-7.20 (m, 4H),
8.34 (s, 2H), 8.92 (s, 4H) ppm; 13 C NMR (75 MHz, CD 3 0D)
0 18.7, 26.7, 32.0, 32.4, 36.5, 62.3, 126.8, 129.2, 129.5,
140.0, 142.6, 143.3, 147.6 ppm.

Synthesis of Compound
1,3-bis-(5-isoquinolinium-penty I)-benzene
dibromide [GZ 579 B]
20
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Example 68
Br

Synthesis of Compound
1,3-bis-(5-quinolinium-pentyl)-benzene dibromide
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A mixture of 1,3-bis-(5-bromo-pentyl)-benzene (253 mg,
0.67 mmol) and quinoline (1 mL) was heated at 60-70° C.
for 12 hrs. The resulted mixture was washed with diethyl
ether and then dissolved in water (30 mL), the aqueous

65
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A mixture of 1,3-bis-(5-bromo-pentyl)-benzene (278 mg,
0.74 mmol) and isoquinoline (1 mL) was heated at 60-70° C.
for 12 hrs. The resulted mixture was washed with diethyl
ether and then dissolved in water (30 mL), the aqueous
solution was extracted with chloroform (20 mLx3). Water
was removed by lyophilization to afford 391 mg of the title
compound. Yield: 83%. 1 H NMR (300 MHz, CD 3 0D) o
1.43 (m, 4H), 1.64 (m, 4H), 2.17 (m, 4H), 2.49 (t, 1=7.5 Hz,
4H), 4.88 (t, 1=7.5 Hz, 4H), 6.81-7.06 (m, 4H), 8.01 (t, 1=7.8
Hz, 2H), 8.19 (t, 1-7.5 Hz, 2H), 8.28 (d, 1=8.4 Hz, 2H), 8.53
(t, 1=6.9 Hz, 4H), 8.79 (dd, 1=6.9, 0.9 Hz, 2H), 10.16 (s, 2H)
ppm; 13 C NMR (75 MHz, CD 3 0D) o 26.6, 31.8, 32.2, 36.3,
62.6, 126.7, 127.4, 128.3, 128.7, 129.1, 129.4, 131.4, 132.3,
135.7, 138.1, 138.5, 143.1, 150.4 ppm.

US 9,499,518 B2

65

66

Example 70
Synthesis of compound N,N'-[(1,1'-biphenyl)-4,4'di -(3-prop any I)]-bis-[3-(2' -S-1-methy1-pyrrolidin-2yl)-pyridinium] dibromide

4,4'-Bis-(3-bromo-propyl)-biphenyl was added to a solution of 5-nicotine (3 mmol) in acetonitrile and the solution
refluxed for 24 hours. The acetonitrile was removed in
vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no S-nicotine left in the aqueous layer. The
resulting aqueous solution of the product was lyophilized to
yield the pure product. (75%). 1 H NMR (300 MHz, D 2 0,
ppm), 9.10 (s, 2H), 9.01 (d, 1=6.0, 2H), 8.52 (d, 1=7.8, 2H),
8.05 (dd, 2H), 7.49 (d, 1=8.1, 4H), 7.33 (d, 1=8.1, 4H), 4.79
(t, 1=7.5, 4H), 3.53 (t, 1=8.1, 2H), 3.23 (m, 2H), 2.83 (t,
1=7.5, 4H), 2.30-2.45 (m, 6H), 2.20 (s, 6H), 1.85-1.97 (in,
4H). CNMR, 145.85, 144.42, 143.74, 143.54, 139.48,
138.65, 129.07, 128.23, 126.81, 67.32, 61.64, 56.83, 39.90,
35.21, 32.87, 31.99, 23.09.

Synthesis of Compound N,N'-[(1,1 '-biphenyl)-4,4'di -(3-propanyl) ]-bis-(3,4-dimethylpyridinium)
dibromide [ZZ 55 C]
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4,4'-Bis-(3-bromo-propyl)-biphenyl was added to a solution of 3,4-lutidine (3 mmol) in acetonitrile and the solution
refluxed for 24 hours. The acetonitrile was removed in
vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no 3,4-lutidine left in the aqueous layer. The
resulting aqueous solution of the product was lyophilized to
yield the pure product. (75%). 1 H NMR (300 MHz, D 2 0,
ppm), 8.82 (s, 2H), 8.73 (d, 1=6.3, 2H), 7.78 (d, 3=63, 2H),
7.47 (d, 1=8.4, 4H), 7.29 (d, 1=8.4, 4H), 4.64 (t, 1=7.2, 4H),
2.79 (t, 1=7.2, 4H), 2.470 (s, 6H), 2.32-2.42 (m, 10H).
CNMR, 158.42, 143.02, 141.37, 139.56, 138.50, 138.32,
129.04, 128.32, 126.56, 60.61, 32.56, 31.97, 19.44, 16.12.
Example 73

A

Synthesis of Compound N,N'-[(1,1 '-biphenyl)-4,4'di -(3-propanyl) ]-bis-(2,4-dimethylpyridinium)
dibromide

k~
4,4'-Bis-(3-bromo-propyl)-biphenyl was added to a solution of3,5-lutidine (3 mmol) in acetonitrile and the solution
refluxed for 24 hours. The acetonitrile was removed in
vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no 3,5-lutidine left in the aqueous layer. The
resulting aqueous solution of the product was lyophilized to
yield the pure product. (75%). 1 H NMR (300 MHZ, D 2 0,
ppm), 8.79 (s, 4H), 8.15 (s, 2H), 7.46 (d, 1=8.1, 4H), 7.31 (d,
1=8.1, 4H), 4.66 (t, 1=7.5, 4H), 2.81 (t, 1=7.5, 2.46 (s, 12H),
2.34-2.39 (m, 4H). CNMR, 146.52, 141.58, 139.58, 139.00,
138.36, 129.05, 126.55, 61.28, 32.58, 32.05, 17.58.

Br

Br

Example 71
Synthesis of Compound N,N'-[(1,1 '-biphenyl)-4,4'di-(3-propanyl)]-bis-(3,5-dimethylpyridinium)
dibromide [ZZ 1 55 D]

Example 72
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4,4'-Bis-(3-bromo-propyl)-biphenyl was added to a solution of 2,4-lutidine (3 mmol) in acetonitrile and the solution
refluxed for 24 hours. The acetonitrile was removed in
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vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no 2,4-lutidine left in the aqueous layer. The
resulting aqueous solution of the product was lyophilized to
yield the pure product. (75%). 1 H NMR (300 MHZ, D 2 0,
ppm), 8.83 (d, 1=6.3, 2H), 7.79 (d, 1=1.5, 2H), 7.68 (dd,
1=7.8, 1=1.5, 2H), 7.52 (d, 1=8.4, 4H), 7.37 (d, 1=8.4, 4H),
4.58 (t, 1=7.5, 4H), 3.60 (t, 1=7.2, 4H), 2.85 (t, 1=7.2, 4H),
2.75 (s, 6H), 2.54 (s, 6H), 2.22-2.27 (m, 4H). CNMR,
159.10, 154.11, 144.30, 139.67, 138.39, 130.59, 129.22,
126.70, 126.55, 56.89, 31.94, 31.73, 31.02, 19.51.

-continued
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Example 74
Synthesis of Compound N,N'-[(1,1 '-biphenyl)-4,4'di -(3-propanyl) ]-bis-[3-(3 -hydroxy-propy1)-pyridinium]dibromide [ZZ 55 G]
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4,4'-Bis-(3-bromo-propyl)-biphenyl was added to a solution of 5,6,7,8-tetrahydroquinoline (3 mmol) in acetonitrile
and the solution refluxed for 24 hours. The acetonitrile was
removed in vacuum and the resulting residue was partitioned
between ether and water. The aqueous layer was washed
extensively with ether until no 5,6,7,8-tetrahydroquinoline
left in the aqueous layer. The resulting aqueous solution of
the product was lyophilized to yield the pure product. (75% ).
1
H NMR (300 MHz, D 2 0, ppm), 8.79 (d, 1-6.3, 2H), 8.19 (d,
1=7.2, 2H), 7.77 (dd, 1=6.3, 1=7.8, 2H), 7.54 (d, 1=7.8, 4H),
7.36 (d, 1=7.8, 4H), 4.59 (t, 1=7.8, 4H), 3.07 (t, 1=6.3, 4H),
2.97 (t, 1=6.0, 4H), 2.87 (t, 1=7.5, 4H), 2.30 (p, 1=7.5, 4H),
1.93-1.99 (m, 4H), 1.81-1.87 (m, 4H). CNMR, 154.12,
145.55, 143.40, 139.94, 139.38, 138.83, 128.99, 126.66,
124.51, 56.85, 31.93, 31.52, 28.77, 26.88, 21.54, 20.63.

Example 76
Synthesis of Compound N,N'-[(1,1 '-biphenyl)-4,4'di -(3-propany I) ]-bis-[ 5,6, 7 ,8-tetrahydroisoquinolinium] dibromide

4,4'-Bis-(3-bromo-propyl)-biphenyl was added to a solution of 3-(3-hydroxypropyl)-pyridine (3 mmol) in acetoniBr

Br

-

~

~~
40

trile and the solution refluxed for 24 hours. The acetonitrile
was removed in vacuum and the resulting residue was
partitioned between ether and water. The aqueous layer was
washed extensively with ether until no 3-(3-Hydroxypropyl)-pyridine left in the aqueous layer. The resulting aqueous
solution of the product was lyophilized to yield the pure
product. (75%). 1 H NMR (300 MHz, D 2 0, ppm), 8.96 (s,
2H), 8.87 (d, 1=6.0, 2H), 8.42 (d, 1=7.8, 2H), 7.96 (dd, 1=6.0,
1=7.8, 2H), 7.48 (d, 1=8.1, 4H) 5 7.29 (d, 1=8.1, 4H), 4.70
(t, 1=7.5, 4H), 3.60 (t, 1=6.3, 4H), 2.92 (t, 1=6.3, 4H), 2.81
(t, 1=7.5, 4H), 2.41 (p, 3=72, 4H), 1.87-1.95 (m, 4H).
CNMR, 145.47, 144.22, 143.95, 142.22, 139.27, 138.77,
128.87, 127.75, 126.76, 61.55, 60.46, 32.94, 32.56, 31.96,
29.09.
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4,4'-Bis-(3-bromo-propyl)-biphenyl was added to a solution of 5,6,7,8-tetrahydroisoquinoline (3 mmol) in acetonitrile and the solution refluxed for 24 hours. The acetonitrile
was removed in vacuum and the resulting residue was
partitioned between ether and water. The aqueous layer was
washed extensively with ether until no 5,6,7,8-tetrahydroisoquinoline left in the aqueous layer. The resulting
aqueous solution of the product was lyophilized to yield the
pure product. (75%). 1 H NMR (300 MHz, D 2 0, ppm), 8.67
(s, 2H), 8.60 (d, 1=6.3, 2H), 7.68 (d, 1=6.3, 2H), 7.48 (d,
1=8.4, 4H), 7.29 (d, 1=8.4, 4H), 4.59 (t, 1=7.2, 4H), 2.94 (br,
4H), 2.86 (br, 4H), 2.81 (t, 1=7.2, 4H), 2.39 (p, 1-7.5, 4H),
1.74-1.85 (m, 10H), CNMR, 158.38, 143.86, 140.21,
139.39, 138.64, 138.48, 128.86, 127.91, 126.56, 60.78,
21.12, 32.00, 29.31, 26.22, 21.11.

Example 75

Example 77

Synthesis of Compound N,N'-[(1,1 '-biphenyl)-4,4'di-(3-propanyl)]-bis-[5,6,7,8-tetrahydroquinolinium]
dibromide

Synthesis of Compound N,N'-[(1,1 '-biphenyl)-4,4'di-(3-propanyl) ]-bis-(4-methylpyridinium) dibromide
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Example 79

2Br

Synthesis of Compound N,N'-[(1,1 '-biphenyl)-4,4'di-(3-propanyl)]-bis-(2-methylpyridinium) dibromide

e

~N

4,4'-Bis-(3-bromo-propyl)-biphenyl was added to a solution of 4-picoline (3 mmol) in acetonitrile and the solution
refluxed for 24 hours. The acetonitrile was removed in
vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no 4-picoline left in the aqueous layer. The
resulting aqueous solution of the product was lyophilized to
yield the pure product. (75%). 1 H NMR (300 MHz, D 2 0,
ppm), 8.90 (d, 1=6.6, 4H), 7.85 (d, 1=6.3, 4H), 7.48 (d,
1=8.4, 4H), 7.32 (d, 1=8.4, 4H), 4.68 (t, 1=7.5, 4H), 2.78 (t,
1=7.8, 2.58 (s, 6H), 2.34 (m, 4H). CNMR, 159.77, 143.71,
139.52, 138.51, 129.08, 128.73, 126.76, 60.72, 32.76, 31.91,
21.27.

Br
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Example 78
Synthesis of Compound N,N'-[(1,1 '-biphenyl)-4,4'di-(3-propanyl)]-bis-(3-methylpyridinium) dibromide
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4,4'-Bis-(3-bromo-propyl)-biphenyl was added to a solution of 2-picoline (3 mmol) in acetonitrile and the solution
refluxed for 24 hours. The acetonitrile was removed in
vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no 2-picoline left in the aqueous layer. The
resulting aqueous solution of the product was lyophilized to
yield the pure product. (75%). 1 H NMR (300 MHz, D 2 0,
ppm), 9.02 (d, 3=6.3, 2H), 8.40 (dt, 1=1.5, 1=7.8, 2H), 7.97
(d, 1=7.8, 2H), 7.90 (t, 1=6.3, 2H), 7.53 (d, 1-8.1, 4H), 7.38
(d, 1=8.1, 4H), 4.65 (t, 1=7.8, 4H), 2.86 (t, 1=7.8, 4H), 2.82
(s, 6H), 2.24-2.32 (m, 4H) CNMR, 155.49, 145.33, 145.23,
139.56, 138.54, 130.41, 129.21, 126.78, 125.89, 57.71,
31.93, 31.71, 19.75.
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4,4'-Bis-(3-bromo-propyl)-biphenyl was added to a solution of 3-picoline (3 mmol) in acetonitrile and the solution
refluxed for 24 hours. The acetonitrile was removed in
vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no 3-picoline left in the aqueous layer. The
resulting aqueous solution of the product was lyophilized to
yield the pure product. (75%). 1 H NMR (300 MHz, D 2 0,
ppm), 9.00 (s, 2H), 8.92 (d, 1=6.3, 2H), 8.35 (d, 1=7.8, 2H),
7.93 (dd, 1=6.0, 1=8.1, 2H), 7.46 (d, 1=8.4, 4H), 7.32 (d,
1=8.4, 4H), 4.72 (t, 1=7.5, 4H), 2.80 (t, 1=7.5, 4H), 2.50 (s,
6H), 2.35-2.44 (m, 4H). CNMR, 146.06, 144.41, 141.92,
139.82, 139.55, 138.42, 129.11, 127.61, 126.70, 61.45,
32.76, 31.99, 17.80.

Synthesis of Compound N,N'-{ 2,2'-[ oxybis-(2,1ethandiyloxy) ]bis-ethyl }-bis-[3-(2'-S-1-methyl-pyrrolidin-2-yl)-pyridinium]dichloride
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1-Chloro-2-{ 2-[2-(2-chloro-ethoxy)-ethoxy]-ethoxy }ethane was added to a solution of S-nicotine (3 mmol) in
acetonitrile and the solution refluxed for 24 hours. The
acetonitrile was removed in vacuum and the resulting residue was partitioned between ether and water. The aqueous
layer was washed extensively with ether until no S-nicotine
left in the aqueous layer. The resulting aqueous solution of
the product was lyophilized to yield the pure product. (75% ).
1
H NMR (300 MHZ, D 2 0, ppm), 8.63-6.64 (m, 4H), 8.38 (d,
1=8.1, 2H), 7.90 (dd, 1=7.8, d=6.6, 2H), 2.61-2.63 (m, 4H),
3.85 (t, 1=4.8, 4H), 3.36-3.47 (m, 10H), 3.04-3.04 (m, 2H),
2.20-2.38 (m, 4H), 2.04 (s, 6H), 1.60-1.84 6H).
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Synthesis of Compound N,N'-{ 2,2'-[ oxybis-(2, 1ethandiyloxy) ]bis-ethyl} -bis(2-methy lpyridinium)
dichloride
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1-Chloro-2-{ 2-[2-(2-chloro-ethoxy )-ethoxy]-ethoxy }ethane was added to a solution of 2-picoline (3 mmol) in
acetonitrile and the solution refluxed for 24 hours. The
acetonitrile was removed in vacuum and the resulting residue was partitioned between ether and water. The aqueous
layer was washed extensively with ether until no 2-picoline
left in the aqueous layer. The resulting aqueous solution of
the product was lyophilized to yield the pure product. (75%).
1
H NMR (300 MHz, D 2 0, ppm), 8.55 (dd, 1=6.3, 1=1.2,
2H), 8.23 (dt, 1=7.8, 1-1.5, 2H), 7.75 (d, 1=7.8, 2H), 7.68 (dt,
1=7.8, 1=1.5, 2H), 4.62 (t, 4H), 3.82 (t, 4H), 3.40-3.44 (m,
4H), 3.35-3.39 (m, 4H), 2.36 (s, 6H).

15

1-Chloro-2-{ 2-[2-(2-chloro-ethoxy)-ethoxy]-ethoxy }ethane was added to a solution of 4-picoline (3 mmol) in
acetonitrile and the solution refluxed for 24 hours. The
acetonitrile was removed in vacuum and the resulting residue was partitioned between ether and water. The aqueous
layer was washed extensively with ether until no 4-picoline
left in the aqueous layer. The resulting aqueous solution of
the product was lyophilized to yield the pure product. (75% ).
1
H NMR (300 MHz, D 2 0, ppm), 8.47 (d, 1=6.9, 4H), 7.70
(d, 1=6.3, 4H), 4.54 (t, 1=4.8, 4H), 3.83 (t, 1=4.8, 4H),
3.43-3.47 (m, 4H), 3.35-3.38 (m, 4H), 2.47 (s, 6H). CNMR,
160.56, 143.63, 128.52, 69.92, 69.57, 68.95, 60.27, 21.58.
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Example 84
Synthesis of Compound N,N'-{ 2,2'-[ oxybis-(2,1ethandiyloxy) ]bis-ethyl} -bis(5,6, 7,8-tetrahydroquinolinium) dichloride

0

Example 82
30

Synthesis of Compound N,N'-{ 2,2'-[ oxybis-(2, 1ethandiyloxy) ]bis-ethyl} -bis(3 -methy lpyridinium)
dichloride
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1-Chloro-2-{ 2-[2-(2-chloro-ethoxy)-ethoxy]-ethoxy }ethane was added to a solution of tetrahydroquinoline (3
N/'......./ ~o~ ~N8(
mmol) in acetonitrile and the solution refluxed for 24 hours.
I0
4o The acetonitrile was removed in vacuum and the resulting
2c1 8
#
residue was partitioned between ether and water. The aqueous layer was washed extensively with ether until no tetrahydroquinoline left in the aqueous layer. The resulting
1-Chloro-2-{ 2-[2-(2-chloro-ethoxy )-ethoxy]-ethoxy }product was lyophilized to yield the
ethane was added to a solution of 3-picoline (3 mmol) in 45 aqueous solution of the
pure product. (75% ). 1 H NMR (300 MHZ, D 2 0, ppm), 8.39
acetonitrile and the solution refluxed for 24 hours. The
(d, 1=6.3, 2H), 8.04 (d, 1=8.1, 2H), 7.55 (dd, 1=8.1, 1=6.3,
acetonitrile was removed in vacuum and the resulting resi2H), 4.57 (t, 1=4.5, 4H), 3.83 (t, 1=4.5, 4H), 4.43-3.49 (m,
due was partitioned between ether and water. The aqueous
4H), 3.36-3.38 (m 4H), 2.98 (t, 6.3, 4H), 2.82 (t, 1=6.3, 4H),
layer was washed extensively with ether until no 3-picoline
left in the aqueous layer. The resulting aqueous solution of 50 1.79-1.83 (m, 4H), 1.63-1.69 (m, 4H). CNMR, 154.58,
145.92, 143.59, 139.99, 123.92, 70.19, 69.74, 68.40, 56.28,
the product was lyophilized to yield the pure product. (75%).
49.10, 28.72, 27.26, 21.40, 20.45.
1
H NMR (300 MHZ, D 2 0, ppm), 8.54 (s, 2H), 8.49 (d,
1=6.0, 8.22 (d, 1=8.1, 2H), 8.76 (dd, 1=8.1, 1=6.0, 2H), 4.57
Example 85
(t, 1=4.8, 4H), 3.84 (t, 1=5.1, 4H), 3.43-3.48 (m, 4H),
3.35-3.39 (m, 4H), 2.69 (s, 6H). CNMR, 146.48, 144.22, 55
Synthesis of Compound N,N'-{ 2,2'-[ oxybis-(2,1141.89, 139.81, 127.33, 69.93, 69.60, 68.95, 60.97, 17.89.
ethandiyloxy) ]bis-ethyl} -bis(5,6, 7, 8-tetrahydroisoquinolinium) dichloride
Example 83
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Synthesis of Compound N,N'-{ 2,2'-[ oxybis-(2, 1ethandiyloxy )]bis-ethyl }-bis(4-methylpyridinium)
dichloride

CI~ ~o~ ~c1
0

0

-

60

CI~ ~o~ ~c1

0

65

CG

0

-

./'......./o~o~o-......../'N80

10

2c1 8

#

US 9,499,518 B2
73

74

1-Chloro-2-{ 2-[2-(2-chloro-ethoxy )-ethoxy]-ethoxy }ethane was added to a solution of tetrahydroisoquinoline (3
mmol) in acetonitrile and the solution refluxed for 24 hours.
The acetonitrile was removed in vacuum and the resulting
residue was partitioned between ether and water. The aqueous layer was washed extensively with ether until no tetrahydroisoquinoline left in the aqueous layer. The resulting
aqueous solution of the product was lyophilized to yield the
pure product. (75%). 1 H NMR (300 MHz, D 2 0, ppm), 8.33
(s, 2H), 8.24 (d, 1=6.3, 2H), 7.52 (d, 1=6.3, 2H), 4.47 (t,
1=4.8, 4H), 3.81 (t, 1=4.8, 4H), 3.42-3.45 (m, 4H), 3.33-3.37
(m, 4H), 2.81-2.84 (br, 4H), 2.70-2.74 (br, 4H), 1.63-1.70
(m, 8H). CNMR, 159.33, 143.61, 140.12, 138.77, 127.74,
69.96, 69.60, 69.02, 60.12, 29.40, 26.18, 20.98, 20.95.

resulting aqueous solution of the product was lyophilized to
yield the pure product. (75%). 1 H NMR (300 MHZ, D 2 0,
ppm), 8.72 (s, 2H), 8.65 (d, 1=6.0, 8.39 (d, 1=7.8, 2H), 7.91
(t, 1=6.9, 2H), 4.69 (t, 1=4.8, 4H), 4.64 (s, 4H), 3.89 (t, 1=4.2,
4H), 3.41-3.49 (m, 8H).
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Example 88
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Synthesis of Compound N,N'-{ 2,2'-[ oxybis-(2,1ethandiyloxy) ]bis-ethyl} -bis-(2,4-dimethy lpyridinium) dichloride
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Synthesis of Compound N,N'-{ 2,2'-[ oxybis-(2, 1ethandiy loxy) ]bis-ethyI}-bis- [3 -(3 -hydroxypropy I)pyridinium] dichloride
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1-Chloro-2-{ 2-[2-(2-chloro-ethoxy )-ethoxy]-ethoxy }ethane was added to a solution of 3-(3-hydroxypropyl)pyridine (3 mmol) in acetonitrile and the solution refluxed
for 24 hours. The acetonitrile was removed in vacuum and
the resulting residue was partitioned between ether and
water. The aqueous layer was washed extensively with ether
until no 3-(3-hydroxypropyl)-pyridine left in the aqueous
layer. The resulting aqueous solution of the product was
lyophilized to yield the pure product. (75%). 1 H NMR (300
MHz, D 2 0, ppm), 8.59 (s, 2H), 8.53 (d, 1=6.0, 8.29 (d,
1=8.4, 2H), 7.81 (dd, 1=8.4, 1=6.0, 2H), 4.60 (t, 1-4.8, 4H),
3.85 (t, 1=4.5, 4H), 3.44-3.49 (m, 8H), 3.36-3.39 (m, 4H),
2.76 (t, 1=7.8, 4H), 1.74-1.80 (m, 4H). CNMR, 145.99,
144.09, 143.35, 142.35, 127.64, 69.96, 69.64, 68.96, 61.06,
60.60, 31.21, 28.81.
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Example 89
Synthesis of Compound N,N'-{ 2,2'-[ oxybis-(2,1ethandiyloxy) ]bis-ethyl} -bis-(3,4-dimethy lpyridinium) dichloride
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Example 87
Synthesis of Compound N,N'-{ 2,2'-[ oxybis-(2, 1ethandiy loxy) ]bis-ethyI} -bis-(3 -hydroxymethy lpyridinium) dichloride

0

1-Chloro-2-{ 2-[2-(2-chloro-ethoxy)-ethoxy]-ethoxy }ethane was added to a solution of 2,4dimethylpyridine (3
mmol) in acetonitrile and the solution refluxed for 24 hours.
The acetonitrile was removed in vacuum and the resulting
residue was partitioned between ether and water. The aqueous layer was washed extensively with ether until no 2,4dimethylpyridine left in the aqueous layer. The resulting
aqueous solution of the product was lyophilized to yield the
pure product. (75%). 1 H NMR (300 MHZ, D 2 0, ppm), 3.35
(d, 1=6.6, 2H), 7.58 (s, 2H), 7.50 (d, 1-6.6, 2H), 4.54 (t, 1-4.8,
4H), 3.82 (t, 1=4.8, 4H), 3.41-3.45 (m, 4H), 3.34-3.36 (m,
4H), 2.62 (s, 6H). 2.40 (s, 6H). CNMR, 159.76, 154.44,
144.47, 130.31, 126.00, 70.16, 69.66, 68.42, 56.36, 49.10,
21.27, 19.90.
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1-Chloro-2-{ 2-[2-(2-chloro-ethoxy )-ethoxy]-ethoxy }ethane was added to a solution of 3-hydroxymethylpyridine
(3 mmol) in acetonitrile and the solution refluxed for 24
hours. The acetonitrile was removed in vacuum and the
resulting residue was partitioned between ether and water.
The aqueous layer was washed extensively with ether until
no 3-hydroxymethylpyridine left in the aqueous layer. The
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1-Chloro-2-{ 2-[2-(2-chloro-ethoxy )-ethoxy]-ethoxy }ether and water. The aqueous layer was washed extensively
with ether until no 2-picoline left in the aqueous layer. The
ethane was added to a solution of 3,4-dimethylpyridine (3
mmol) in acetonitrile and the solution refluxed for 24 hours.
resulting aqueous solution of the product was lyophilized to
The acetonitrile was removed in vacuum and the resulting
yield the pure product. (75%). 1 H NMR (300 MHz, D 2 0,
residue was partitioned between ether and water. The aque- 5 ppm), 8.58 (d, 2H), 8.18-8.24 (m, 2H), 7.65-7.74 (m 4H),
ous layer was washed extensively with ether until no 3,44.40 (t, 4H), 2.68 (s, 6H), 2.21 (t, 4H), 1.84-1.94 (m, 4H),
dimethylpyridine left in the aqueous layer. The resulting
1.46-1.54 (m, 4H). CNMR, 155.29, 145.16, 144.78, 130.32,
125.75, 77.89, 65.52, 57.61, 28.78, 24.44, 18.19.
aqueous solution of the product was lyophilized to yield the
pure product. (75%). 1 H NMR (300 MHZ, D 2 0, ppm), 8.36
10
(s, 2H), 8.30 (d, 1=6.3, 2H), 7.61 (d, 1=6.3, 2H), 4.49 (t,
Example 92
1=4.8, 4H), 3.81 (t, 1=4.8, 4H), 3.42-3.45 (m, 4H), 3.34-3.37
(m, 4H), 2.37 (s, 6H). 2.25 (s, 6H). CNMR, 159.23, 142.79,
Synthesis of Compound N,N'-(5,7-dodecadiyn-1,12141.27, 138.49, 128.06, 69.92, 69.58, 69.01, 60.08, 49.07,
19.75, 16.32.
diyl)-bis-(3-methylpyridinium) dichloride
15
Example 90
Synthesis of Compound N,N'-{ 2,2'-[ oxybis-(2, 1ethandiyloxy) ]bis-ethyl} -bis-(3 ,5 -dimethy lpyridinium) dichloride
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1,12-Dibromo-dodeca-5,7-diyne was added to a solution
of 3-picoline (3 mmol) in acetonitrile and the solution
#
refluxed for 24 hours. The acetonitrile was removed in
vacuum and the resulting residue was partitioned between
30
ether and water. The aqueous layer was washed extensively
8
2c1
with ether until no 3-picoline left in the aqueous layer. The
resulting aqueous solution of the product was lyophilized to
yield the pure product. (75%). 1 H NMR (300 MHz, D 2 0,
1-Chloro-2-{ 2-[2-(2-chloro-ethoxy )-ethoxy]-ethoxy }ethane was added to a solution of 3,5-dimethylpyridine (3 35 ppm), 8.72 (s, 2H), 8.66 (d, 2H), 8.38 (d, 2H), 7.94 (dd, 2H).
mmol) in acetonitrile and the solution refluxed for 24 hours.
4.59 (t, 4H), 2.58 (s, 6H), 2.32 (t, 4H), 2.28 (p, 4H), 1.59 (p,
The acetonitrile was removed in vacuum and the resulting
4H). CNMR, 146.17, 143.83, 141.40, 140.11, 127.60, 77.95,
residue was partitioned between ether and water. The aque65.54, 61.35, 30.00, 24.36, 18.22, 18.00.
ous layer was washed extensively with ether until no 3,5dimethylpyridine left in the aqueous layer. The resulting 40
Example 93
aqueous solution of the product was lyophilized to yield the
pure product. (75%). 1 H NMR (300 MHz, D 2 0, ppm), 8.34
(s, 4H), 8.06 (s, 2H), 4.52 (t, 1=4.8, 4H), 3.83 (t, 1=4.8, 4H),
Synthesis of Compound N,N'-(5,7-dodecadiyn-1,123.42-3.46 (m, 4H), 3.35-3.38 (m, 4H), 2.31 (s, 12H).
diyl)-bis-( 4-methylpyridinium) dichloride
CNMR, 146.98, 141.42, 138.93, 69.95, 69.61, 69.01, 60.75, 45
49.08, 17.68.
Example 91
Synthesis of Compound N,N'-(5,7-dodecadiyn-1,12diyl)-bis-(2-methylpyridinium) dichloride
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1,12-Dibromo-dodeca-5,7-diyne was added to a solution
of 2-picoline (3 mmol) in acetonitrile and the solution
refluxed for 24 hours. The acetonitrile was removed in
vacuum and the resulting residue was partitioned between

65

1,12-Dibromo-dodeca-5,7-diyne was added to a solution
of 4-picoline (3 mmol) in acetonitrile and the solution
refluxed for 24 hours. The acetonitrile was removed in
vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no 4-picoline left in the aqueous layer. The
resulting aqueous solution of the product was lyophilized to
yield the pure product. (75%). 1 H NMR (300 MHz, D 2 0,
ppm), 8.48 (d, 4H), 7.68 (d, 4H), 4.38 (t, 4H), 2.46 (s, 6H),
2.18 (t, 4H), 1.86-1.98 (m, 4H), 1.34-1.44 (m, 4H). CNMR,
160.12, 143.13, 128.77, 77.87, 65.47, 60.61, 29.86, 24.30,
21.56, 18.17.
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Synthesis of Compound N,N'-(5,7-dodecadiyn-1,12diyl)-bis-(3,4-dimethylpyridinium) dichloride

2Br

15

1,12-Dibromo-dodeca-5,7-diyne was added to a solution
of 3,4-Iutidine (3 mmol) in acetonitrile and the solution
refluxed for 24 hours. The acetonitrile was removed in
vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no 3,4-lutidine left in the aqueous layer. The
resulting aqueous solution of the product was lyophilized to
yield the pure product. (75%). 1 H NMR (300 MHz, D 2 0,
ppm), 8.35 (s, 2H), 8.29 (d, 2H), 7.60 (d, 2H), 4.32 (t, 4H),
2.38 (s, 6H), 2.24 (s, 6H), 2.16 (t, 4H), 1.86-1.94 (m, 4H),
1.30-1.42 (m 4H).

20

8

1,12-Dibromo-dodeca-5,7-diyne was added to a solution
of tetrahydroisoquinoline (3 mmol) in acetonitrile and the
solution refluxed for 24 hours. The acetonitrile was removed
in vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no tetrahydroisoquinoline left in the aqueous
layer. The resulting aqueous solution of the product was
lyophilized to yield the pure product. (75%). 1 H NMR (300
MHZ, D 2 0, ppm), 8.34 (s, 2H), 8.22 {d, 1=6.3, 2H), 7.54 (d,
1-6.3, 2H), 4.31 (t, 1=7.2, 4H), 2.82-2.84 (br, 4H), 2.71-2.73
(br, 4H), 2.12 (t, 1=6.6, 4H), 1.81-1.91 (m, 4H), 1.64-1.69
(m, 8H), 1.29-1.38 (m, 4H). CNMR, 158.94, 143.15, 139.67,
139.05, 128.01, 77.81, 65.50, 60.46, 29.92, 29.41, 26.26,
24.38, 21.02, 21.05, 18.20.
Example 97

25

Synthesis of Compound N,N'-[(1,4-phenylene)-bis(4-butynyl)]-bis-(3-methyl-pyridinium) dibromide

Example 95
30

Synthesis of Compound N,N'-(5,7-dodecadiyn-1,12diyl)-bis-(3,5-dimethylpyridinium) dichloride
Br
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1,12-Dibromo-dodeca-5,7-diyne was added to a solution
of 3,5-lutidine (3 mmol) in acetonitrile and the solution
refluxed for 24 hours. The acetonitrile was removed in
vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no 3,5-lutidine left in the aqueous layer. The
resulting aqueous solution of the product was lyophilized to
yield the pure product. (75%). 1 H NMR (300 MHz, D 2 0,
ppm), 8.32 (s, 4H), 8.00 (s, 2H), 4.36 (t, 4H), 2.34 (s, 12H),
2.18 (t, 4H), 1.86-1.94 (m, 4H), 1.34-1.44 (m, 4H). CNMR,
146.62, 140.97, 139.15, 77.88, 65.41, 61.05, 29.88, 24.28,
18.14, 17.70.
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1,4-Bis-(4-bromo-but-1-ynyl)-benzene was added to a
solution of 3-picoline (3 mmol) in acetonitrile and the
solution refluxed for 24 hours. The acetonitrile was removed
in vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no 3-picoline left in the aqueous layer. The
resulting aqueous solution of the product was lyophilized to
yield the pure product. (75%). 1 H NMR (300 MHz, D 2 0,
ppm), 8.67 (s, 2H), 8.60 (d, 1=6.0 Hz, 2H), 8.25 (d, 1=8.0 Hz,
2H), 7.80 (dd, 1=6.0 Hz, 1=8.0 Hz, 2H), 7.14 (s, 4H), 4.63
(m, 4H), 3.02 (t, 1=6.3 Hz, 4H), 2.36 (s, 6H). CNMR,
146.68, 144.11, 141.66, 139.87, 131.59, 127.39, 122.22,
86.10, 84.40, 59.68, 21.95, 17.90.
Example 98

Example 96
Synthesis of Compound N,N'-(5,7-dodecadiyn-1,12diyl)-bis-(5,6,7,8-tetrahydroisoquinolinium) dichloride
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Synthesis of Compound N,N'-[(1,4-phenylene)-bis(4-butynyl)]-bis-( 4-methyl-pyridinium) dibromide
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1,4-Bis-(4-bromo-but-1-ynyl)-benzene was added to a
solution of 4-picoline (3 mmol) in acetonitrile and the
solution refluxed for 24 hours. The acetonitrile was removed
in vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no 4-picoline left in the aqueous layer. The
resulting aqueous solution of the product was lyophilized to
yield the pure product. (75%). 1 H NMR (300 MHz, D 2 0,
ppm), 8.60 (d, 1=6.6 Hz, 4H), 7.73 (d, 1=6.6 Hz, 4H), 7.15
(s, 4H), 4.60 (t, 1=6 Hz, 4H), 3.01 (t, 1=6.0 Hz, 2.49 (s, 6H).
CNMR, 160.87, 143.41, 131.58, 128.57, 122.26, 86.16,
84.25, 59.03, 21.87, 21.68.
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1,4-Bis-(4-bromo-but-1-ynyl)-benzene was added to a
solution of 3,4-lutidine (3 mmol) in acetonitrile and the
solution refluxed for 24 hours. The acetonitrile was removed
in vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no 3,4-lutidine left in the aqueous layer. The
resulting aqueous solution of the product was lyophilized to
yield the pure product. (75%). 1 H NMR (300 MHZ, D 2 0,
ppm), 8.50 (s, 2H), 8.44 (d, 1-6.3 Hz, 2H), 7.65 (d, 1=6.3 Hz,
2H), 7.13 (s, 4H), 4.57 (t, 1=6.3 Hz, 4H), 2.99 (t, 1=6.3 Hz,
4H), 2.38 (s, 6H), 2.24 (s, 6H).

Example 99

Example 101

Synthesis of Compound N,N'-[(1,4-phenylene)-bis(4-butynyl) ]-bis-(5,6, 7,8-tetrahydroisoquiolinium)
dibromide

Synthesis of Compound N,N'-[(1,4-phenylene)-bis(4-butynyl)]-bis-(3,5-dimethyl-pyridinium) dibromide [ZZ 1 111]
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1,4-Bis-(4-bromo-but-1-ynyl)-benzene was added to a
solution of terahydroisoquinoline (3 mmol) in acetonitrile
and the solution refluxed for 24 hours. The acetonitrile was
removed in vacuum and the resulting residue was partitioned
between ether and water. The aqueous layer was washed
extensively with ether until no terahydroisoquinoline left in
the aqueous layer. The resulting aqueous solution of the
product was lyophilized to yield the pure product. (7 5%). 1 H
NMR (300 MHz, D 2 0, ppm), 8.46 (s, 2H), 8.35 (d, 1=6.6
Hz, 2H), 7.56 (d, 1=6.6 Hz, 2H), 7.09 (s, 4H), 4.54 (t, 1=6.3
Hz, 4H), 2.98 (t, 1-6.3 Hz, 4H), 2.83 (t, 1=6.0 Hz, 4H), 2.66
(t, 1=5.4 Hz, 4H), 1.64-1.68 (m, 8H).
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1,4-Bis-(4-bromo-but-1-ynyl)-benzene was added to a
solution of 3,5-lutidine (3 mmol) in acetonitrile and the
solution refluxed for 24 hours. The acetonitrile was removed
in vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no 3,5-lutidine left in the aqueous layer. The
resulting aqueous solution of the product was lyophilized to
yield the pure product. (75%). 1 H NMR (300 MHZ, D 2 0,
ppm), 8.46 (s, 4H), 8.04 (s, 2H), 7.11 (s, 4H), 4.59 (t, 1=6.3
Hz, 4H), 2.99 (t, 1=6.3 Hz, 4H), 2.29 (s, 12H). CNMR,
147.17, 141.31, 138.96, 131.59, 122.24, 86.31, 84.46, 59.45,
21.99, 17.73.
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Example 100
Synthesis of Compound N,N'-[(1,4-phenylene)-bis(4-butynyl)]-bis-(3,4-dimethyl-pyridinium) dibromide [ZZ-1-110]

Example 102
Synthesis of Compound N,N'-[(1,1 '-biphenyl)-4,4'di-(1-propyn-3-yl)]-bis-(3-methylpyridinium) dibromide
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4,4'-Bis-(3-bromo-prop-1-ynyl)-biphenyl (1 mmol) was
added to a solution of 3,4-lutidine (3 mmol) in acetonitrile
and the solution refluxed for 24 hours. The acetonitrile was
removed in vacuum and the resulting residue was partitioned
between ether and water. The aqueous layer was washed
extensively with ether until no 3,4-lutidine left in the aqueous layer. The resulting aqueous solution of the product was
lyophilized to yield the pure product. (75% ). 1 H NMR (300
MHz, d 6 -DMSO, ppm), 9.02 (s, 2H), 8.88 (d, 2H), 8.0 (d,
2H), 7.8 (d, 4H), 7.6 (d, 4H), 5.9 (s, 4H), 2.46 (s, 6H), 2.40
(s, 6H). CNMR, 159.64, 143.10, 141.96, 140.39, 138.65,
133.12, 128.88, 127.68, 120.88, 88.83, 83.08, 50.41, 20.66,
17.19.
It will be appreciated that, although specific embodiments
of the invention have been described herein for purposes of
illustration, various modifications may be made without
departing from the spirit and scope of the invention. All such
modifications and variations are intended to be included
herein within the scope of this disclosure and the present
invention and protected by the following claims.

5

4,4'-Bis-(3-bromo-prop-1-ynyl)-biphenyl (1 mmol) was
added to a solution of3-picoline (3 mmol) in acetonitrile and
the solution refluxed for 24 hours. The acetonitrile was
removed in vacuum and the resulting residue was partitioned
between ether and water. The aqueous layer was washed
extensively with ether until no 3-picoline left in the aqueous
layer. The resulting aqueous solution of the product was
lyophilized to yield the pure product. (75%). 1 H NMR (300
MHz, d 6 -DMSO, ppm), 9.16 (s, 2H), 9.12 (s, 2H), 8.54 (d,
2H), 8.22 (dd, 2H), 7.8 (d, 4H), 7.62 (d, 4H), 5.8 (s, 4H), 2.4
(s, 6H). CNMR, 147.52, 144.53, 142.46, 140.44, 139.73,
133.14, 128.36, 127.69, 120.85, 89.16, 82.81, 51.19, 18.79.
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Example 103
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Synthesis of Compound N,N'-[(1,1 '-biphenyl)-4,4'di-(1-propyn-3-yl)]-bis-(4-methylpyridinium) dibromide

Example 105
Persistent Inflammatory Pain Model
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4,4'-Bis-(3-bromo-prop-1-ynyl)-biphenyl (1 mmol) was
added to a solution of 4-picoline (3 mmol) in acetonitrile and
the solution refluxed for 24 hours. The acetonitrile was
removed in vacuum and the resulting residue was partitioned
between ether and water. The aqueous layer was washed
extensively with ether until no 4-picoline left in the aqueous
layer. The resulting aqueous solution of the product was
lyophilized to yield the pure product. (75%). 1 H NMR (300
MHZ, d 6 -DMSO, ppm), 9.05 (d, 4H), 8.06 (d, 4H), 7.78 (d,
4H), 7.62 (d, 4H), 5.8 (s, 4H), 2.62 (s, 6H). CNMR, 160.67,
144.10, 140.41, 133.11, 129.27, 127.69, 120.85, 89.06,
82.97, 50.56, 22.39.
Example 104
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Synthesis of Compound N,N'-[(1,1 '-biphenyl)-4,4'di-(1-propyn-3-yl)]-bis-(3,4-dimethylpyridinium)
dibromide [ZZ-1-61 C]
55
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Example 106
Study of the Anti-Hyperalgesic Effects of
ZZ-1-61 C Following Intraperitoneal Administration
in a Rodent Model of Chemotherapy-Induced Pain
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A rat model of tonic inflammatory pain (the formalin test)
was used in this study (Wheeler-Aceta and Cowan, 1991).
Fifty ul offormalin (5%) was injected subcutaneously (SC)
into the dorsal surface of the left hind paw. This procedure
typically produces a biphasic behavioral response consisting
of flinching, lifting and licking. The first phase (0-10 min) is
thought to result from direct stimulation of nociceptors
(nociceptive pain) whereas the second phase (20-60 min) is
thought to involve central sensitization resulting from continued activation of receptors (TRPA1) with an important
role in inflammatory pain. Rats were pretreated 15 min prior
to formalin (SC) injection with ZZ-16-1C as synthesized in
Example 104 and administered by the I.P. route. Saline
served as control. Incidences of formalin-induced flinching
were counted continuously in 5 min intervals for 60 min.
Each rat received only one treatment. The results are presented in FIGS. 1 and 2. FIG. 1 shows the time course of the
effect of intraperitoneal administration of varying doses of
ZZ-16-1 C in the rodent model of tonic inflammatory pain.
The drug produced a decrease in the number of twitches in
both phases of the formalin test indicating it's a analgesic
effect in this. The effect of the drug remained significant
even at 60 min. FIG. 2 shows the dose response effect of
ZZ-16-1 C following intraperitoneal administration in the
rodent model of tonic inflammatory pain. The effect of the
drug was dose-related. Both phases of the formalin test were
affected, however, ZZ-6-1C was more effective in phase 2
than phase 1.

65

A study was performed to screen the analgesic activity of
ZZ-1-61 C following administration by the intraperitoneal
(IP) route in the rodent model of chemotherapy-induced
pain. A well accepted preclinical model of neuropathic pain
that produced enhanced pain sensitivity similar to that
observed as a result of chemotherapy administration in
humans was employed (Polomano and Bennett, 2001 ). Rats
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were injected (IP) with vincristine, a vinca alkaloid antitumor agent, using two 5-day cycles (100 ug/kg/day). Rats
typically develop a neuropathic pain state with hypersensitivity to pain as a result of nerve damage induced by the
vincristine. The ability of ZZ-1-61C to prevent chemotherapy-induced neuropathic pain was determined as follows. Male rats (N=6) were given 100 ug/kg ofZZ-1-61C in
combination with vincristine. The control group (N=6) was
given vincristine alone. Mechanical hyperalgesia was
assessed employing the paw pressure test (32 g/sec, 300 g
cut-off) as described by Randal and Selitto (1957) using a
Basile Analgesimeter (UGO Basile, Italy) with vocalization
as an end-point. The results are presented in FIG. 3. The
ZZ-1-61C was effective in blocking the development of
chemotherapy-induced neuropathic pain (anti-hyperalgesic
effect) by the vincristine.

with hypersensitivity to pain as a result of nerve damage
induced by the vincristine accompanied by weight loss. The
ability of ZZ-1-61C to prevent chemotherapy-induced toxicity manifested as weight loss was determined as follows.
Male rats (N=6) were given 100 ug/kg of ZZ-1-61C in
combination with vincristine. The control group (N=6) was
given vincristine alone. Body weight was assessed on a daily
basis. The results are presented in FIG. 5. The ZZ-1-61 C was
able to obtund the weight loss in the rats normally seen as
a result of vincristine administration in the chemotherapyinduced pain model.
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Example 109

Example 107
Study of the Anti-Allodynic Effect of ZZ-1-61 C
Following Intraperitoneal Administration in a
Rodent Model of Chemotherapy-Induced Pain
A study was performed to screen the analgesic activity of
ZZ-1-61 C following administration by the intraperitoneal
(IP) route in the rodent model of chemotherapy-induced
pain. A well accepted preclinical model of neuropathic pain
that produced enhanced pain sensitivity similar to that
observed as a result of chemotherapy administration in
humans was employed (Polomano and Bennett, 2001). Rats
were injected (IP) with vincristine, a vinca alkaloid antitumor agent, using two 5-day cycles (100 ug/kg/day). Rats
typically develop a neuropathic pain state with hypersensitivity to pain as a result of nerve damage induced by the
vincristine. The ability of ZZ-1-61C to prevent chemotherapy-induced neuropathic pain was determined as follows. Male rats (N=6) were injected with vincristine as
describe above. The rats were then given ZZ-1-61 C at a dose
of 100 ug/kg following completion of the chemotherapy
regimen. A second group of rats (N=6) was given vincristine
alone. The control group received saline. Rats were placed
on an elevated mesh floor and von Frey Filaments (Stoelting,
Wood Dale, Ill.) with bending forces of 4 g and 15 gm were
applied to the plantar surfaces of both hind paws. A positive
response was regarded as a sharp withdraw! of the paw. The
results are presented in FIG. 4. The ZZ-1-61C was effective
in reducing the allodynia (anti-allodynic effect) produced by
vincristine.
Example 108

Bis Analogs Ability to Block a9a 10 nAChR
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Results are shown in Table I. SEM represents the standard
error of the mean. The results indicate that bis compounds
consisting of a variety of different structures are activity at
blocking a9a 10 nAChRs, the therapeutic target.
TABLE I

50

Study of the Effect of ZZ-1-61C on the Toxicity
(Body Weight Loss) of Vincristine in a Rodent
Model of Chemotherapy-Induced Pain
55

A study was performed to assess the ability of ZZ-1-61C
to prevent loss of body weight typically induced by vincristine follow administration in a rodent model of chemotherapy-induced pain. A well accepted preclinical model of
neuropathic pain that produced enhanced pain sensitivity
similar to that observed as a result of chemotherapy administration in humans was employed (Polomano and Bennett,
2001 ). Rats were injected (IP) with vincristine, a vinca
alkaloid anti-tumor agent, using two 5-day cycles (100
ug/kg/day). Rats typically develop a neuropathic pain state

Bis analogs were tested for their ability to block a9a 10
nAChRs. Cloned nAChR subunits were heterologously
expressed in Xenopus oocytes, voltage-clamped and
exposed to ACh and compounds as previously described in
Vincler, M. et a!., Molecular mechanism for analgesia
involving specific antagonism of alpha9alpha1 0 nicotinic
acety!choline receptors, Proc Nat! A cad Sci USA 2006, 103:
17880-17884 and Cartier G E eta!., A new alpha-Conotoxin
which targets alpha3best2Nicotinic Acetylcholine Receptors, J. Bioi. Chern. 1996, 271:7522-7528. Briefly, the
oocyte chamber consisting of a cylindrical well (-30 fll in
volume) was gravity perfused at a rate of -2 ml/min with
ND96 containing 0.01% (wt/vol) BSA. Oocytes were
exposed once a minute to 1 sec pulses of ACh. The ACh
concentration was 10 f.LM. Compounds were applied at the
beginning of a 5 min static bath incubation. The %block was
calculated as a% ofND96 control (no compound) response.
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Compound
GZ
GZ
GZ
GZ
GZ
GZ
GZ
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GZ
GZ

585 B
582 B
581 B
584 B
581 A
584A
578 B
570 B
571 A
579 B
zz 1 81
zz 1 82
zz 1 110
zz 1 111
ZZ 55 G
zz 55 c
ZZ 1 55 D
zz 161 c

%Block
at 100 nM

SEM

68.9
72.0
68.7
28.0
32.4
-24.4
37.3
23.1
58.4
62.5
63.3
2.9
89.4
23.8
65.4
10.7
-13.8
91.9

8.6
3.9
5.8
6.9
16.9
10.2
7.7
11.9
6.7
6.6
11.3
9.9
4.6
8.3
9.8
10.8
4.6
6.1
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We claim the following:
1. A method of blocking the nicotinic acetylcholine receptor a9alOnAChR, comprising administering to a mammalian subject in need thereof a pharmaceutically acceptable
amount of a compound-of Formula (I)
X 2 8EBR 1-H2 C-L 1-Q-L2 -CH2 -R2 EB8X 1
18

bromo, hydroxymethyl or hydroxypropyl; R7 is hydrogen or methyl; R9 is hydrogen; and R 11 is hydrogen; or
R 1 Eil and R 2 Eil are

45

+

50
(I)

N::

CO

28

wherein X ' and X ' are each independently an organic
or inorganic anion; and
wherein -L 1 -Q-L 2 - is -(CH 2 ) 4 -1,2-phenyl-(CH 2 ) 4 - ;
55
R 1 Eil and R 2 Eil are rings represented by the formula

or

#

or
wherein -L 1 -Q-L2 - is -(CH 2 ) 4 -1,3-phenyl-(CH 2 ) 4 - ;
R 1 Eil and R 2 Eil are rings represented by the formula

60

65

wherein R3 is hydrogen or methyl; R5 is hydrogen,
methyl, ethyl, butyl, phenyl, 1-methyl-2-pyrrolidinyl,

US 9,499,518 B2
91

92

wherein R3 is hydrogen or methyl; R5 is hydrogen,
methyl, ethyl, butyl, phenyl, 1-methyl-2-pyrrolidinyl,
bromo, hydroxymethyl or hydroxypropyl; R 7 is hydrogen or methyl; R 9 is hydrogen or methyl; and R 11 is
hydrogen; or R 1 Eil and R 2 Eil are

+
N::

CO
#

+

10

or
wherein -L 1 -Q-L 2 - is -(CH~ 2-C C-1,2-phenylC C-(CH 2 ) 2 - ; R 1 Eil and R 2 are rings represented
by the formula

N::

CO
#

or

or
15

or
wherein -L 1 -Q-L 2 - is -(CH 2 k1,4-phenyl-(CH 2 ) 3 - ;
R 1 Eil and R 2 Eil are rings represented by the formula

20

wherein R 3 is hydrogen or methyl; R5 is hydrogen,
methyl, ethyl, butyl, phenyl, 1-methyl-2-pyrrolidinyl,
bromo, hydroxymethyl or hydroxypropyl; R 7 is hydrogen or methyl; R 9 is hydrogen or methyl; and R 11 is
hydrogen; or R 1 Eil and R 2 Eil are

25

30

wherein R 3 is hydrogen or methyl; R 5 is hydrogen,
methyl, ethyl, butyl, phenyl, 1-methyl-2-pyrrolidinyl,
bromo, hydroxymethyl or hydroxypropyl; R 7 is hydrogen or methyl; R 9 is hydrogen; and R 11 is hydrogen; or
R 1 Eil and R 2 Eil are

+
N::

CO

35

#

or

or

+

40

wherein -L 1 -Q-L 2 - is -(CH~ 2-C C-1,3-phenylC C-(CH 2 ) 2 - ; R 1 Eil and R 2 are rings represented
by the formula

N::

CO
#

45
or

or
wherein -L 1 -Q-L 2 - is -(CH 2 ) 2 -4,4'-biphenyl-(CH 2 ) 2 - ;
R 1 Eil and R 2 Eil are rings represented by the formula

50

55

60

wherein R3 is hydrogen or methyl; R5 is hydrogen, ethyl,
butyl, phenyl,
1-methyl-2-pyrrolidinyl, bromo,
hydroxymethyl or hydroxypropyl; R7 is hydrogen or
methyl; R9 is hydrogen or methyl; and R 11 is hydrogen;
or R 1 Eil and R 2 Eil are

wherein R3 is hydrogen or methyl; R5 is hydrogen,
methyl, ethyl, butyl, phenyl, 1-methyl-2-pyrrolidinyl,
bromo, hydroxymethyl or hydroxypropyl; R7 is hydrogen or methyl; R9 is hydrogen or methyl; and R 11 is
hydrogen; or R 1 Eil and R 2 Eil are

+
N::

65

CO
#

or

US 9,499,518 B2
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93
or

!ian subject in need thereof a pharmaceutically acceptable
amount of a compound selected from the group consisting
wherein -L 1-Q-L 2- is ---CH 2---C C-1,4-phenyl-C==Cof:
CH2-; R 1Eil and R 2Eil are rings represented by the
N,N'[ 1,4-phenylenedi-(4-butanyl) ]-bis-(3,4-dimethylformula
pyridinium) dibromide;
1,2-bis-[ 5-(3,4-dimethyl-pyridinium)-pent-1-ynyl]-benzene dibromide;
1,2-bis-[ 5-(3,5-dimethyl-pyridinium)-pent-1-ynyl]-benzene dibromide;
1,2-bis-[ 5-isoquinolinium-pent-1-ynyl)-benzene dibro10
mide;
1,2-bis-[5-(3,4-dimethyl-pyridinium)-pentyl]-benzene
dibromide;
1,2-bis- [5-isoquinolinium-penty1)- benzene dibromide;
1,3-bis-[ 5-(3,4-dimethyl-pyridiniiim)-pent-1-ynyl]-benwherein R3 is hydrogen or methyl; R5 is hydrogen, 15
zene dibromide;
methyl, ethyl, butyl, phenyl, 1-methyl-2-pyrrolidinyl,
1,3-bis-(5-quinolinium-pent-1-ynyl)-benzene dibromide;
bromo, hydroxymethyl or hydroxypropyl; R7 is hydro1,3-bis-[5-(3,4-dimethyl-pyridinium)-pentyl]-benzene
dibromide;
gen or methyl; R9 is hydrogen or methyl; and R 11 is
hydrogen; or R 1Eil and R 2Eil are
1,3-bis-(5-isoquinolinium-penty1)- benzene dibromide;
20
N,N'-[ (1, 1'-biphenyl)-4,4'-di -(3-propanyl)]-bis-[3-(3-hydroxy-propyl)-pyridinium] dibromide;
N,N'-[ (1 ,4-phenylene)-bis-(4-butynyl)]-bis-(3,4-dimethyl-pyridinium) dibromide;
N,N'-[ (1 ,4-phenylene)-bis-(4-butynyl)]-bis-(3,5-dim25
Wethyl-pyridinium) dibromide; and
N,N'-[ (1, 1'-biphenyl)-4,4'-di -(1-propyn-3-yl)]-bis-(3,4dimethylpyridinium) dibromide.
or
#
3. The method of claim 2, wherein the compound is
N,N'-[ (1, 1'-biphenyl)-4,4'-di-(1-propyn-3-yl) ]-bis-(3,4-dim30 ethylpyridinium) dibromide.
or
4. The method of claim 2, wherein the compound is
wherein -L 1-Q-L 2- is ---C C-4,4'-biphenyl-C C-;
N,N'-[ (1 ,4-phenylene)-bis-(4-butynyl) ]-bis-(3,4-dimethylR 1Eil and R 2Eil are rings represented by the formula
pyridinium) dibromide.
5. The method of claim 1, wherein -L 1-Q-L 2- is
1
2
35 -(CH ) -1,2-phenyl-(CH ) 2 4 and R Eil and R Eil are each
24

+

CO

40

+
W-

wherein R3 is hydrogen or methyl; R5 is hydrogen,
methyl, ethyl, butyl, phenyl, 1-methyl-2-pyrrolidinyl,
bromo, hydroxymethyl or hydroxypropyl; R7 is hydrogen or methyl; R9 is hydrogen or methyl; and R 11 is
hydrogen; or R 1Eil and R 2Eil are

+

45

#

.

6. The method of claim 1, wherein X 18' and X 28 ' are each

bromide, -L 1-Q-L 2- is -(CH 2)4 -1,2-phenyl-(CH 2)4 - , and
R 1Eil and R2Eil are each
50

W-

CO

CO

+
W-

55
or

2. A method of blocking the nicotinic acetylcholine receptor a9a10nAChR, comprising administering to a mamma-

CO

.
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